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by	 reducing	 the	 regulatory	 and	 economic	 barriers.	 The	 incentives	 of	 the	ODA	
have	been	effected	through	market	protection,	tax	credit,	fee	waiver	and	grants	
to	 increase	 the	accessibility	of	orphan	products	 for	 the	public.	The	number	of	
orphan	 drugs	 available	 in	 the	 market	 has	 risen	 sharply	 from	 just	 ten	 in	 the	
decade	before	1983	to	over	400	since	1983.	This	increase	implies	a	substantial	
improvement	of	the	healthcare	of	patients	suffering	rare	diseases	and	a	success	
of	 the	 orphan	drug	 legislation	with	 the	 aim	 to	motivate	 the	 development	 and	
manufacture	 of	 products	 that	 have	 low	 commercial	 potentials.	 Although	 it	 is	
evident	 that	 the	 ODA	 has	 successfully	 stimulated	 drug	 companies	 to	 develop	





In	 this	 thesis,	 we	 have	 analyzed	 the	 long-term	 evolution	 of	 the	 bio-
pharmaceutical	industry.	In	particular,	we	have	examined	drug	discovery	in	the	
period	 of	 random	 screening,	 rational	 design	 and	 network	 collaboration,	 and	
explored	 the	 influence	 of	 the	 ODA.	We	 have	 taken	 the	 theory	 of	 the	 sectoral	
system	 of	 innovation,	 and	 combined	 it	 with	 the	 complex	 adaptive	 model	 of	
innovation,	 and	 found	 that	 the	 complex	 version	 of	 that	 theory	 is	 capable	 of	
explaining	the	comprehensive	drug	innovation	system.	
	







in	 the	 process	 of	 orphan	 drug	 innovation.	 Through	 this	 model,	 we	 have	





Drawing	 upon	 the	 results	 of	 the	 simulation,	 we	 provide	 a	 sound	 basis	 for	
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been	 founded	 to	 develop	 these	 drugs	 and	 successfully	 market	 them.	 These	
specific	 drugs	 now	 account	 for	 over	 40%	 of	 the	 new	 FDA-approved	 drugs	




to	 the	particularly	 small	market	 resulting	 from	the	 low	prevalence,	most	drug	
companies	did	not	invest	in	orphan	drugs	before	the	1980s.		
	
The	 significant	 increase	 in	 orphan	 drug	 innovation	 after	 1983	 was	 due	 to	 a	
breakthrough	in	the	orphan	drug	legislation.	The	enactment	of	the	Orphan	Drug	
Act	(ODA)	in	1983	denotes	the	landmark	act	shifting	the	orphan	drug	R&D	from	
depression	 to	 prosperity.	 By	 offering	market	 exclusivity,	 tax	 credit,	 assistance	
and	 grants	 for	 drug	 development,	 the	 ODA	 has	 productively	 motivated	 drug	
companies	 to	 address	 the	 need	 for	 patients	 with	 the	 rare	 disease.	 In	 the	 30	
years	after	1983,	more	than	400	orphan	drugs	have	been	approved	in	the	US.	In	
2015,	 orphan	 drugs	 accounted	 for	 approximately	 18%	 of	 global	 prescription	
sales,	 and	 this	 is	projected	 to	 increase	 to	20.2%	 in	2020	 (Hadjivasiliou	2015).	








in	 recent	 times	 (Haffner	 2006).	 However,	 despite	 its	 success	 over	 the	 last	 30	
years,	the	ODA	has	been	criticized	for	its	7-year	market	exclusivity	that	leads	to	
the	 high	 price	 of	 orphan	 drugs.	 Currently,	 ‘orphans’	 are	 no	 longer	 ignored	 by	
drug	 companies;	 instead,	 they	 are	 the	 golden	 opportunity	 that	 companies	
scramble	to	grasp.	
	
This	 chapter	 consists	 of	 three	 sections.	 The	 first	 section	 contains	 a	 brief	
introduction	 to	 the	 pharmaceutical	 industry,	 including	 the	 opportunities	 and	
challenges	faced	by	the	sector.	The	second	section	concentrates	on	the	ODA	and	





The	 pharmaceutical	 industry	 has	 faced	 extraordinary	 challenges	 in	 the	 last	
several	years,	although	it	has	been	very	successful	in	creating	a	stream	of	novel	
drugs	 with	 significant	 therapeutic	 benefits.	 The	 industry	 underwent	 a	 wide	
range	 of	 unprecedented	 changes,	 such	 as	 massive	 losses	 from	 patent	
expirations,	 high-cost	 pressure,	 declining	 productivity	 and	 enormous	
uncertainties	 from	 regulatory	 regimes	 (Kola	 and	 Landis	 2004,	 Hendry	 and	
Brown	 2005).	 At	 the	 same	 time,	 significant	 advances	 in	 biotechnology	 and	
genomics,	 venture	 capital	 investments	 pouring	 in,	 close	 collaborations	 among	



















commercial	 applications	 by	 facilitating	 the	 transfer	 of	 knowledge	 from	
universities	 and	 non-profit	 research	 institutions	 to	 the	 industry.	 Since	 then,	
drug	discovery	has	become	more	dependent	on	basic	research,	and	its	practical	




The	 development	 of	 science	 and	 technology,	 especially	 the	 rapid	 advance	 of	
biochemical	 and	 genetic	 processes,	 boosted	 the	 growth	 of	 discovery	 and	




antibodies	 and	 tissue-engineered	 products.	 The	 diversity	 of	 orphan	 drugs	 is	
reflected	 by	 the	 range	 of	 conditions	 targeted	 such	 as	 cancer,	 cystic	 fibrosis,	
renal	 disease,	 rheumatoid	 arthritis	 and	 cardiovascular	 disease.	 The	




hand,	 this	 is	 the	first	 instance	that	an	 innovation	 in	biotechnology	has	directly	
resulted	 in	 clinical	 success	 in	 rare	 conditions	 such	 as	 multiple	 sclerosis,	





innovations	 have	 significantly	 enhanced	 therapies	 already	 existing	 for	 more	
prevalent	conditions	such	as	Hepatitis	B.	
	
Biotechnology	 has	 also	 contributed	 to	 other	 sectors	 by	 creating	 many	 job	
opportunities	 and	 subsequently	 revenue	 for	 the	 companies.	 Public	 research	
organizations	 have	 developed	 a	 close	 relationship	 with	 the	 biotechnology	
industry	 for	developing	and	marketing	 their	 inventions.	A	vast	majority	of	 the	
biotechnology	 firms	 started	 by	 licensing	 the	 promising	 work	 done	 in	 the	
laboratory	 settings.	 The	 close	 relationship	 improves	 the	 knowledge	 transfer	
between	academic	institutions	and	industry.		
	
In	 short,	 the	 vibrancy	 of	 biotechnology	 has	 had	 a	 significant	 impact	 on	 the	
healthcare	 system	 including	 academic	 research,	 pharmaceutical	 industry	 and	



























17%	(Paul,	Mytelka	 et	 al.	 2010).	Therefore,	 improving	productivity,	 especially	




Drug	 discovery	 and	 development	 is	 a	 costly	 and	 time-consuming	 innovation	
process.	According	 to	Figure	2,	 the	R&D	of	an	approved	drug	takes	13.5	years	
and	 costs	 $1,778	 million	 on	 average.	 The	 cost	 of	 new	 biopharmaceutical	
products	 is	 approximately	 $198	 million	 in	 the	 preclinical	 phase	 and	 $361	
million	 at	 the	 clinical	 stage.	 Adding	 the	 cost	 of	 time,	 the	 numbers	 increase	 to	
$615	million	and	$626	million,	with	the	total	cost	coming	to	$1241	million	for	










































Biotechnology	 companies	 have	 faced	 an	 increasing	 number	 of	 challenges	 to	
access	 sufficient	 capital	 in	 the	 resource-constrained	 realities.	 Venture	
capitalists,	 public	 investors,	 and	 alliances	with	 big	 pharmaceutical	 companies	












global	 economic	 crisis	 froze	 the	 path	 to	 capital	 that	 is	 the	 lifeline	 for	 the	
research-intensive	 industry	 like	 biotechnology	 industry.	 Venture	 capitalists,	




The	 process	 of	 drug	 discovery	 and	 development	 is	 significantly	 influenced	
legislation.	The	United	States	Federal	Food,	Drug	and	Cosmetic	Act	(FFDCA)	of	
1938	 gave	 the	 authority	 to	 FDA	 to	 oversee	 the	 safety	 of	 food,	 drugs	 and	
cosmetics.	 Manufacturers	 were	 required	 to	 provide	 evidence	 to	 demonstrate	
that	drugs	are	safe.	With	 the	aim	of	protecting	 the	public	health	 from	wasting	
money	 and	 endangering	 their	 health	 on	 ineffective	 medicines,	 in	 1962,	 the	
Kefauver	 Harris	 Amendment	 (K-H	 amendment)	 also	 required	 companies	 to	
provide	 proof	 of	 both	 the	 effectiveness	 and	 safety	 of	 their	 products	 for	 FDA	
approval	 review.	 The	 K-H	 amendment	 necessitated	 that	 drug	 companies	
demonstrate	that	new	drugs	are	both	safe	and	effective	based	on	the	three-stage	
clinical	trial	data.	These	two	acts	exert	their	influence	on	drug	R&D	in	two	ways:	
firstly,	 sponsors	 have	 to	 provide	 evidence	 of	 not	 only	 safety	 but	 also	





costs	 from	 $4.7	 to	 an	 estimated	 $54	 million	 (Asbury	 1992).	 Even	 with	 the	
protection	 from	Bayh-Dole	Act,	 because	making	profits	 is	 the	ultimate	 goal	 of	
pharmaceutical	industry,	products	with	little	prospect	of	commercial	return	had	
been	 neglected	 by	 the	 industry.	 For	 instance,	 drugs	 treating	 rare	 disease	
generally	 indicated	 a	 relatively	 low	 return	 from	 the	 sales	 on	 the	 R&D	
investment,	so	these	drugs	were	scarce	in	the	market	before	the	1980s.	
	
The	 average	 cost	 of	 new	 biological	 agents	 for	 cancer	 and	 other	 rare	 life-






pressure	 amidst	 budget	 deficits	 balloon	 and	 unemployment.	 The	 potential	
returns	on	 the	pipeline	will	be	affected	by	 increased	 rebate.	As	 the	patents	of	
blockbuster	drugs	are	scheduled	to	go	off	patent	in	these	years,	the	revenue	and	
cash	flow	will	inevitably	reduce.	Only	the	most	innovative	and	affordable	drugs	
can	meet	 the	 demand	 of	 the	 government.	 It	 is	 critical	 for	 drug	 companies	 to	







populations.	 Historically,	 healthcare	 system	 and	 drug	 companies	 did	 not	 pay	




Besides	 the	 small	 market,	 the	 R&D	 of	 orphan	 drugs	 faces	 other	 difficulties.	
Firstly,	 the	market	 for	 these	 drugs	was	 so	 small	 that	 drug	 companies	 cannot	
recoup	the	costs	of	drug	discovery	and	development.	Secondly,	the	small	sample	











Although	 an	 individual	 rare	 disease	 affects	 a	 relatively	 small	 cohort,	
approximately	 30	 million	 Americans	 are	 affected	 altogether.	 With	 advocacy	
efforts	of	National	Organization	for	Rare	Disorders	(NORD),	in	1983,	President	
Ronald	 Reagan	 signed	 the	 ODA	 into	 the	 legislation	 of	 United	 States	 for	 the	
creation	of	incentives	to	change	the	situation.	In	addition,	the	ODA	symbolizes	a	
triumph	of	patient	advocacy	collaborating	with	government,	public	media	and	




The	 public	 awareness	 of	 rare	 diseases	 had	 increased	 in	 the	 1970s.	 Although	
they	are	not	very	prevalent,	over	30	million	Americans	suffer	from	about	7000	
rare	 diseases.	 Hence,	 the	 healthcare	 of	 patients	 with	 rare	 diseases	 should	 be	
handled	 with	 the	 same	 priority	 as	 other	 patients	 regardless	 of	 commercial	
interests.	Patient	advocacy	groups	had	played	a	significant	role	in	promoting	the	
orphan	 drug	 legislation.	 In	 1983,	 the	 ODA	 emerged	 from	 the	 influences	 of	
various	 factors	 including	 technological	 advances,	 public	 and	 congressional	
concern,	regulatory	and	industrial	entities	in	the	United	States	(Asbury	1992).		
	
The	 Orphan	 Drug	 Act	 provides	 three	major	 incentives.	 The	 first	 is	 offering	 a	
seven-year	period	of	market	exclusivity	to	the	sponsors	with	approved	orphan	
products.	 The	 seven-year	 market	 exclusivity	 is	 only	 authorized	 for	 the	 drug	
treating	 the	rare	disease.	Secondly,	 the	act	provides	 tax	credit	 to	cover	half	of	
the	costs	of	clinical	trials.	Since	the	remaining	50%	of	the	costs	are	deductible,	
the	 total	 reduction	 in	 tax	 liability	 is	 73%	 (Asbury	 1992).	 Thirdly,	 the	 act	
authorized	Orphan	Products	Grants	Program	administered	by	the	FDA	to	fund	
the	 clinical	 trials	 of	 promising	 orphan	 products.	 The	 Orphan	 Products	 Grants	







partly	 funded	 by	 the	 grants	 (Needleman	 2012).	 In	 1997,	 Congress	 created	 an	
additional	incentive	that	provided	exemption	from	the	drug	application	user	fee	
of	at	least	$500,000	charged	by	FDA	(OIG	2001).	Some	of	the	sponsors	can	also	





drugs	 to	meet	 the	 same	 standards	 of	 effectiveness	 and	 safety.	 Indeed,	 as	 the	
result	of	a	small	number	of	patients	available	to	be	enrolled	in	the	clinical	trial,	
the	 drug	 can	 only	 be	 tested	 in	 a	 very	 small	 population.	 FDA	 and	 patient	
advocacy	 groups	 provide	 various	 assistance	 to	 help	 the	 sponsors	 design	 and	
organize	clinical	trials,	and	solve	the	problems	emerging	in	the	trials.	Using	an	
extreme	 example,	 the	 orphan	 drug	 approved	 with	 the	 smallest	 scale	 of	 the	
clinical	 test	 is	 bovine	 pegademase	 (Adagen)	 treating	 Severe	 Combined	
Immunodeficiency	 Syndrome	 (SCID)	 (Haffner	 2006).	 The	 clinical	 trial	 for	 this	
involved	only	eight	patients,	since	there	were	only	14	patients	afflicted	with	this	


















In	 the	25th	 anniversary	 of	 the	US	Orphan	Drug	Act	 in	 2008,	 it	was	 estimated	
that	 over	 17	 million	 people	 had	 benefited	 from	 orphan	 drugs	 in	 the	 US.	
Nowadays,	orphan	drugs	account	for	an	increasing	percentage	of	all	new	FDA-




by	 incentives	of	 the	ODA.	 In	 addition,	 approximately	50%	of	 all	 the	biological	
products	 with	 the	 FDA	 market	 approval	 in	 the	 US	 have	 orphan	 status	 from	
1983.	 The	 categories	 of	 these	 biological	 products	 are	 diverse,	 and	 include	
therapeutic	 and	 diagnostic	monoclonal	 antibodies,	 cell	 therapy,	 gene	 therapy,	
enzyme-replacement	 therapy	 for	metabolic	 disorders	 and	novel	 drug	delivery	
biomolecules	(Haffner,	Whitley	et	al.	2002).	
	
Several	 factors	 have	 contributed	 to	 propelling	 the	 development	 of	 these	
biological	orphan	products.	The	first	one	is	the	nature	of	the	rare	disease.	Since	
rare	diseases	are	generally	serious	and	life-threatening	conditions	with	limited	





known	 approaches	 fail.	 Since	 most	 rare	 diseases	 are	 generic,	 discovering	
treatment	 for	 them	 needs	 to	 rely	 on	 biotechnology.	 The	 second	 factor	 is	 the	
financial	 incentives	 of	 the	 ODA,	which	 provides	 grants	 for	 drug	 development,	
tax	credit	of	clinical	test,	fee	reduction	of	drug	approval	and	market	exclusivity	




The	 ODA	 not	 only	 benefits	 the	 patients	 affected	 by	 the	 rare	 disease	 but	 also	
benefits	neglected	diseases.	Many	of	the	drugs	used	to	treat	neglected	diseases	
in	the	developing	countries	also	qualify	as	orphan	drugs	in	the	US,	since	many	
neglected	diseases	 in	developing	countries	affect	 less	 than	200,000	persons	 in	
the	US	(Goodman	2010).	Besides,	the	basic	and	clinical	research	on	rare	disease	
not	only	facilitates	orphan	drug	R&D	but	also	improve	our	understanding	of	the	




The	 ODA	 has	 a	 significant	 economic	 influence	 on	 the	 growth	 of	 the	
biotechnology	 industry	 (Haffner	2003).	The	development	of	recombinant	DNA	
technology	 in	 1970s	 led	 to	 the	 subsequent	 creation	 of	 several	 biotechnology	
companies	 till	 the	early	1980s.	These	companies	 focused	on	rare	diseases	and	
developed	novel	drugs	 for	 them.	 	 For	 example,	 the	 first	marketed	products	of	
Genentech,	Amgen	and	Genzyme	Corporation	as	well	as	most	US	biotechnology	
companies	are	orphan	drugs	(WÄStfelt,	Fadeel	et	al.	2006).	Orphan	indications	
have	 become	 the	 target	 of	 biotechnology	 companies	 (Mullard	 2013).	 The	
favorable	 regulatory	 environment	 such	 as	 accelerated	 approvals,	 priority	








The	 innovation	 system	 of	 the	 orphan	 drug	 involves	 the	 sharing	 of	 resources	
among	various	organizations.	To	reduce	the	cost	and	expedite	the	progress,	the	
orphan	drug	 innovation	 system	has	established	an	active	 collaboration	with	a	
wide	 range	 of	 public	 and	 private	 organizations,	 including	 research	
organizations,	 government	 agencies,	 advocacy	 groups,	 biotechnology	





Drug	 companies	 have	 used	 various	models	 to	 achieve	 higher	 productivity	 by	
sharing	costs	and	risk.	On	one	hand,	most	sponsors	are	small-	to	medium-sized	
firms,	 with	 many	 focusing	 only	 on	 orphan	 drugs	 (Needleman	 2012).	
Biotechnology	 companies	 share	 the	 costs	 and	 findings	 of	 early-stage	 rare	
disease	 research	 with	 research	 organizations	 and	 share	 the	 expertise	 and	
marketing	resources	with	pharmaceutical	companies	during	the	late-stage	drug	
development	 and	 commercialization.	 On	 the	 other	 hand,	 the	 collaboration	
among	 drug	 companies,	 advocacy	 groups,	 and	 government	 agencies	 has	
contributed	 a	 lot	 to	 the	 design	 of	 the	 clinical	 trial	 to	 satisfy	 FDA	 criteria.	
Although	 the	 development	 of	 orphan	 drugs	 may	 yield	 fewer	 trials	 and	 less	
money,	 clinical	 trials	 for	orphan	drugs	 is	 limited	by	 the	small	 sample	size	and	
distribution	 of	 trial	 population.	 In	 order	 to	 enroll	 a	 sufficient	 number	 of	 rare	
disease	patients,	Office	of	Rare	Disease	(ORD)	provides	support	for	the	clinical	
research	 and	 assists	 patient	 advocacy	 groups;	 FDA	 offers	 flexibility	 for	




Rare	 diseases	 had	 been	 neglected	 for	 a	 long	 time,	 and	 the	 morbidity	 of	 the	





response,	patient	groups	have	attempted	 to	 improve	 their	physical,	 emotional	
and	 financial	 conditions	 by	 providing	 funding,	 policy-making,	 and	 offering	
support	 for	 the	 research	 process.	 The	 largest	 patient	 advocacy	 group,	 NORD,	
provides	 an	 important	 platform	 for	 research	 organizations,	 drug	 companies,	
patients	 and	 policy-makers	 to	 accelerate	 the	 innovation	 of	 orphan	 drug.	 The	
number	 of	 advocacy	 groups	 keeps	 increasing,	 which	 not	 only	 reinforces	 the	





also	 the	 most	 challenging	 area	 to	 administrate.	 Due	 to	 the	 small	 number	 of	
patients,	 FDA	 provides	 flexible	 approaches	 to	 establishing	 safety	 and	
effectiveness	standards.	FDA	introduces	regulations,	such	as	Fast	Track,	Priority	
Review,	and	Accelerated	Approval,	aiming	at	speeding	the	approval	process	for	
novel	medicines;	 these	 approaches	 ensure	 that	 patients	 get	 the	 treatments	 as	
soon	as	possible.	Despite	 the	 fact	 that	 the	orphan	drug	 should	meet	 the	 same	
requirements	 of	 safety	 and	 efficacy,	 it	 seems	 easier	 to	 complete	 the	 data	
collection	and	analysis	in	the	case	of	running	a	clinical	trial	with	the	small	size	of	
patient	 population	 than	 conducting	 trials	 involving	 several	 thousands	 of	
patients.			
	
In	 all,	 the	 orphan	 drug	 innovation	 system	 is	 a	 complex	 adaptive	 system	with	





that	 its	 influence	 had	 spread	 to	 other	 countries,	 including	 Singapore	 in	 1991,	





introduced	 legislation	 to	 encourage	 drug	 development	 for	 rare	 diseases.	 The	
European	Union	 (EU)	passed	orphan	drug	 regulation	 in	1999.	The	EU	orphan	
drug	 regulation	 is	 similar	 to	 the	 US	 Orphan	 Drug	 Act,	 and	 provides	 six	main	




(EMA)	 and	 the	 FDA.	 The	 first	 study	 showed	 that	 the	 number	 of	 approvals	
between	2000	to	2005	was	three	times	higher	in	the	US	than	in	the	EU	(Faden	




orphan	 drug	 innovation	worldwide.	However,	 some	 orphan	 drugs	 “have	 been	
approved	and	available	in	EU,	but	not	in	the	US,	and	vice	versa	(Sardana,	Zhu	et	
al.	 2011)”.	 In	 the	 current	 regulatory	 climate,	 collaboration	 among	 regulatory	
agencies	 is	 necessary.	 EMA	 and	 FDA	 jointly	 signed	 a	 Confidentiality	





Although	 the	 ODA	 has	 successfully	 generated	many	 orphan	 products	 to	 treat	




















The	most	common	criticism	of	 the	ODA	has	been	 the	high	price	of	 the	orphan	
drug,	which	usually	exceeds	the	marginal	cost	of	drug	development.	Some	of	the	
blockbuster	 orphan	 drugs	 have	 earned	 huge	 profits	 from	 the	 ODA	 market	
protection.	 The	 original	 goal	 of	 the	 legislation	was	 to	 ensure	 drug	 companies	
make	 a	 reasonable	 profit	 on	 orphan	 products	 instead	 of	 yielding	 enormous	
profits.	 However,	 the	 reality	 is	 that	 although	 the	 industry	 has	 brought	
treatments	to	millions	of	patients	in	the	US,	these	products	are	not	cheap.		
	
The	 high	 price	 of	 orphan	 drugs	 is	 attributed	 to	 the	 seven-year	 market	
exclusivity,	which	 has	 been	 criticized	 for	 the	 lack	 of	 the	 balance	 between	 the	
objective	 to	 stimulate	 innovation	 in	 orphan	 drugs	 and	 the	 public	 benefit	
associated	with	 affordable	 treatments.	 NORD	 complains	 that	 the	 ODA	 is	 very	


























































the	 protection	 of	 legislation	 designed	 to	 stimulate	 the	 development	 of	 drugs	
with	a	small	market	and	little	commercial	value.		
	










Historically,	 public	 interventions	 have	 played	 major	 role	 in	 shaping	 the	
pharmaceutical	innovation:	the	Food,	Drug	and	Cosmetic	Act	in	1938	shaped	the	
foundation	 of	 drug	 development	 by	 giving	 authority	 to	 FDA	 to	 oversee	 the	





drug	 approval	 by	 requiring	 drug	 manufacturers	 to	 demonstrate	 scientifically	
that	 a	 medication	 is	 not	 only	 safe	 but	 also	 effective;	 Patent	 and	 Trademark	
Amendments	(Bayh-Dole	Act)	 in	1980	exerted	a	significant	 influence	of	public	
research	on	the	drug	discovery	and	development	by	permitting	university,	small	
business,	 and	 non-profit	 institution	 to	 pursue	 the	 ownership	 of	 an	 invention	
from	 federal	 government-funded	 research;	 and	 Patent	 Term	 Restoration	 Act	
(Hatch-Waxman	 Amendments)	 in	 1984	 changed	 the	 market	 environment	 of	
drug	 commercialization	 by	 enabling	 generic	 pharmaceutical	manufacturers	 to	
develop	a	copy	of	the	patented	innovative	drug	without	duplicating	the	clinical	
and	non-clinical	studies.	The	above	acts	encourage	drug	companies	to	develop	
innovative	drugs	by	offering	 them	a	period	of	marketing	exclusivity	 to	 recoup	
the	 R&D	 costs,	 and	 facilitate	 the	 rapid	 availability	 of	 lower	 priced	 generic	
version	of	the	innovative	drugs	after	the	expiry	of	patent	protection.	
	
Moreover,	 public	 intervention	 has	 played	 a	 critical	 role	 in	 encouraging	 the	
innovation	of	orphan	drug.	The	ODA	is	the	first	and	most	successful	legislation	
focusing	 on	 rare	 disease	 area.	 After	 its	 success,	 many	 countries	 enacted	 the	
orphan	 drug	 legislation.	 Only	 a	 handful	 of	 drugs	 treating	 rare	 disease	 were	
available	 before	 1983,	 but	 since	 the	 enactment	 of	 the	 ODA,	 more	 than	 2000	
medical	therapies	have	been	designated	as	the	orphan	drug,	and	nearly	500	of	
these	 therapies	 have	 been	 authorized	marketing	 approval.	 The	 orphan	 drugs	
used	to	the	treatment	of	sclerosis,	cystic	fibrosis	and	hemophilia	are	considered	
as	 the	 biggest	 breakthrough	 therapies	 (OIG	 2001),	 as	 they	 have	 significantly	
improved	 the	 healthcare	 of	 rare	 disease	 patients.	 The	 orphan	 indication	 has	






incentives.	 Most	 criticisms	 focus	 on	 the	 highly	 profitable	 orphan	 drugs	





the	 ODA	 incentives,	 such	 as	 shortening	 the	 duration	 of	 market	 exclusivity	 or	
setting	 conditions	 for	 companies	 to	 enjoy	 the	 rights	 of	 market	 protection.	 A	
thorough	 understanding	 of	 the	 system	 is	 essential	 before	 changing	 the	
legislation,	but	no	empirical	study	has	been	conducted	to	explore	the	dynamics	
of	 the	 orphan	 drug	 innovation	 system	 and	 how	 the	 incentives	 stimulate	 the	
production	of	orphan	drugs	in	this	complex	adaptive	system.		
	




necessary	 to	 evaluate	 whether	 the	 ODA	 under-protects	 or	 over-protects	 the	
orphan	drug	innovation	to	its	jurisdiction.	The	effects	of	under-protection	mean	
that	orphan	drug	development	is	being	under-promoted;	while	over-protection	
refers	 to	 the	 excessively	 long	 duration	 of	monopoly	 pricing	 and	 the	waste	 of	
public	costs.	The	outcome	of	this	research	provides	a	sound	basis	for	adjusting	
the	market	exclusivity	 terms	 to	strike	a	balance	between	giving	 the	monopoly	
power	to	the	private	sector	and	offering	the	benefits	to	the	public	sector.		
	
Our	main	 research	 questions	 are	 1)	 what	 is	 the	 dynamic	 of	 the	 orphan	 drug	
innovation	 system?	 2)	 How	 do	 the	 ODA	 incentives	 influence	 orphan	 drug	
innovation?	 3)	 How	 can	 the	 current	 ODA	 be	 improved	 to	 encourage	 more	



















The	 thesis	 consists	 of	 two	 parts,	 the	 first	 part	 describes	 the	 orphan	 drug	
innovation	system	and	introduces	the	conceptual	model	of	the	sectoral	system	





definition	 of	 the	 orphan	 drug,	 the	 orphan	 drug	 innovation	 process,	 the	
background	 of	 the	 ODA,	 and	 the	 influence	 of	 the	 ODA	 on	 the	 orphan	 drug	
innovation	system.	
	
Chapter	 2	 focuses	 on	 developing	 the	 conceptual	 framework	 for	 assessing	 the	
orphan	drug	 innovation	system.	After	reviewing	 the	 literature,	 several	gaps	 in	

















model,	 non-linear	 model,	 and	 network	 model	 need	 to	 be	 updated.	 In	 this	
research,	the	orphan	drug	innovation	system	is	modeled	as	a	complex	adaptive	
system.	 Thus,	 Chapter	 2	 starts	 with	 a	 review	 of	 literature	 on	 knowledge	 and	




illustrated	 in	 the	 following	 chapters,	 this	 theoretical	 model	 incorporates	 the	
advantages	 of	 knowledge-based	 view	 of	 the	 company	 and	 focuses	 on	 the	
features	 of	 complexity	 and	 dynamics	 to	 enhance	 the	 explanatory	 power	 of	
theory	of	the	system	of	innovation	at	the	sector	level.		
	
Chapter	 3	 is	 dedicated	 to	 the	 Orphan	Drug	 Act.	 This	 chapter	 concentrates	 on	
reviewing	the	incentives	offered	by	the	ODA	and	the	influences	exerted	by	these	
incentives.	 It	 analyses	 the	 success	 of	 the	 ODA	 in	 bringing	 a	 number	 of	
treatments	to	rare	disease	patients,	and	identifies	the	inefficiency	caused	by	the	
7-year	market	exclusivity	and	other	abuses	which	make	the	ODA	controversial.	




conceptual	 model	 of	 orphan	 drug	 innovation.	 More	 specifically,	 this	 chapter	
introduces	the	orphan	drug	 innovation	process	and	various	roles	of	players	 in	
the	 system;	 in	 addition,	 the	 technological	 and	 structural	 changes	 and	 their	
influences	on	 this	 sector	during	 last	decades	are	discussed.	 It	 firstly	describes	
the	 orphan	 drug	 discovery	 process	 and	 its	 evolution	 from	 1983,	 followed	 by	
explaining	 the	 unique	 orphan	 drug	 designation,	 and	 then	 presents	 how	 to	









construct	 a	 computational	 model	 of	 orphan	 drug	 innovation,	 including	 the	
methodology	 of	 social	 simulation;	 the	 explanations	 about	 the	 logic	 behind	
modeling,	the	modeling	tools;	the	ways	applied	to	model	the	complex	adaptive	






activities	 are	 modeled	 as	 the	 process	 of	 organizational	 learning,	 and	 the	
innovation	 outcomes	 of	 the	 organization	 by	 different	 learning	 strategies	 are	
discussed.	
	
Chapter	 7	 examines	 the	 orphan	 drug	 innovation	 system.	 It	 first	 presents	 the	


















factors	 in	 the	 turbulent	 business	 environment.	 Knowledge	 is	 the	 core	 of	
innovation	 studies,	 and	 the	 public	 policies	 for	 science,	 technology,	 and	
innovation	 have	 always	 facilitated	 knowledge	 creation	 and	 diffusion.	
Knowledge-intensive	 industries	 are	 believed	 to	 be	 at	 the	 core	 of	 economic	
growth;	thus,	knowledge-intensive	sectors	have	gained	much	attention	in	recent	
years	 with	 the	 aim	 of	 identifying	 factors	 influencing	 knowledge	 creation,	
diffusion,	 and	 application.	 The	 methodology	 in	 generating	 knowledge	 has	
become	 the	 main	 agenda	 for	 companies	 and	 policymakers	 in	 knowledge-
intensive	sectors,	including	the	biopharmaceutical	industry.		
	
The	 rapid	 changes	 in	 science	 and	 technology	 drive	 organizations	 to	 develop	
innovative	 products,	 so	 it	 is	 vital	 for	 them	 to	 generate	 knowledge	 efficiently.	
With	 intangible	 assets	 becoming	 increasingly	 critical	 to	 a	 company’s	
competitiveness,	 organizational	 learning	 is	 the	 way	 to	 prompt	 innovation.	
Organizational	 learning	 is	 a	 trial-and-error,	 path-dependent,	 and	 target-




Traditionally,	 innovation	 is	 the	 discovery	 of	 new	 scientific	 or	 technical	
principles.	 This	 contrasts	 with	 modern	 innovation	 theory,	 which	 bases	
innovation	 on	 learning	 that,	 not	 only	 includes	 the	 discovery	 of	 new	 technical	
and	 scientific	 principles	 (exploration)	 but	 also	 stresses	 on	 the	 recombination	
and	adaption	of	existing	knowledge	(exploitation).	The	exploitation-exploration	





exploitation	 is	 the	 refinement	 and	 extension	 of	 existing	 competencies,	





Innovation	 is	 an	 important	 competitive	 weapon	 in	 the	 era	 of	 globalization.	
Globalization	 has	 increased	 the	 complexity	 of	 innovation,	 and	 the	 research	
surrounding	 it	 reflects	 this	 shift	 from	 a	 linear	 to	 more	 complex	 manner.	 For	
example,	 in	 recent	 years,	 research	 has	 begun	 to	 apply	 a	 systems	 approach	 to	
study	 innovation.	 Based	 on	 the	 system	 view,	 the	 system	 of	 innovation	 (SI)	
comprises	of	components	and	relations.	The	components	refer	to	organizations	
and	 institutions,	 such	 as	 companies,	 universities	 and	 public	 agencies	
responsible	 for	making	 policy,	while	 the	 connections	 refer	 to	 the	 interactions	
among	these	organizations.	The	SI	approach	is	 focused	around	knowledge	and	
the	 learning	 process,	 so	 it	 specifically	 emphasizes	 the	 creation	 of	 new	





thesis.	 	We	 firstly	 take	up	 the	 issue	with	 the	SI	by	 introducing	knowledge	and	




innovation.	The	boundaries	of	 the	SI	 can	be	 classified	as	national,	 regional,	 or	
sectoral.	 All	 these	 approaches	 are	 complementary	 rather	 than	 exclusive.	 The	
third	 part	 of	 the	 chapter	 describes	 the	 evolution	 of	 the	 different	 models	 of	
innovation,	 which	 enable	 us	 to	 understand,	 assess	 and	 optimize	 the	 SI.	 The	
model	 of	 innovation	 is	 developed	 from	 the	 early-stage	 model	 that	 considers	






the	 network	 model	 that	 includes	 diverse	 actors	 and	 the	 actors’	 interactions.	
Later,	it	shifted	to	the	latest	system	model	of	innovation—the	complex	adaptive	
model	 that	 emphasizes	 on	 the	 socio-economic	 context.	 The	 concluding	 part	
makes	 some	 key	 observations	 of	 studying	 the	 innovation	 of	 knowledge-
intensive	sector	and	presents	the	framework	of	the	complex	adaptive	model	of	





“It	 is	 assumed	 that	 the	most	 fundamental	 resource	 in	 the	modern	economy	 is	
knowledge	 and,	 accordingly,	 that	 the	 most	 important	 process	 is	 learning	
(Lundvall	 2010)”.	 Organizations	 have	 become	more	 knowledge-intensive	 and	
reliant	on	innovative	knowledge	to	create	values.	The	creation	of	knowledge	is	




From	 the	 economic	 perspective,	 innovation	 is	 regarded	 as	 an	 outcome	 of	
knowledge	 production:	 firstly,	 innovation	 represents	 something	 new	 and	



















sequence	 of	 coordinated	 behavior	 that	 is	 ordinarily	 effective	 relative	 to	 its	
objectives,	 given	 the	 context	 in	which	 it	 normally	 occurs	 (Nelson	 and	Winter	
1982)”.		
	
Know-who	 refers	 to	 “specific	 and	 selective	 social	 relations”	 and	 implies	
knowledge	 about	what	 others	 know	and	 the	 extent	 to	which	 their	 knowledge	
can	be	applied	to	solve	someone’s	own	problem.		
	
The	 above	 explanations	 about	 different	 types	 of	 knowledge	 have	 helped	 in	
understanding	 knowledge	 creation	 and	 learning	 in	 the	 innovation	 system	
(Lundvall	2010).		Know-what	and	know-why	can	be	obtained	by	reading	books,	





knowledge	 (Nonaka	 and	Konno	 2005).	 Explicit	 knowledge	 is	 characterized	 as	
declarative	knowledge;	it	can	be	codified	in	numbers	or	words	and	shared	in	the	
form	of	data.	Know-what	and	know-why	are	similar	to	explicit	knowledge.	Tacit	
knowledge	 refers	 to	 the	knowledge	 that	 is	 neither	 visible	nor	 expressible;	 it’s	
deeply	rooted	in	the	individual’s	actions	and	experience,	which	makes	it	difficult	
to	communicate	and	share.	Know-how	consists	of	a	considerable	amount	of	tacit	







Firms	 can	 directly	 attain	 competitive	 advantage	 from	 innovation.	 The	
innovation	ability	of	any	firm	depends	on	its	knowledge	and	its	ability	to	utilize	
it.	 The	knowledge-based	view	 (KBV)	 emphasizes	on	 the	 role	of	 knowledge	on	
firm’s	 innovation	 performance.	 KBV	 has	 improved	 the	 understanding	 of	 the	




identifies	 factors	 that	 impact	knowledge	creation,	diffusion,	and	application.	 It	
also	 conceptualizes	 firms	 as	 organizations	 for	 developing	 and	 transferring	
knowledge,	 since	 firms	 develop	 their	 knowledge	 by	 learning	 within	 and	







Learning	 can	 occur	 at	 different	 social	 levels.	 It	 can	 be	 differentiated	 between	
individual	 process	 and	 collective	 processes.	 At	 the	 micro	 level,	 although	
learning	 occurs	 as	 an	 individual	 process,	 it	 does	 not	 take	 place	 only	 at	 the	
individual	 level.	 Learning	 is	 also	 an	 interactive	 process	 between	 people	 and	
organizations.	It	involves	intense	and	complex	interactions	within	and	between	
organizations.	 Individual	 learning	 means	 the	 acquisition	 of	 knowledge,	
understanding,	 skills,	 and	 competencies	 by	 individuals	 through	 the	 form	 of	









Intra-organizational	 learning	 refers	 knowledge	 created	 and	 developed	 within	
the	boundaries	of	the	organization.	 In	contrast	to	new	knowledge,	 the	existing	
knowledge	or	knowledge	base	is	the	sum	of	the	knowledge	an	organization	has	
achieved.	 Organizations	 can	 learn	 by	 improving	 existing	 knowledge,	 which,	
integrated	with	 the	knowledge	base,	 leads	 to	new	products	or	processes.	 It	 is	
evident	 that	 the	 knowledge	 base	 is	 developing	while	 the	 organization	 learns;	






process	 of	 knowledge	 creation.	 Exploitation	 refers	 to	 “learning	based	on	 local	
search,	 experiential	 refinement	 and	 selection,	 and	 reuse	 of	 existing	 routines;	
exploration	 refers	 to	 learning	 based	 on	 the	 process	 of	 concerted	 variation,	
planned	 experimentation	 and	 play	 (Baum,	 Li	 et	 al.	 2000)”.	 The	 outcome	 of	
exploitation	 is	 predictable,	 while	 the	 outcome	 of	 exploration	 is	 much	 more	





















learning	 opportunities.	 Such	 organizations	 are	 termed	 as	 ambidextrous	
organizations.	 Both	 patterns	 of	 learning	 require	 very	 different	 strategies,	
structures,	processes	and	cultures	(O	Reilly	and	Tushman	2004).		
	
The	 methodology	 behind	 dividing	 resources	 between	 exploration	 and	
exploitation	 affects	 the	 performance	 of	 the	 organization.	 The	 uncertain	 and	
unclear	feedback	links	exploration	to	its	slower	and	less	precise	outcomes	than	
is	the	case	with	exploitation.	For	instance,	basic	research	is	generally	a	very	long	
journey	 with	 less	 certain	 outcomes,	 because	 it	 compromises	 the	 certainty	 of	
success	 for	 the	 novelty	 of	 the	 knowledge,	 longer	 time	 horizons	 and	 more	
diverse	 influences	 that	 surpass	 existing	ones.	 In	 the	 field	of	 rapid	 science	and	
technology	 development,	 organizations	 have	 to	 adapt	 considerably,	 and	 can	
change	 their	 behavior	 incrementally	 by	 exploitation	 or	 radically	 through	
exploration.	 In	 most	 cases,	 organizations	 exhibit	 a	 mixture	 of	 both	 learning	
regimes;	thus,	it	is	important	for	the	company	to	choose	an	appropriate	learning	





There	 is	 a	 gap	 in	 the	 organizational	 learning	 studies	 examining	 the	 process	




Inter-organizational	 learning	 refers	 to	 the	 transfer	of	knowledge	 from	outside	
through	 collaboration	 and	 acquisition.	 By	 establishing	 networks	 with	 other	
organizations,	 firms	 can	 gain	 the	 knowledge	 they	 lack.	 Specifically,	 in	






found	 not	 only	 in	 the	 organization	 but	 also	 in	 the	 connection	 of	 inter-
organizational	relations	(Powell,	Koput	et	al.	1996).		
	
The	 organization	 is	 able	 to	 achieve	 better	 performance	 by	 engaging	 in	
exploration	 and	 exploitation	 at	 the	 broader	 level	 of	 the	 social	 system	 rather	
than	 individual	 organizations	 (Gupta,	 Smith	 et	 al.	 2006).	 Some	 organizations	
may	 specialize	 in	 exploration	 while	 others	 may	 excel	 at	 exploitation,	 so	
collaboration	will	yield	a	better	outcome.	The	 inter-organizational	exploration	
implies	 that	 the	organizations	 in	an	alliance	 transfer	and	absorb	 the	partners’	
knowledge	base,	while	inter-organizational	exploitation	refers	to	organizations	
accessing	 their	 partners’	 knowledge	 base	 for	 complementarities	 and	
maintaining	 its	 distinctive	 base	 of	 specialized	 knowledge	 (Grant	 and	 Baden-
Fuller	2004).		
	




















but	 in	 the	 collaboration	with	 partners.	 The	 partners	 include	 firms	 (suppliers,	
customers,	 competitors,	 etc.),	 or	 non-firm	 organizations	 such	 as	 universities,	
government,	and	other	intermediaries.	One	of	the	main	features	of	the	system-
oriented	 approach	 to	 studying	 innovation	 is	 the	 emphasis	 on	 the	
interdependency	and	interactive	learning	(Edquist	2001).	Various	organizations	
and	 the	 interactions	 among	 them	 make	 the	 system	 approach	 very	 useful	 in	
understanding	 and	 analyzing	 the	 innovation.	 In	 the	 system	 approach	 of	
innovation,	 the	 interdependencies	 and	 interactions	 between	 the	 actors	 in	 the	




The	 system	 of	 innovation	 (SI)	 stresses	 on	 the	 complex	 interdependent	
interactions	 among	 various	 elements	 in	 the	 innovation	 process.	 The	 system	











structure.	 The	 SI	 can	 be	 classified	 by	 geographical	 scale,	 technology,	 and	






sectoral	 level.	 The	 main	 emphasis	 was	 initially	 on	 the	 national	 innovation	




each	 other.	 As	 shown	 in	 Figure	 5,	 there	 are	 two	 NSIs	 (NSI-1	 refers	 to	 NSI	 of	
country	1	and	NSI-2	refers	to	NSI	of	country	2),	three	RSIs	(RSI-a	refers	to	RSI	of	
the	 region	a,	RSI-b	 refers	 to	RSI	of	 the	 region	b	and	RSI-c	 refers	 to	RSI	of	 the	
region	 c),	 and	 one	 SSI.	 From	 Figure	 5,	 we	 can	 see	 the	 regional	 systems	 of	
innovation	are	embedded	in	national	systems	of	 innovation;	moreover,	 it’s	not	







The	 notion	 of	 the	 National	 System	 of	 Innovation	 (NSI)	 was	 introduced	 by	














The	 NSI	 is	 a	 “set	 of	 distinct	 institutions,	 which	 jointly	 and	 individually	
contribute	 to	 the	development	 and	diffusion	of	 new	 technologies	 and	provide	
the	 framework	 within	 which	 governments	 form	 and	 implement	 policies	 to	
influence	 the	 innovation	 process.	 As	 such,	 it	 is	 a	 system	 of	 interconnected	
institutions	that	create,	store	and	transfer	knowledge,	skills,	and	artefacts	which	
define	 new	 technologies	 (Metcalfe	 1995)”.	 The	 NSI	 comprises	 the	 economic,	
social,	 political,	 and	 organizational	 factors	 that	 influence	 the	 development,	
diffusion,	and	use	of	 innovation	(Edqujst	and	Johnson	1997).	The	actors	of	the	
NSI	are	from	both	private	and	public	sectors,	so	their	behaviors	and	interactions	
play	 an	 important	 role	 in	 the	 innovation	 process	 at	 the	 national	 level.	 The	





reasons:	 the	 first	 reason	 is	 the	 big	 difference	 between	 the	 various	 national	








that	 the	 innovation	can	vary	significantly	 in	 terms	of	actors,	 relationships	and	
the	 role	 of	 public	 policy	 (Korres	 2013).	 There	 is	 growing	 empirical	 evidence	
that,	 in	 many	 cases,	 the	 learning	 process	 is	 highly	 localized.	 Consequently,	
researchers	 have	 developed	 a	 regionally	 based	 approach	 of	 the	 innovation	
system,	and	the	 ‘region’	usually	refers	to	a	geographical	area	within	a	country.	
The	 concept	 of	 RSI	 has	 gained	 much	 attention	 from	 researchers	 and	





framework	 for	 improving	 our	 understanding	 of	 the	 innovation	 process	 at	 the	
regional	level.		
	
The	 main	 features	 of	 the	 RSI	 are:	 “agglomeration	 economies,	 institutional	




innovation	 process,	 learning	 has	 specific	 and	 local	 characteristics	 and	 can	 be	













as	 R&D	 process,	 product	 regulation,	 government	 policy,	 and	 market	
characteristics.	 These	 technology-specific	 differences	 have	 significantly	
influenced	 the	 innovativeness	 of	 different	 sectors.	 Therefore,	 some	 scholars	
suggest	 that	 the	 technical	 system	 can	 be	 analyzed	 at	 the	 sector	 level.	 The	








Sectors	 are	 characterized	 by	 “specific	 knowledge	 bases,	 technologies,	
production	 processes,	 complementarities,	 demand	 and	 population	 of	
heterogeneous	firms,	non-firm	organizations	and	institutions	”(Malerba	2002).	
Different	 from	 the	 SI	 approach	 described	 in	 the	 previous	 sections,	 the	 SSI	 is	
defined	based	 on	 related	 or	 substitutable	 product	 groups	 that	 serve	 a	 certain	
demand	and	have	a	similar	knowledge	base.	The	SSI	is	based	on	three	building	




Knowledge	 plays	 a	 critical	 role	 in	 innovation,	 which	 has	 been	 strongly	
emphasized	by	evolutionary	literature	and	knowledge-based	economics.	In	the	






organizational	 structures	 and	 learning	 processes.	 They	 interact	 through	 the	
process	of	innovation.	
	
In	 the	 SSI,	 firms	 are	 at	 the	 center	 as	 they	 are	 involved	 in	 the	 innovation,	
production,	and	distribution	of	sectoral	products,	and	in	the	creation,	adoption,	
and	 diffusion	 of	 new	 knowledge.	 The	 firms	 are	 featured	 by	 productive	
technological	and	market	specialization,	and	they	have	different	competencies,	
structures	in	the	process	of	learning	and	knowledge	accumulation.	Other	types	
of	actors	 in	 the	SSI	are	non-firm	organizations	 including	universities,	 financial	







In	 the	 SSI,	 heterogeneous	 agents	 are	 connected	 in	 different	 ways	 through	
market	 and	non-market	 relations	 (Malerba	2002).	 The	networks	 are	different	
because	of	the	different	characteristics	of	the	knowledge	base,	learning	process,	






knowledge	 and	 learning	 process,	 so	 their	 demands	 are	 heterogeneous.	 In	 the	
SSI,	the	demand	of	system	is	not	the	simple	sum	of	each	actor’s	demands,	but	a	
set	 of	 interacting	 actors	 under	 the	 influence	 of	 institutions.	 The	 demand	 is	 a	
stimulus	 for	 innovation	 as	well	 as	 a	 constraint.	 Coupled	with	 knowledge	 and	
technology,	 demands	 determine	 the	 nature	 of	 the	 problems	 that	 firms	 aim	 to	









Besides	 institutional	 differences,	 the	 national	 institutions	 among	 sectors	 are	
different	 and	 thus	 have	 different	 influence.	 In	 some	 countries,	 the	 features	 of	
national	 institutions	 favor	 some	 sectors	 better	 than	 in	 other	 countries.	
Therefore,	some	specific	sectoral	systems	are	thriving	in	a	country	because	the	
institutions	 of	 that	 country	 provide	 a	 more	 suitable	 environment	 for	 these	







According	 to	 the	 SSI	 concept,	 the	 successful	 innovations	 emerge	 from	 a	














to	 the	knowledge	base,	 learning	process	and	 the	heterogeneity	of	actors,	non-
firm	organizations	and	institutions.	Moreover,	it	emphasizes	the	evolution	of	the	
system.	Thirdly,	the	approach	of	the	SSI	delimited	to	specific	technological	fields	
or	 products	 is	 a	 good	 way	 to	 understand	 the	 dynamics	 of	 an	 industry	 and	
identify	 the	 factors	 influencing	 the	 performance	 of	 the	 system	 and	 finally	
contribute	to	developing	public	policy	indications.	It	has	been	applied	in	many	






certainly	 has	 some	 limitations.	 The	 SSI	 has	 been	 criticized	 on	 different	 levels.	
For	example,	 the	system	boundary	based	on	existing	products	did	not	account	









concept	 of	 SSI	 is	 a	 relevant	 and	 appealing	 framework.	 The	 sectoral	 system	of	
innovation	 features	 a	well-articulated,	multi-dimensional,	 integrated,	 dynamic	





conceptual	 framework,	 the	 SSI	 concept	 enables	 the	 analysis	 of	 actors	 and	
innovation	performance	at	the	sectoral	level.	However,	many	SSIs	do	not	show	
national	 differences	 in	 its	 framework;	 it	 does	not	 explain	how	and	why	many	
pioneering	 companies	within	 a	 particular	 industry	 usually	 come	 from	 certain	
countries.	The	innovation	activities	and	performances	primarily	rely	on	sector-












































The	definition	of	 the	SSI	 is	 flexible	 to	allow	researchers	 to	 focus	on	what	 they	
think	 is	critical	 to	system	innovation.	 It	has	been	pointed	out	how	the	SSI	and	
NSI	 exist	 interdependently,	 and	 how	 sectors	 usually	 tend	 to	 cluster	 from	 the	
viewpoint	of	RSI.	The	‘system’	could	be	applied	and	defined	loosely	based	on	the	
research	 aim	 and	 object.	 It	 is	 evident	 that	 as	 the	 industry	 becomes	 more	
globalized,	the	SSI	is	more	likely	to	be	analyzed	at	the	global	level.	The	research	
on	 the	 sectoral	 patterns	 of	 innovation	 activities	 has	 shown	 that	 there	 is	 a	 big	
difference	 between	 sectors,	 and	 even	 within	 the	 same	 sector,	 the	 innovation	
activities	 differ	 between	 countries.	 The	 sectoral	 patterns	 of	 innovation	 are	
determined	 by	 the	 technological	 regimes,	 knowledge	 base,	 learning	 process,	
public	 organizations	 and	 related	 regulations,	 all	 of	 which	 are	 somewhat	
different	 across	 countries;	 and	 the	 national	 systems	 of	 innovation	 have	 a	 big	
influence	on	the	sectoral	pattern	of	innovation	(Malerba	2002).		
	
For	 studying	 the	orphan	drug	 innovation	 in	 the	US,	 it	 is	proposed	 to	 consider	
the	SSI-NSI	interface	with	a	particular	emphasis	on	the	SSI	components.	As	the	



















‘Model’	 as	 a	 research	 framework	 has	 been	 widely	 used	 in	 the	 study	 of	
innovation.	It	is	an	important	notion	in	explaining	how	innovation	is	generated	
and	what	 factors	affect	 the	outcome	of	 the	 innovation	process.	The	model	 is	a	
representation	of	complex	reality,	but	it	cannot	take	all	the	factors	into	account	




Understanding	 the	 process	 of	 innovation	 has	 evolved	 throughout	 recent	
decades	 from	 the	 simple	 linear	 model	 to	 the	 complex	 models	 embodying	
diverse	 feedbacks,	 multiple	 players	 and	 changing	 social-economic	
environments.	 Four	 generations	 of	 the	 innovation	 model	 are	 summarized	 in	
























































The	 first	conceptual	 framework	 for	understanding	 innovation	 is	considered	 to	









perform	 under	 various	 conditions	 (Plesk	 and	Wilson	 2001).	 The	 best	 way	 to	
improve	 the	 performance	 of	 a	mechanical	 system	 is	 to	 decompose	 the	whole	





1986),	which	 suggests	 that	 innovation	 happens	 in	 a	 linear	 fashion	 from	basic	
research,	development,	production	 to	diffusion	 (Figure	6).	These	activities	are	














based	 on	 new	 technology	 that	 emerged	 in	 the	 1950s	 to	 1960s,	 such	 as	
semiconductors,	pharmaceuticals,	and	new	materials.	These	industries	focused	
on	 the	R&D	to	commercialize	 the	 technological	 changes	and	satisfy	 the	unmet	
demand	 of	 customers.	 The	 innovation	 process	 of	 the	 ‘technology	 push’	model	
starts	from	scientific	discovery,	through	technological	development,	and	ends	in	
the	 market.	 From	 mid-1960s	 to	 early	 1970s,	 new	 products	 were	 introduced	
based	 on	 existing	 technology,	 and	 the	 supply	 and	 demand	 were	 somewhat	
balanced.	 As	 the	 competition	 became	 more	 intense,	 companies	 shift	 from	
developing	new	products	with	new	technology	to	developing	new	products	by	





feedback	 that	 is	 the	 inherent	 and	 essential	 part	 of	 innovation	 (Kline	 and	
Rosenberg	1986).	According	to	that,	on	one	hand,	the	innovation	process	is	not	
smooth	 rather	 than	 highly	 uncertain	 without	 adequate	 information	 at	 the	
beginning.	The	shortcomings	and	failures	are	part	of	the	 learning	process,	and	
in	 a	 learning	 process	 that	 is	 both	 radical	 and	 incremental,	 the	 rapid	 and	
accurate	 feedbacks	 with	 appropriate	 follow-on	 actions	 lead	 to	 effective	
innovations.	On	the	other	hand,	not	all	the	innovation	process	flows	from	basic	
science	 to	 applied	 science	 and	 then	 to	 the	 product.	 Sometimes,	 the	 design	 is	






are	 a	 variety	 of	 organizations	 contributing	 to	 the	 generation	 of	 innovation.	
Innovation	 is	 characterized	 as	 a	 fundamentally	 social	 process	 in	 nature	
(Lundvall	2010),	which	means	that	innovation	is	a	collective	process	involving	a	





cooperation	among	organizations	 is	 important	 for	 the	successful	 innovation.	A	
firm’s	capability	to	innovate	is	further	shaped	by	the	government	intervention,	
which	is	also	neglected	by	the	linear	model.	The	linear	model	also	implies	that	if	










By	 definition,	 non-linearity	means	 ‘not	 in	 a	 straight	 line’	 or	 ‘the	 output	 is	 not	
directly	 proportional	 to	 the	 input’.	 In	 the	 non-linear	model	 of	 innovation,	 the	
activity	does	not	happen	sequentially	from	beginning	to	the	end	and	the	process	
of	 innovation	 is	 uncertain.	 Different	 from	 the	 linear	 mechanic	 system,	
innovation	management	cannot	be	implemented	by	hierarchical	decomposition,	







innovation.	 The	 chain-linked	 model	 differs	 from	 the	 linear	 model	 in	 the	
following	ways:	 firstly,	according	to	Kline	and	Rosenberg	(1986),	 in	 the	chain-
linked	 model	 innovation	 is	 market-driven,	 the	 central	 process	 starts	 with	
market	 need,	 which	 drives	 research	 and	 design,	 production,	 marketing,	 and	







In	Figure	7,	 the	 feedback	paths	 (C)	 link	each	downstream	steps	 in	 the	 central	
chain,	and	 feedback	 loops	 (f)	 connect	back	 from	market	 to	upstream	research	
and	design;	 thirdly,	 the	knowledge	 is	not	 solely	 generated	at	 the	beginning	of	
the	 process	 but	 rather	 in	 the	 whole	 process	 of	 innovation,	 the	 accumulated	
knowledge	can	be	drawn	upon	along	the	central	chain	of	innovation	(K),	when	
the	accumulated	knowledge	fails	to	solve	the	problem	a	need	arise	for	research	
to	 create	new	knowledge	 (R).	Finally,	 the	 research	sometimes	 leads	 to	 radical	
innovation	(D)	that	is	rare	but	marks	major	changes	in	its	area,	in	addition,	the	
innovation	products	 contribute	 to	 the	 science	 (I,	 S)	 through	 the	application	of	






In	 the	model,	we	 can	understand	 innovation	 in	 two	variables	uncertainty	 and	
product	 lifecycle(Kline	 and	 Rosenberg	 1986).	 Innovation	 implies	 uncertainty,	
and	the	degree	of	uncertainty	is	associated	with	the	amount	of	improvement	in	
the	 innovation.	 In	 the	early	 stage	of	product	 life	 cycle,	 the	 innovation	 is	more	
related	to	big	changes	in	the	product	design,	once	the	accumulated	knowledge	is	










between	 technology	 and	market	 is	 another	 attempt	 to	 add	 uncertainty	 to	 the	
linear	model	with	 complex	 structure	and	multiple	 feedbacks	 (Rothwell	1994).	
But	the	same	as	the	linear	model,	as	a	firm-level	model,	the	inter-organizational	






The	 technological	 change	 can	 influence	 the	 social	 structure,	 and	 the	 social	
structure	places	 its	 impact	on	an	organization’s	 ability	 to	produce	knowledge.	
From	2.3.3,	we	 found	 the	 external	 sources	of	 the	 knowledge	 are	 important	 to	
the	 innovation.	 The	 ability	 to	 explore	 and	 exploit	 external	 knowledge	 is	
obviously	a	critical	component	of	the	innovation	capability.	Hence,	the	research	
of	 innovation	 has	 moved	 from	 an	 intra-organizational	 level	 to	 inter-
organizational	level.		
	
The	 term	 ‘network’	 is	 an	 abstract	 concept	 referring	 to	 a	 set	 of	 nodes	 and	 ties	
linking	 each	 other.	 Network	 is	 derived	 from	 natural	 science,	 for	 example	 the	
neural	 network,	 but	 it	 has	 been	 widely	 used	 in	 the	 social	 science	 including	
organization	 theory,	 operational	 research,	 healthcare	 and	 linguistics.	 The	
network	approach	marks	a	shift	 from	research	 that	centers	on	 individual	 firm	
towards	 a	more	 systemic	way	 of	 addressing	 social	 phenomenon	 (Burt	 2002).	







The	 typical	 innovation	 network	 includes	 nodes	 representing	 individual	
organizations,	and	ties	representing	the	collaborative	relationship	between	two	
organizations.	 Figure	 8	 is	 an	 illustration	 of	 a	 network	 of	 innovation	 in	 the	
biopharmaceutical	 industry,	 the	 node	 A	 represents	 a	 biopharmaceutical	
company,	B	represents	a	university,	and	C	represents	a	biotechnology	company.	
The	ties	among	them	mean	they	have	collaborative	relationships.	The	benefits	
of	 the	 network	 include	 getting	 access	 to	 the	 new	 market	 and	 knowledge;	
speeding	products	to	market;	and	sharing	risks.	The	network	not	only	plays	an	
















and	 assess	 their	 performances.	 The	 network	 position	 and	 the	 absorptive	















influence	on	 the	 innovation	output	by	 facilitating	knowledge	sharing,	bringing	
complementary	 resources,	 and	 enlarging	 the	 project	 scale	 (Ahuja	 2000).	 The	
greater	the	number	of	the	collaborative	relationships	formed	by	a	start-up,	the	
more	 patents	 it	 could	 achieve	 (Shan,	 Walker	 et	 al.	 1994).	 Building	 a	 large	
number	of	indirect	ties	may	be	a	more	effective	way	for	actors	in	terms	of	taking	
the	 advantage	 of	 the	 network	 size	 without	 paying	 the	 cost	 of	 network	
maintenance	 than	 engaging	 in	 direct	 ties	 (Burt	 2009).	 The	 second	 notable	
contrast	 is	 the	distinction	between	strong	ties	(for	example,	 the	tie	between	A	
and	B)	and	weak	ties	(for	example,	the	tie	between	A	and	E).	A	strong	tie	means	
the	interactions	between	organizations	are	on	a	regular	basis,	while	a	weak	tie	
is	 an	 acquaintance	 (Granovetter	 1973).	 The	 strong	 ties	 built	 on	 common	





and	 it’s	measured	by	 the	percentage	of	 the	number	of	existing	 ties	divided	by	
the	number	of	all	possible	ties.	Dense	network	improves	the	knowledge	transfer	
through	efficient	commutation	and	trustful	cooperation.	Closed	network	means	
everyone	 is	 connected	 to	 each	 other.	 It	 creates	 an	 advantage	 for	 the	 firm	 by	
getting	access	to	the	external	knowledge	and	lowering	the	risk	of	cooperation.	
However,	 frequent	 long-term	 interactions	 between	 a	 limited	 number	 of	 firms	
can	result	in	generating	increasingly	conformable	and	homogeneous	knowledge	
and	 thereby	 less	 innovative	 product	 (March	 1991).	 Dense	 networks	 are	
associated	 with	 substandard	 performance	 (Burt	 2000).	 By	 contrast,	 a	 more	





benefitting	 from	alliances.	 The	 study	 of	 biotechnology	 start-ups	 indicates	 that	







degree	 of	 A	 is	 6	 and	 the	 degree	 of	 F	 is	 0).	 Its	 high	 value	 indicates	 that	 the	
company	is	highly	connected,	so	firms	can	control	and	brokerage	knowledge	in	
the	network	(Knoke	and	Yang	2008).	In	the	research	of	the	formation	of	inter-




the	 large	 number	 of	 R&D	 ties	make	 an	 organization	 central	 connected,	 while	







that	 the	 company	 collaborates	 with.	 Innovation,	 particularly	 complex	 and	




to	 the	 relationship	between	universities.	The	 incremental	 innovation	relies	on	
partnering	with	customers,	while	radical	innovation	demands	more	interaction	
with	suppliers	(Pittaway,	Robertson	et	al.	2004).	Both	 incremental	and	radical	
innovations	 are	 important	 for	 companies	 to	 achieve	 successful	 innovation.	
Another	study	shows	that	organizations	with	better	global	positions	can	more	
easily	reach	varied	resources	in	pursuit	of	novelty,	and	these	opportunities	can	








Another	 important	 dimension	 of	 a	 firm’s	 network	 is	 the	 degree	 of	 the	
connectivity	 between	 a	 firm’s	 partners.	 A	 structural	 hole,	 by	 definition,	 is	 a	
relationship	 of	 non-redundancy	 between	 two	 nodes	 (Burt	 2009).	 In	 Figure	 8,	
the	 gap	 between	 A	 and	 C	 is	 a	 structure	 hole	 with	 B	 bridging	 the	 hole	 and	
providing	 the	 network	 benefits	 that	 are	 in	 some	 degree	 additive	 rather	 than	
overlapping.	 The	 structural	 hole	 creates	 a	 competitive	 advantage	 for	 the	 firm	
whose	 network	 spans	 the	 hole	 which	 brings	 the	 advantage	 by	 increasing	 the	
value	of	cooperation;	moreover,	the	firm	in	the	structural	hole	is	able	to	broker	
the	 flow	 of	 knowledge	 between	 two	 sides	 and	 control	 the	 projects	 that	 bring	
together	 the	 firm	 from	 the	 opposite	 side	 (Burt	 2002).	 The	 organizations	 on	
either	side	of	a	structural	hole	 transfer	 the	 information	 in	different	 flows,	and	
the	 structural	 hole	 enables	 the	 organization	 to	 reach	 more	 organizations	
indirectly	with	less	redundant	information.	The	evidence	shows	that	there	is	a	
brokerage	 advantage	 in	 producing	 ideals	 (Burt	 2004).	 The	 organization	
bridging	 the	 structural	 hole	 has	 an	 edge	 in	 information	 about	 both	 sides;	
therefore	 the	 organization	 brokers	 the	 connection	 between	 two	 sides	 and	
enjoys	the	economic	benefits	of	controlling	the	collaboration.	The	brokerage	is	
more	 valuable	 for	 the	 network	 in	 which	 organizations	 are	 closely	
interconnected	 (Burt	 2009).	 According	 to	 the	 research,	 in	 a	 network	 where	




	“Social	 capital	 is	 the	 sum	of	 the	 resources,	 actual	or	virtual,	 that	accrue	 to	an	
individual	or	a	group	by	virtue	of	possessing	a	durable	network	of	more	or	less	
institutionalized	 relationships	 of	 mutual	 acquaintance	 and	 recognition	
(Bourdieu	and	Wacquant	1992)”.	The	source	of	social	capital	is	derived	from	the	










The	 brokerage	 across	 the	 structural	 hole	 is	 social	 capital,	 the	 networks	 that	
span	 structural	 hole	 are	 correlated	 with	 learning,	 creativity,	 adaptive	
implementation,	 and	 more	 positive	 evaluations	 (Burt	 2002).	 But,	 a	 study	
provides	 an	 example	 of	 the	 distinctions	 between	 social	 capital	 and	 structural	
hole.	In	the	early	stage	of	network	formation,	structural	holes	are	more	valuable,	
but	 as	 the	 network	 becomes	 more	 well-established,	 the	 startups	 prefer	 to	
increase	 social	 capital	 rather	 than	 exploiting	 structural	 holes,	 because	 the	




has	 focused	 on	 examining	 the	 impact	 of	 the	 actors’	 position	 and	 ties	 in	 the	
network	 or	 the	 network’s	 structure.	 Before	 2000,	 few	 studies	 had	 applied	
longitudinal	data	 to	 analyze	network	and	 little	 attention	had	been	paid	 to	 the	
evolution	 of	 the	 entire	 network.	 A	 study	 about	 the	 biotechnology	 industry	
accounts	for	the	dynamics	of	innovation	network	during	the	period	from	1988	
to	1999,	and	its	results	 indicated	that	the	network	had	become	more	cohesive	
and	 diverse	 (Powell,	 White	 et	 al.	 2005).	 It	 also	 indicated	 that	 the	 early	
dominator-large	 multinationals	 and	 first-generation	 biotech	 firms	 had	
collaborated	to	commercialize	the	lead	products.		
	




the	 network	 dynamics	 are	 generated	 from	 a	 field	 where	 social,	 economic,	
political	and	scientific	factors	shape	the	patterns	of	actors’	behavior.	Therefore,	









to	 find	 that	 innovation	 should	 be	 viewed	 as	 changes	 in	 a	 complete	 system,	
which	 includes	 knowledge,	 facilities	 and	 products,	 social	 and	 political	
environment.	Compared	with	 the	network	model	of	 innovation,	which	 focuses	
on	the	’network’,	the	system	model	of	innovation	stresses	on	the	‘actor’	and	the	
‘network’.	 As	 discussed	 in	 2.3,	 the	 innovation	 network	 approach	 studies	
knowledge	 generation	 and	 diffusion	 based	 on	 network	 structure.	 In	 contrast,	




The	 social	 dimension	of	 the	 innovation	had	been	 ignored	 for	 a	 long	period	of	
time,	 because	 the	 technical	 change	 was	 considered	 as	 a	 socially	 exogenous	
phenomenon	 (Schienstock	 and	 Hämäläinen	 2001).	 However,	 innovation	 is	 a	
socially	 embedded	 process,	 and	 it	 emerges	 among	 social	 organizations.	 The	
process	of	learning	involves	a	variety	of	social	actors	from	different	parts	of	the	
economic	 structure.	 The	 narrow	 definition	 of	 the	 actors	 in	 the	 system	 of	
innovation	 includes	 firms,	 universities,	 research	 intuitions,	 and	 government	
technology	 agents.	 The	wide	 definition	 of	 the	 innovation	 system	 includes	 the	
organizations	 facilitating	 the	 learning	 process	 and	 providing	 additional	 input	
into	 the	 innovation	 process.	 Examples	 of	 supporting	 organizations	 include	
training	 organization,	 banks,	 venture	 capitalists,	 and	 government	 agents.	
Altogether,	 the	 innovation	 system	 includes	 “all	 important	 economic,	 social,	
political,	 organizational,	 institutional	 and	 other	 factors	 that	 influence	 the	
development,	diffusion	and	use	of	innovations	(Edquist	2005)”.			
	
In	an	effort	 to	 further	develop	 the	complex	adaptive	model	of	 innovation,	 it	 is	








As	 shown	 in	 Figure	 9,	 linear	 systems	 have	 a	 very	 high	 level	 of	 certainty	 (the	
outcomes	 from	 actions)	 and	 agreement	 (among	 the	 agents	 involved	 in	 the	
actions),	 so	 they	 are	 easily	 controlled	 and	 planned.	 For	 chaos	 systems,	 there	
have	 very	 little	 certainty	 and	 agreements,	 so	 they	 produce	 very	 intricate	 and	
unpredictable	 dynamics.	 The	 complex	 system	 is	 a	 state	 between	 order	 and	







Complex	 behaviors	 that	 arise	 as	 a	 result	 of	 non-linear	 interactions	 between	
different	 components	 of	 the	 system	 at	 different	 levels	 are	 a	 feature	 of	 both	
natural	 systems	 such	 as	 the	 brain	 or	 the	 immune	 system	 as	well	 as	 artificial	

































Independent	 Agents	 The	 system	 is	 composed	 of	 independent	 agents	 that	
interact	and	adapt	to	learn	(Holland	2006).	Their	behavior	is	based	on	“physical,	




et	 al.	 2005).	 In	 the	 non-linear	 system,	 the	 degree	 of	 change	 (input)	 is	 not	
correlated	with	 the	 outcomes	 (output)	 of	 the	 system.	 A	 large	 stimulus	 to	 the	
system	may	 exert	 a	 little	 or	 no	 influence	 on	 the	 output.	 The	 behavior	 of	 the	
system	 exceeds	 the	 sum	 of	 all	 individual’s	 behavior.	 As	 a	 result,	 the	 system	
behavior	may	show	features	of	randomness	or	chaos	(Rouse	2000).		
	
Emergent	 The	 agents	 in	 the	 system	 are	 intelligent;	 they	 can	 learn,	 gain	
experience	and	change	their	behavior	accordingly.	Because	of	the	adoption	and	
learning,	behavior	patterns	emerge.	Continual	creativity	is	an	inherent	state	of	
the	 system.	 In	 order	 to	 adapt	 to	 the	 changing	 environment,	 new	 elements,	
behavior,	 and	 idea	 will	 spring	 up	 in	 the	 system.	 It	 makes	 the	 system	
unpredictable.		
	
Self-organization	 Self-organization	 is	 the	 unique	 characteristic	 of	 complexity	
science	 (Kaufmann,	 1995;	 Holland,	 1998).	 There	 is	 no	 central	 control	 in	 the	
system.	A	central	body	or	master	actor	does	not	control	other	agents’	individual	











the	 fierce	environment	without	any	connections.	They	are	not	 isolated,	 rather	
than	 they	 are	 connected	 to	 other	 organizations	 to	 get	 access	 to	 external	
resources.	This	has	been	addressed	in	2.2.3.	
	
Non-linearity:	 Firms	 in	 the	 system	 innovate	 through	 collaborations	 built	 on	
complex	 relations	with	 reciprocity	and	 feedback	mechanisms.	The	outcome	of	




Emergent:	Different	 types	 of	 collective	 dynamics	 and	 new	 system	 properties	
emerge	 due	 to	 interactions	 amongst	 organizations	 (Schweitzer	 and	
zimmermann	 2001).	 The	 emergent	 properties	 not	 only	 depend	 on	 the	
organizations	 and	 their	 relationships	 but	 also	 on	 the	 external	 conditions,	 for	
instance,	 regulations,	 standards,	 market	 and	 so	 on.	 Scholar	 claims	 that	 the	
sectoral	 system	 of	 innovation	 is	 “a	 collection	 of	 emergent	 outcome	 of	 the	
interaction	and	co-evolution	of	actors	and	institutions	(Malerba	2002)”.	
	
Self-organization:	 The	 interactions	 give	 rise	 to	 emergent	 properties	 that	 are	
the	consequence	of	self-organization,	which	is	the	result	of	the	system	without	
central	controller	(Tapsell	and	Woods	2010).	As	learning	leads	to	the	adaption	
and	 new	 organizational	 structures	 and	 processes	 help	 organizations	 solve	
technological	problems	or	gain	competitive	advantages,	self-organization	takes	
place	 (Rycroft	 and	 Kash	 2004).	 Technological	 innovation	 is	 featured	 by	 self-
organization	 process	 in	 companies	 and	 other	 organizations.	 The	 innovation	









The	matching	 four	characteristics	with	CAS	reveal	 that	 the	 innovation	process	
can	be	considered	as	an	adaptive,	evolutionary	process	in	the	complex	system.	







The	 CAS	 model	 of	 innovation	 represents	 a	 paradigm	 shift	 in	 the	 way	 we	
understand	the	interaction	of	innovation	and	social-economic	development.	The	
model	 transcends	 the	 prior	 models	 as	 it	 recognizes	 the	 importance	 of	 the	
collaborative	 knowledge	 creation	 and	 socio-economic	 environment.	 An	
increasing	 number	 of	 researchers	 have	 tried	 to	 explore	 the	 application	 of	 the	
CAS	in	the	study	of	 innovation,	 including	the	invention	(Fleming	and	Sorenson	
2001),	 the	diffusion	of	 innovation	(Rogers,	Medina	et	al.	2005),	organizational	
learning	 (Carlisle	 and	 McMillan	 2006),	 new	 product	 development	 (McCarthy,	
Tsinopoulos	et	al.	2006),	and	pharmaceutical	industry	(Smith	2012).	
	
The	 most	 important	 tool	 for	 analyzing	 the	 complex	 adaptive	 model	 of	
innovation	is	the	agent-based	model	using	genetic	algorithms	or	artificial	neural	
networks.	 	 The	 simulation	 of	 the	 CAS	 model	 of	 innovation,	 executed	 on	










Overall,	 we	 can	 conclude	 that	 innovation	 focuses	 on	 all	 activities,	 from	 basic	
research	 to	 the	 products.	 Knowledge	 is	 the	 foundation	 of	 innovation,	 while	
learning,	 as	 the	 core	 of	 innovation,	 generates	 new	 knowledge	 and	 improves	









• The	 process	 of	 the	 innovation	 is	 not	 linear.	 Instead,	 it	 is	 entirely	 non-
linear,	 and	 has	 sub-processed	 that	 are	 connected	 by	 multiple	 loops.	










• The	 systems	 approach	 of	 innovation	 adopts	 a	 holistic	 and	
interdisciplinary	 perspective.	 The	 ‘holistic’	 nature	 is	 reflected	 by	 the	
system	approach	attempting	 to	encompass	 the	 important	determinants	
of	 innovation.	 Similarly,	 the	 approach	 is	 ‘interdisciplinary’	 in	 that	 it	
integrates	perspectives	from	various	social	science	disciplines,	including	









• The	basic	principle	 of	 the	 SI	 approach	 is	 that	 innovation	does	not	 take	
place	 in	 isolation.	 Relations	 are	 central	 to	 the	 innovation	 process.	 The	
systematic	approach	of	SI	addresses	the	innovation	in	a	systematic	way.	
The	 system	 of	 innovation	 is	 composed	 of	 various	 determinants,	 which	
interact	 with	 each	 other.	 The	 SI	 approach	 is	 becoming	 increasingly	
important	for	policy-makers	to	achieve	their	economic	and	social	goals.	
	
• The	National	 Systems	 of	 Innovation	 (NSI)	 and	 the	Regional	 Systems	 of	
Innovation	(RSI)	approaches	use	geographic	delineations	to	characterize	
the	 systems.	 The	 Sectoral	 System	of	 Innovation	 (SSI)	 approach	 focuses	
on	 certain	 sectors	 in	 terms	 of	 knowledge	 and	 products.	 Due	 to	
differences	between	 the	sectors,	 the	dynamics	of	 innovation	also	differ.	
The	SSI	provides	a	new	methodology	for	analyzing	innovation	system.	It	
is	 a	 heuristic	 method	 for	 understanding	 the	 complexity	 of	 technology	
change,	innovation,	and	policy.		
	
• In	 recent	 years,	 the	 complex	 adaptive	 innovation	 model	 that	 has	
emerged	is	rooted	in	complexity	science.	It	is	complex	in	that	the	system	
is	 a	 dynamic	 network	 of	 interactions,	 while	 it	 is	 adaptive	 because	 the	
individuals	 and	 collective	 behaviors	 evolve	 and	 self-organize	 according	
to	the	initial	condition	and	the	changing	environment.	
	
• 	With	 features	 of	 independent	 actors,	 non-linearity,	 emergence,	 self-
organization,	the	complex	adaptive	system	is	a	powerful	way	to	describe	
the	 innovation	 system	 of	 the	 orphan	 drug	 in	 the	 US.	 The	 CAS	 is	 an	
important	 tool	 to	 understand	 factors	 that	 influence	 the	 evolution	 of	










by	 several	 legislations	 since	 the	 1980s,	 including	 the	 Patent	 and	 Trademark	








designed	 to	 prompt	 genetic	 research,	 since	 FDA	 approval	 for	 this	 can	 be	
obtained	 by	 submitting	 bioequivalence	 studies	 without	 conducting	 the	 costly	
clinical	 trials.	 It	 also	 offered	 an	 additional	 period	 of	 marketing	 exclusivity	 to	
cover	 the	 time	a	patented	pipeline	drug	remained	 in	development.	The	aim	of	
Hatch-Waxman	 Act	 is	 to	 balance	 the	 incentives	 for	 encouraging	 innovation	
among	drug	companies	with	 the	opportunities	 for	 facilitating	market	entry	by	




Another	 important	 legislation	 is	 the	 ODA,	 which	 differs	 from	 the	 afore-
mentioned	acts	by	focusing	on	a	particular	set	of	diseases.	The	orphan	drug	is	
developed	specially	to	treat	rare	conditions	that,	by	definition,	affect	fewer	than	
200,000	 people	 in	 the	 United	 States.	 The	 main	 obstacle	 to	 orphan	 drug	
development	is	the	complex	and	costly	FDA	approval	process	(Pulsinelli	1999).	





companies	only	had	 to	demonstrate	 the	safety	and	 labeling	 the	drug	properly.	
After	 the	 amendment	 of	 Food,	 Drug	 and	 Cosmetic	 Act	 in1962,	 efficacy	 was	
added	 to	 the	 drug	 approval	 process.	 Since	 then,	 the	 FDA	 had	 become	 more	
demanding	before	approving	drugs,	and	drugs	have	had	to	cross	more	hurdles	








common	 disease	 that	 affects	 a	 large	 number	 of	 people,	 and	 drug	 companies	
could	 only	 recover	 the	 cost	 of	 development	 from	 the	 large-scale	 sales	 of	 the	
drugs.	The	profitability	of	these	drugs	was	reinforced	with	the	patent	protection,	
which	entitles	drug	 companies	 to	 take	advantage	of	 an	exclusive	market	 right	
(Pulsinelli	 1999).	 The	 size	 of	 the	 market	 combined	 with	 patent	 protection	
determined	 the	 type	 of	 drug	 marketed	 and	 the	 ways	 drugs	 were	 marketed	





Moreover,	 it	 was	 difficult	 to	 develop	 drugs	 affecting	 few	 people.	 Firstly,	
although	 in	 some	 cases	 the	 small	 number	 of	 patients	 made	 orphan	 drug	
development	 less	 expensive	 and	 time-consuming	 than	 non-orphan	 drugs,	 the	
small	number	of	patients	made	the	design	of	effective	clinical	 tests	 for	orphan	
drug	 approval	 more	 difficult	 compared	 with	 non-orphan	 drugs.	 Most	 orphan	
drugs	 were	 not	 eligible	 for	 patent	 protection,	 so	 other	 companies	 can	 easily	
manufacture	 and	 sell	 the	 same	 drug	 without	 incurring	 drug	 approval.	 The	
competition	 among	 them	would	 decrease	 profitability,	which	 exacerbated	 the	









While	 a	 single	 rare	 disease	 affects	 very	 few	 people,	 the	 total	 number	 of	 the	
people	 suffering	 from	 all	 the	 different	 rare	 diseases	 is	 huge.	 There	 are	 over	
7,000	 rare	 diseases	 affecting	 approximately	 30	 million	 US	 patients.	 Patients	
suffering	 from	 the	 rare	 disease	 should	 be	 given	 the	 same	 opportunity	 of	
receiving	safe	and	effective	 treatments	as	other	patients	with	more	 frequently	
occurring	disorders.	Therefore,	 the	US	government	 started	 to	pay	attention	 to	
solve	 this	 problem	 in	 the	 early	 1980s.	 The	 National	 Organization	 for	 Rare	
Disease	 (NORD),	 led	 by	 Abbey	 Meyers,	 had	 played	 a	 very	 important	 role	 in	
promoting	orphan	drug	legislation.		
	
In	 1983,	 President	 Ronald	 Reagan	 signed	 the	 United	 States	 Orphan	 Drug	 Act	
into	law.	The	ODA	is	not	only	the	outcome	of	collaboration	between	the	industry	
and	 government,	 but	 it	 is	 also	 a	 good	 example	 of	 the	 influence	 of	 patient	
advocacy	 (EURORDIS	 2008).	 Since	 then,	 it	 has	 become	 the	 most	 successful	
legislation	 in	 public	 health	 and	 has	 been	 the	 foundation	 of	 designing	 similar	
legislation	 in	 different	 countries.	 For	 example,	 legislations	 to	 improve	 drug	
development	for	the	rare	disease	were	introduced	in	Singapore	in	1991,	Japan	




The	 ODA	 has	 successfully	 brought	 forth	 drugs	 for	 rare	 diseases	 in	 an	
unprecedented	 number	 and	 given	 hope	 to	 millions	 of	 patients.	 In	 the	 25th	
anniversary	of	the	US	ODA	in	2008,	 it	 is	estimated	that	over	17	million	people	








The	 management	 of	 the	 orphan	 drug	 is	 a	 challenging	 task	 for	 all	 countries.	
Although	there	are	over	400	orphan	drugs	reaching	the	market,	it	is	a	very	small	
number	 compared	 to	 5000	 rare	 diseases.	 As	 the	 number	 of	 orphan	 drug	




a	 series	 of	 amendments	 after	 1983.	 Then,	 the	 second	 section	 discusses	 the	
influence	of	the	ODA	in	terms	of	the	number	of	marketed	orphan	products,	the	
expansion	 of	 biotechnology	 companies,	 and	 the	 development	 of	 personalized	
drugs.	 Thirdly,	 the	 ODA	 is	 controversial	 in	 terms	 of	 driving	 orphan	 drug	







Drug	 discovery	 and	 development	 is	 a	 long,	 uncertain,	 and	 expensive	 process.	
Hence,	drug	companies	were	 reluctant	 to	 invest	 in	R&D	 for	 rare	diseases	 that	
affect	a	relatively	small	number	of	the	population	unless	they	can	be	assured	of	
a	 good	 return	 on	 their	 investment.	 The	ODA	passed	 by	 Congress	 in	 1983	 has	
created	political	incentives	to	stimulate	research	organizations	to	participate	in	







The	 ODA	 has	 been	 beneficial	 not	 only	 to	 the	 patients	 suffering	 from	 the	 rare	
disease	 but	 also	 to	 innovation	 in	 pharmaceutical	 industry	 (Yin	 2008).	 The	







market	 exclusivity	 for	 approved	 orphan	 drugs.	 Before	 the	 ODA,	 patent	
protection	 was	 the	 only	 way	 to	 protect	 the	 product	 from	 imitation	 and	







superior	 protection	 to	 the	 patent	 for	 orphan	 drugs	 (Dear,	 Lilitkarntakul	 et	 al.	
2006).	Firstly,	it	is	easier	to	demonstrate	the	orphan	status	of	a	drug	for	market	
exclusivity	than	to	demonstrate	the	novelty	of	the	drug	for	patent.	Some	drugs	
are	 not	 eligible	 for	 patent	 protection	 as	 they	 have	 been	 synthesized	 and	
marketed	before	the	understanding	of	their	medical	use,	whereas	they	can	get	
market	protection	if	they	are	granted	with	the	orphan	designation.	For	example,	
albuterol,	 clonidine	 and	 caffeine	 are	 not	 eligible	 for	 patent	 protection	 but	
eligible	 for	orphan	drug	market	 exclusivity.	 Secondly,	 patents	 are	 applied	 and	
awarded	 in	 the	early	 stage	of	drug	development,	which	wastes	many	years	of	
patent	 protection	 in	 advance	 of	 drug	 commercialization.	 On	 the	 contrary,	 the	
market	 exclusivity	 of	 orphan	 drugs	 is	 valid	 from	 the	 date	 of	 FDA	 market	
approval	 without	 the	 loss	 of	 protective	 years	 on	 product	 development.	










would	 not	 be	 sufficient	 to	 recoup	 their	 R&D	 costs	 if	 there	 is	 no	 market	
protection.	Market	exclusivity	makes	the	orphan	drug	profitable.	On	one	hand,	it	
can	 help	 drug	 companies	 to	 recover	 the	 cost	 of	 drug	 development,	 so	 this	
incentive	provides	motivation	for	manufacturer	to	develop	orphan	drug;	on	the	
other	hand,	the	protection	from	competition	allows	drug	companies	to	charge	a	






of	 the	 amount	of	money	 spent	on	 clinical	 trials.	 In	 theory,	50%	 tax	 credit	 has	
stimulated	orphan	drug	innovation	by	directly	influencing	the	development	cost	
margin	 (Yin	 2008).	 The	 credit	 has	 decreased	 the	 cost	 of	 conducting	 human	
clinical	trials,	which	tests	the	efficacy	and	safety	of	drugs	for	FDA	approval	and	
accounts	 for	a	 large	proportion	of	 the	 total	cost	of	drug	development	 (DiMasi,	
Hansen	et	al.	2003).		
	
The	 incentive	of	 tax	 credits	works	under	 the	 condition	 that	 the	 company	 that	
develops	the	orphan	drugs	has	the	income	from	the	sales	of	other	products	or	
from	 the	 commercial	 distribution	 of	 unapproved	 orphan	 drugs	 (Seoane-
Vazquez,	Rodriguez-Monguio	et	al.	2008).	However,	the	provision	of	tax	credits	
does	 not	 match	 the	 nature	 of	 drug	 development	 in	 the	 biopharmaceutical	
industry,	 which	 make	 this	 incentive	 less	 effective	 (Pulsinelli	 1999).	 On	 one	
hand,	the	process	of	drug	development	includes	human	clinical	trials	and	animal	





expensive	as	 the	 former	one.	On	 the	other	hand,	 the	credits	cannot	be	carried	








on	 the	 safety	and/or	effectiveness	of	products	 for	 rare	diseases	or	 conditions,	
where	 there	 is	 no	 existing	 therapy	 or	 the	 funded	 product	 superior	 to	 the	
existing	treatment.	The	grants	in	the	1983	Act	only	defrayed	the	cost	of	clinical	
tests,	 while	 the	 Amendments	 in	 1988	 extended	 the	 grant	 coverage	 to	 all	 the	
tests.	The	grants	have	supported	 the	orphan	product	development	 in	a	 timely	





The	 Orphan	 Products	 Grants	 is	 the	 FDA‘s	 largest	 grants	 program.	 The	 OOPD	
engages	 in	 this	 program	 (Goodman	 2010).	 Before	 providing	 funds,	 the	 OOPD	
reviews	the	grant	application	to	check	whether	the	program	requirements	are	
satisfied	 and	 convene	peer	 review	panel	 to	 select	 the	 best	 scientific	 proposal.	
After	 that,	 the	 OOPD	 conducts	 tests	 to	 guarantee	 that	 the	 products	 meet	 the	
























$14,035,060 0 $3,033,156 $17,167,256 
FY 2008 
Appropriation 
$14,035,060 0 $3,656,101 $17,691,161 
FY 2009 
Appropriation 
$14,035,060 $2,000,000 $3,805,000 $19,840,060 
FY 2010 
Appropriation 
$14,035,060 $3,000,000 $5,074,741 $22,785,290 
FY 2011 
Appropriation 
$14,035,060 $3,000,000 $6,643,628 $23,678,688 
FY 2012 
Appropriation 
$14,035,060 $3,000,000 $6,601,140 $23,636,200 
FY 2013 
Appropriation 
$12,960,744 $3,000,000 $7,179,153 $23,139,897 
FY 2014 
Appropriation 
$14,035,060 $3,000,000 $7,710,105 $24,745,165 
FY 2015 
Appropriation 




given	 fiscal	 year.	 The	 major	 portion	 goes	 towards	 the	 continued	 funding	 of	
previously	approved	grants.	For	instance,	Orphan	Grants	Program	supported	22	
new	clinical	studies	and	about	40	continued	studies	of	prior	approved	grant	in	
FY	 2009,	with	 a	 total	 funding	 of	 $14,035,060	 	 (Table	 5).	 In	 FY	 2014,	 15	 new	
grants	 were	 awarded	 (out	 of	 99	 grant	 applications),	 and	 the	 grants	 program	
also	continued	support	for	approximately	60	other	ongoing	clinical	projects.	
	
Since	 the	 inception	 of	 this	 program,	 OOPD	 has	 received	 more	 than	 1800	
applications,	 reviewed	 over	 1400	 applications	 and	 funded	 over	 700	 clinical	
studies.	 More	 than	 55	 orphan	 products	 approved	 by	 FDA	 for	 marketing	 are	
supported	by	the	Orphan	Grant	Program,	and	approximately	10%	of	the	orphan	
product	 approvals	 are	 funded	 by	 this	 program	 (FDA	 2016).	 A	 number	 of	
outcomes	 from	 the	 funded	 research	 have	 been	 published	 in	 peer-reviewed	
journals,	 which	 has	 contributed	 a	 lot	 to	 the	 health	 of	 people	 suffering	 rare	
diseases	 worldwide.	 The	 achievements	 have	 demonstrated	 that	 the	 Orphan	












However,	 the	 Grants	 have	 been	 contributing	 less	 to	 the	 cost	 of	 conducting	
clinical	tests.	On	the	one	hand,	as	shown	in	Figure	10,	there	is	a	steady	increase	
of	 Grants	 from	 1983	 to	 1994,	 as	 the	 amount	 adjusted	 for	 inflation	 started	 to	
decrease	from	1995.	Since	2005,	the	nominal	value	of	the	Grants	has	kept	at	$14	
million	with	a	slight	decrease.	On	the	other	hand,	the	rapid	increase	in	the	cost	
of	clinical	 trials	and	 the	complexity	of	clinical	 trial	design	 for	 the	orphan	drug	
has	decreases	the	number	of	new	OOPD	grants.	From	1995,	the	number	of	new	
grants	 has	 decreased	 and	maintained	 at	 around	 20	 (Figure	 11).	 For	 instance,	











Due	 to	 the	 high	 complexity	 and	 cost	 of	 FDA	 approval,	 drug	 companies	 have	
faced	 too	 many	 uncertainties	 to	 secure	 the	 approval.	 FDA	 provides	 direct	
assistance	 for	 sponsors	 to	 facilitate	 the	 process	 of	 approval	 by	 providing	 the	
information	 about	 the	 kind	 of	 tests	 drug	 companies	 need	 to	 complete	 and	




The	 OOPD	 in	 FDA	 keeps	 a	 close	 relationship	 with	 research	 organizations,	
patient	advocacy	groups,	and	other	government	agencies.	It	helps	the	sponsors	
in	 providing	 expertise	 about	 clinical	 trial	 design	 and	 review.	 The	 OOPD	 also	
provides	 training	 courses	 for	 drug	 companies	 on	 orphan	 drug	 discovery	 and	
development.	The	strong	communications	between	companies	and	FDA	lead	to	
the	 increase	 of	 the	 successful	 outcomes	 (Pariser	 2010).	 Due	 to	 the	 scare	
resources	 of	 organizing	 clinical	 trials,	 FDA	 provides	 flexibility	 to	 the	 orphan	
drug	development.	The	FDA	reviews	the	clinical	data	and	makes	the	decision	on	







The	 program	 of	 fee	 exemptions	 and	 waivers	 was	 started	 in	 1992	 under	 the	
PDUFA	(Prescription	Drug	User	Fee	Act).	The	PDUFA	authorizes	FDA	to	collect	
fees	 from	 drug	 companies,	 and	 directs	 FDA	 to	 waive	 and	 reduce	 fees	 under	
certain	 circumstances,	 such	 as	 when	 paying	 fee	 is	 an	 obstacle	 to	 innovation	
because	of	 the	 limited	resources	available	 to	sponsors,	or	when	 the	 fees	 to	be	
paid	will	be	more	than	the	expected	costs	of	reviewing	drug	application	or	when	
it	 is	necessary	 to	protect	 the	public	health	 through	 fee	exemption	and	waiver.	



























Another	 way	 the	 ODA	 stimulates	 drug	 innovation	 is	 the	 open	 protocol	 for	
clinical	trials.	The	provision	is	applied	for	designated	orphan	drugs	that	are	 in	











can	also	receive	answers	 to	 the	questions	relating	 to	 the	criteria	 for	approval.	
 FY2007 FY 2008 FY 2009 FY 2012 FY 2011 
Orphan Product 21.3 27.8 23.8 21.8 32.5 
Previously Submitted 4.5 4.0 7.5 4.0 5.0 
Total Exemptions 25.8 31.8 31.3 25.8 37.5 
Total Value of Exempted 
Application Fees 
$23,077,150 $37,401,500 $38,975,000 $36,191,625 $57,825,000 
Orphan Product Fee Exemptions  14 16 27 27 
Value of Product Fee Exemptions  $910,420 $1,144,320 $2,152,440 $2,336,040 
Orphan Establishment Fee 
Exemptions 
 
5.24 7.45 11.49 13.79 
Value of Establishment Fee 
Exemptions 
 
$2,056,963 $3,169,869 $5,252,314 $6,857,382 
Total Product and Establishment 
Fee Exemptions 
 
$2,967,383 $4,314,189 $7,404,754 $9,193,422 






for	 it.	 The	 sponsors	 do	 not	 need	 orphan	 drug	 designation	 to	 receive	 protocol	
assistance.	 It	 is	an	 important	support	 for	the	orphan	drug	development	taking	
the	unique	challenges	associated	with	developing	these	products	into	accounts.	
However,	 due	 to	 the	 changes	 in	 the	 FDA	 regulations	 and	 the	 rules	 of	
Investigational	 New	 Drug,	 and	 New	 Drug	 Application	 process,	 the	 protocol	
assistance	is	seldom	used	in	the	US	(Shah	2006).		
	
Overall,	 the	ODA	 consists	 both	market-pull	 and	 technology-push	 incentives	 to	
reduce	 the	 cost	 of	 drug	 development	 and	 increase	 the	 possibilities	 of	making	
profits	 by	 market	 protection	 (Milne	 and	 Tait	 2009).	 As	 shown	 in	 Figure	 12,	
these	 incentives	support	orphan	drug	 innovation	 in	multiple	ways	and	benefit	
various	 actors	 in	 the	 drug	 R&D	 processes.	 Both	 large	 and	 small	 companies	
benefit	 from	 seven-year	market	 exclusivity;	 tax	 credits	 are	more	 valuable	 for	
drug	 companies	 which	 have	 revenues	 than	 for	 start-ups	 without	 marketed	








































All	 the	 incentives	 in	 the	 1983	 Orphan	 Drug	 Act	 have	 encouraged	 drug	







affect	 very	 few	 patients	 that	 drug	 companies	 cannot	 recover	 the	 cost	 of	 drug	
development	from	the	sale	of	drugs.	The	vague	definition	made	drug	companies	




to	 include	diseases	 affecting	 fewer	 than	200,000	people	 in	 the	US.	During	 the	
five	months	after	 the	amendment,	 the	number	of	orphan	designations	granted	
by	 the	FDA	 increased	 from	22	 to	53.	According	 to	 this	definition,	 the	Office	of	
Rare	 Diseases	 Research	 (ORDR)	 listed	 6845	 rare	 diseases.	 There	 are	






ODA	 was	 that	 the	 drug	 must	 be	 unpatented	 or	 un-patentable,	 which	 created	
many	problems	in	some	cases.	For	instance,	some	drugs	were	patented,	but	the	







Congress	 resolved	 this	 problem	 by	 simply	 removing	 this	 requirement.	
Therefore,	FDA	can	provide	market	exclusivity	to	both	patented	and	unpatented	
orphan	 products.	 Thus,	 orphan	 drug	 designations	 are	 granted	 independent	 of	
the	patent	system	(Wellman-Labadie	and	Zhou	2010).		
	
This	 amendment	 also	 extended	orphan	 status	 to	 antibiotics	 and	 established	 a	
National	Commission	on	Orphan	Diseases	to	assess	the	public	and	private	sector	
efforts	 on	 developing	 and	marketing	 orphan	 drugs	 (Asbury	 1992).	 The	 1985	
ODA	 amendment	 also	 expanded	 the	 availability	 of	 grants	 to	 support	 all	




The	 1988	 Amendment	 did	 not	 have	 the	 significant	 influence	 that	 previous	
amendments	 did,	 since	most	 simply	 corrected	minor	 errors	 (Pulsinelli	 1999).	
However,	 one	 of	 the	 changes	 is	 that	 sponsors	 can	 apply	 for	 the	 orphan	 drug	
designation	 at	 any	 time	 before	 the	 submission	 of	 the	 application	 for	 drug	
marketing	 approval.	 This	 change	 allowed	 sponsors	 to	 apply	 orphan	 drug	
designation	 for	 any	 unapproved	 use	 of	 the	 drug	 with	 or	 without	 previous	
marketing	approval	for	other	indications	(Seoane-Vazquez,	Rodriguez-Monguio	
et	al.	2008).	Many	orphan	drugs	were	previously	launched	as	non-orphan	drugs	
or	 currently	 in	 the	process	 of	 non-orphan	drug	 approval,	 and	 they	were	 later	
granted	 marketing	 approval	 for	 treating	 rare	 diseases.	 Nearly	 half	 of	 the	














legislation	 clearer	 and	 orphan	 drug	 innovation	 more	 attractive	 to	 drug	





It	 is	 obvious	 that	 the	 ODA	 has	 played	 an	 important	 role	 in	 motivating	 drug	









drugs	 (9	NMEs,	4	BLAs)	 in	2009.	 In	2012,	more	 than	50%	of	newly	approved	









Someone	 believes	 that	 the	 successful	 approval	 of	 a	 drug	 would	 stop	 further	
innovation	activities	in	the	same	area,	which	is	not	true	for	the	orphan	drug.	In	







Name	 Compound	 Company	 Approval	date	in	US	
Therapeutic	
class	
Ceredase	 Alglucerase	 Genzyme	 1991	 Enzyme	





VPRIV	 Velaglucerase	alfa	 Shire	Plc	 2010	 Enzyme	














The	 ODA	 has	 been	 beneficial	 not	 only	 to	 the	 patients	 suffering	 from	 rare	





There	are	 two	main	manufacturers	 in	 the	biopharmaceutical	 industry,	namely	
pharmaceutical	 companies	 and	 biotechnology	 companies.	 While	 large	
pharmaceutical	 companies	 have	 traditionally	 thrived	 on	 blockbusters,	
biotechnology	firms	have	played	an	important	role	 in	orphan	drug	innovation.	
However,	 because	 the	 blockbuster	 model	 is	 less	 effective,	 pharmaceutical	
companies	have	started	to	consider	orphan	drugs	seriously	to	strengthen	their	




In	 Table	 8,	 the	 top	 10	 pharmaceutical	 companies	 accounted	 for	 half	 of	 the	
orphan	 drug	 sponsored	 by	 pharmaceutical	 companies.	 For	 instance,	 Pfizer,	
Novartis,	 Johnson	 &	 Johnson,	 GlaxoSmithKline,	 AstraZeneca,	 and	 Roche	 had	
contributed	over	25	orphan	designations.	50%	of	orphan	drug	approvals	were	
obtained	 by	 biotechnology	 companies,	 among	 which	 Amgen	 (14	 approved	
orphan	drug),	Genzyme	and	Genentech	(9	and	8	approved	orphan	drugs	each)	
were	 the	 most	 active	 companies.	 The	 earlier	 stage	 of	 orphan	 drug	 R&D	 is	
















can	 be	 attributed	 to	 the	 priorities	 of	 developing	 drugs	 for	 larger	 patients	 to	
make	bigger	profits.	In	addition,	the	ODA	incentives	are	extremely	appealing	for	
start-up	biotechnology	companies.	For	instance,	Genzyme	is	the	first-generation	
biotechnology	 company.	 Ceredase,	 the	 first	 orphan	 drug	 for	 patients	 with	
Gaucher	 disease	 receiving	 FDA	 approval,	 is	 also	 the	 first	 product	 of	 the	
Genzyme.	 In	 2010,	 Genzyme	 became	 the	 world's	 third-largest	 biotechnology	
company,	 and	 it	was	 acquired	 by	 Sanofi-Aventis	 in	 February	 2011.	 There	 are	
very	few	small	biotechnology	companies	with	non-orphan	products,	which	can	





rare	 genetic	 disorder	 where	 patients	 cannot	 produce	 the	 essential	 enzyme,	
glucocerebrosidase,	 to	 break	 down	 fat	 deposits	 in	 cells.	 The	 basic	 research	








Like	 any	 other	 drug	 company,	 Genzyme	 faced	 big	 risks	 of	 drug	 development.	
Even	after	obtaining	FDA	approval,	these	drugs	may	not	be	profitable,	because	
they	may	 face	competition	 from	similar	drugs	and	alternative	 treatments.	The	
ODA	is	of	great	significance	for	the	birth	of	Ceradase,	which	was	believed	with	
the	 limited	potential	market	and	not	qualified	for	patent	protection	(Goldman,	
Clarke	 et	 al.	 1992).	 Genzyme	 launched	 clinical	 trials	 in	 1984	 and	 got	 FDA	
approval	 for	 algucerase	with	 trademarks	 for	 Ceredase	 in	 1991.	 Its	 total	 R&D	
cost	 was	 $58	 million,	 and	 the	 sales	 of	 Ceredase	 were	 $39.6	 million	 in	 1991.	
Three	years	later,	Genzyme	introduced	Cerezyme	that	is	the	second-generation	
product	 of	Ceradase.	 Cerezyme	 cost	 $200,000	per	patients	per	 year.	 It	 is	 now	




One	 of	 the	 significant	 influences	 of	 the	 ODA	 is	 that	 it	 provides	 the	 successful	
model	 for	 other	 countries	 to	 design	 the	 similar	 legislation.	 Based	 on	 the	
successful	experience	in	the	United	States,	European	Union	established	Orphan	
Drug	Regulation	in	1999	with	the	aim	to	promote	the	development	of	drugs	for	







are	 several	 differences	 between	 them.	 The	 designation	 and	 marketing	
exclusivity	of	orphan	drugs	are	governed	at	the	European	Union	level,	but	other	






individual	 member	 states,	 so	 the	 implementation	 of	 the	 tax	 credits	 is	 not	
possible	in	the	extensive	range	of	Europe.	Moreover,	orphan	drug	research	also	











































In	 2007,	 the	 US	 and	 European	 drug	 regulatory	 agencies	 started	 to	 adopt	 the	
same	 orphan	 designation	 application	 forms	 for	 both	 agencies.	 This	 approach	
simplifies	 and	 accelerates	 the	 process	 for	 sponsors	 seeking	 orphan	 drug	
designations	 in	 both	 the	 US	 and	 Europe.	 Now,	 about	 50%	 of	 the	 orphan	
designation	 applications	 submitted	 to	 the	 EMA	 are	 done	 in	 parallel	 with	 the	
FDA,	 and	 about	 30%	 to	 40%	 of	 the	 applications	 used	 the	 joint	 FDA-EMA	
application	 forms	 (Mariz,	 Reese	 et	 al.	 2016).	 The	 joint	 orphan	 designation	
application	 has	 enabled	 patients	 with	 rare	 disease	 to	 get	 access	 to	 the	





As	 the	number	of	 the	orphan	drugs	 reaching	 the	market	 is	 increasing,	a	 lot	of	
attentions	 have	 been	 paid	 to	 the	 limitations	 of	 the	 current	 ODA.	 These	
limitations	have	been	viewed	as	a	shortcut	to	faster	market	approval	for	drugs	




from	 rare	 cancers,	 and	 1%	 of	 drugs	 were	 withdrawn	 after	 approval	
(Stockklausner,	Lampert	et	al.	2016).	The	accessibility	and	availability	of	orphan	
drugs	are	questionable.	There	was	approximately	US$	60	billion	 in	 sales	 for	a	
relatively	small	patient	population,	and	patients	paid	twice	for	the	drugs	as	the	
public	 funds	 for	 supporting	 R&D	 as	well	 as	 the	 cost	 of	 treatments	 (Wellman-
Labadie	 and	 Zhou	 2010).	 Moreover,	 in	 order	 to	 subsidize	 the	 lower	 price	 in	
other	 countries,	 drug	 companies	 have	 to	 increase	 the	 drug	 price	 in	 the	 US	














patent	protection,	 the	ODA	protects	orphan	drugs	by	 refusing	 the	 approval	 of	
other	drugs	that	 treat	 the	same	rare	disease.	The	price	of	drugs	under	market	
protection	 is	 higher	 the	 marginal	 cost	 due	 monopoly	 by	 pharmaceutical	
companies	(Cutler	and	Ericson	2010).	Market	exclusivity	is	an	effective	way	to	







orphan	drugs,	 increased	by	127%	in	 the	US,	158%	in	 the	UK,	227%	in	France	
and	 235%	 in	 Germany	 (Danzon	 and	 Furukawa	 2006).	 There	 were	 43	 brand	

















the	 initial	 one	 or	 two	 years	 (Pulsinelli	 1999).	 Furthermore,	 the	 annual	 global	











Elaprase	 Shire	 Type	II	Mucopolysaccharidoses	 375	000	
Naglazyme	 Biomarin	 Type	II	Mucopolysaccharidoses	 365	000	
Folotyn	 Allos	 Lymphoma	peripheral	T	cell 360	000	
Cinryze	 Viropharma	 Hereditary	angioedema	 350	000	




Ceredase/Cerezyme	 Genzyme	 Type	I	Gaucher	disease	 200	000	
Fabrazyme	 Genzyme	 Fabry	disease	 200	000	
Aldurazyme	 Genzyme/Biomarin	 Type	I	Mucopolysaccharidoses 200	000	
	
As	 shown	 in	Table	10,	 there	are	9	orphan	drugs	with	 the	cost	per	patient	per	
year	 over	 US$	 200,000.	 For	 example,	 Soliris,	 used	 to	 treat	 a	 rare	 kidney	
condition,	 costs	 over	 US$	 0.4	 million	 annually,	 making	 it	 the	 most	 expensive	










price	 of	 lots	 of	 orphan	 drugs	 remains	 extremely	 high	 even	 after	 the	 7-year	
market	exclusivity.		
	
Overall,	 the	 current	 pricing	 framework	 of	 orphan	 drugs	 is	 not	 based	 on	 the	







cover	 100%	 of	 the	 cost,	 and	 there	 are	 47	 million	 people	 uninsured	 who	 are	
excluded	 from	 the	 ODA	 benefit	 in	 the	 US.	 (EURORDIS	 2008).	 Moreover,	 the	
increasing	 price	 of	 drugs	 is	 putting	 orphan	 drugs	 beyond	 the	 reach	 of	 many	
people.	 Because	 there	 is	 usually	 no	 alternative,	 the	 access	 to	 orphan	 drugs	 is	
influenced	by	the	affordability	for	rare	disease	patients.	
		









From	 Figure	 14,	 it	 is	 obvious	 that	 compared	 with	 non-orphan	 drugs,	 orphan	



















patient	 population.	 Some	 orphan	 drugs	 are	 not	 originally	 developed	 to	 treat	
diseases	 with	 the	 small	 patient	 population.	 Firstly,	 many	 orphan	 drugs	 have	
been	 proved	 to	 be	 effective	 at	 treating	more	 than	 one	 rare	 disease.	 Secondly,	




For	 example,	 the	 FDA	 approved	 the	 new	 version	 of	 colchicine	 (brand	 name:	
Colcrys)	as	a	 treatment	 for	Familial	Mediterranean	Fever	 (FMF),	and	 the	drug	
developer	received	7-year	market	exclusivity.	Colchicine	is	not	new,	because	the	



































a	generic	prescription	drug	 in	 the	US	since	 the	past	century.	But,	due	 to	some	






This	 story	 reveals	a	major	 limitation	of	 the	ODA.	The	market	protection	as	an	
incentive	to	attract	dug	R&D	is	not	taking	into	consideration	the	real	value	and	
quality	 of	 the	 product.	 To	 discover	 new	 uses	 of	 an	 old	 drug	 should	 be	
encouraged,	 but	 the	 improvement	 of	 public	 health	 is	 the	 ultimate	 goal	 in	




Considering	 potential	 profits,	 the	 repurposing	 of	 an	 established	 drug	 for	









15).	 These	 drugs	 cover	 only	 8%	 of	 7000	 rare	 diseases,	 and	 nearly	 1/3	 of	












to	market,	while	 others	 are	not.	 FDA	approved	Wellstat	Therapeutics'	 uridine	
triacetate	 based	 on	 a	 4-patient	 trial	 for	 the	 treatment	 of	 hereditary	 orotic	
aciduria	 (HOA),	 which	 is	 a	 very	 rare	 indication	 with	 20	 patients	 reported	
worldwide	(Mullard	2015).		
	
Altogether,	 the	abuses	of	 the	ODA	made	 the	orphan	products	enjoy	enormous	
sales	 under	 the	 protection	 of	 the	 legislation	 designed	 to	 stimulate	 the	
development	and	marketing	of	drugs	with	limited	commercial	value.	The	abuse	







The	 limited	 availability,	 high	 price,	 and	 unknown	 safety	 effects	 illustrate	 that	









industry	 leaders	 and	 patients	 (Simoens	 2011).	 Several	 solutions	 have	 been	
proposed	to	enhance	the	availability	of	orphan	drugs	for	rare	disease	patients.	






Several	 proposals	 have	 been	 put	 forward	 to	 change	 the	 duration	 of	 market	
exclusivity.	 The	 Orphan	 Drug	 Amendment	 of	 1992	 proposed	 reducing	 the	
period	 of	 exclusivity	 to	 2	 years	 and	 withdrawing	 the	 exclusivity	 if	 the	 total	
revenue	 exceeds	 $200	 million	 at	 any	 time	 in	 the	 next	 seven	 years.	 The	








pharmaceutical	 companies	 that	 operate	 with	 the	 motivation	 of	 profit-




example.	 Drug	 companies	 in	 Japan	 have	 to	 pay	 1%	 sale	 tax	 on																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
the	 orphan	 drugs	 with	 over	 100	 million	 annual	 profits	 until	 all	 the	 funding	
provided	by	the	government	has	been	repaid	(Cheung,	Cohen	et	al.	2004).	The	
program	 has	 not	 had	 a	 negative	 influence	 on	 stimulating	 orphan	 drug	
development	as	over	100	orphan	products	have	been	approved	since	1993.	It	is	













The	 influence	of	 the	ODA	 is	not	only	 in	 the	area	of	offering	 the	 treatments	 for	
the	patients	suffering	from	the	rare	disease	but	also	in	nurturing	the	expanding	
biotechnology	 sector	 and	 providing	 a	 model	 for	 other	 countries	 to	 enact	 the	
similar	 legislation.	 The	 influence	 of	 the	 act	 has	 spread	 to	 other	 countries.	
Notably,	 laws	 were	 introduced	 to	 improve	 drug	 R&D	 for	 rare	 diseases	 in	
Singapore	in	1991,	Japan	in	1993	and	Australia	in	1997.	
	
The	 success	 of	 the	ODA	 in	 encouraging	 the	 innovation	of	 hundreds	 of	 orphan	
drugs	 is	 undeniable,	 but	 the	 high	 cost	 of	 treatments	 makes	 it	 controversial.	
Since	 the	 objective	 of	 the	 ODA	 is	 to	 stimulate	 the	 development	 of	 drugs	 for	
patients	with	rare	diseases,	it	is	important	to	ensure	that	the	ODA	does	not	lead	
high	prices	that	patients	cannot	afford.	Some	advice	for	 improving	the	current	
ODA	were	proposed,	 but	whether	 this	will	 bring	 about	 the	 expected	effects	 is	
unknown,	such	as	if	the	price	of	orphan	drugs	will	be	lower	without	decreasing	
the	 number	 of	 newly	 marketed	 orphan	 drugs;	 fewer	 orphan	 drugs	 will	 be	
marketed	 at	 lower	 prices;	 or	 fewer	 orphan	 drugs	will	 be	marketed	 at	 higher	
prices.	
	
In	 the	 following	 chapters,	 the	 simulation	 model	 of	 orphan	 drug	 innovation	
system	is	introduced	to	address	the	effectiveness	and	improvements	of	the	ODA.	
Besides	 the	ODA,	 the	 innovation	process,	 the	 actors	 and	 their	 relationships	 in	
the	 system	 are	 the	 important	 components	 in	 the	 orphan	 drug	 innovation	








From	 an	 idea	 to	 an	 approved	 drug	 in	 the	 market,	 orphan	 drug	 innovation	
comprises	 of	 four	 steps:	 discovery,	 designation,	 development	 and	
commercialization.	Drug	designation	is	unique	to	orphan	drug.	Drug	discovery	
and	 development	 are	 complicated,	 expansive	 and	 time-consuming	 processes,	




With	 the	 significant	 advance	 of	 tools	 and	 technologies	 derived	 from	
biotechnology	 and	 genomics,	 in	 the	 recent	 decades,	 pharmaceutical	 research	
has	 evolved	 from	 a	 pattern	 where	 a	 random	 discovery	 dominated	 the	 drug	




FDA	drug	approval	process	 includes	pre-clinical	 studies	 testing	 the	 safety	and	
effectiveness	of	the	drug	in	animals	and	three	phases	of	clinical	trials.	The	drug	
companies	 with	 the	 marketing	 approval	 can	 sell	 the	 drug	 under	 market	
protection.	
	
In	 this	 chapter,	 we	will	 introduce	 the	 entire	 orphan	 drug	 innovation	 process	











Translating	 an	 innovative	 drug	 from	 the	 original	 idea	 to	 a	 potential	 drug	
candidate	is	a	complicated	process.	The	origin	of	the	idea	comes	from	a	variety	
of	 sources,	 such	 as	 academic	 and	 clinical	 research,	 or	 the	 commercial	 sector	
(Hughes,	 Rees	 et	 al.	 2011).	 It	 takes	 many	 years	 to	 build	 up	 a	 collection	 of	
knowledge	 for	 starting	 a	 drug	 discovery	 process,	 and	 the	 new	 knowledge	 is	
developed	through	the	whole	drug	discovery	process.	As	Figure	16	shown,	drug	
discovery	 process	 begins	 from	 initial	 target	 discovery	 and	 validation,	 hit	
identification,	 lead	 optimization	 to	 the	 selection	 of	 a	 candidate	 drug	 for	 the	
further	clinical	trials.	
	
Figure	16   Drug	Discovery	Process	
   
4.1.1	Drug	Discovery	Process	
Drug	discovery	 starts	with	a	disease	or	 clinical	 condition	without	 appropriate	
treatment	 available,	 and	 there	 is	 underlying	 driving	 motivation	 for	 the	
discovery	project.	Most	of	the	fundamental	knowledge	of	drug	discovery	is	from	
research	 organizations,	 which	 further	 develop	 that	 knowledge	 to	 hypotheses	
that	 the	 inhibition	 or	 activation	 of	 a	 protein	 or	 pathway	 will	 lead	 to	 a	
therapeutic	effect	in	a	disease	state.		
	





















proteins	 or	 proteins	 whose	 function	 has	 now	 become	 clearer	 through	 basic	
scientific	research.		
	
Historically,	 drugs	 were	 discovered	 without	 knowledge	 about	 the	 disease.	 A	
large	number	of	early	discoveries	in	the	pharmaceutical	industry	were	through	
serendipity,	where	 thousands	of	chemicals	are	applied	 to	an	assay	 that	allows	
identification	of	compounds	that	produce	the	desired	effect.	Because	drugs	that	
are	 ineffective	 for	 the	disease	or	unsafe	do	not	qualify	 for	FDA	approval,	drug	










Following	 the	 target	 validation	 is	 the	 process	 of	 hit	 identification	 and	 lead	
discovery	 phase.	 Hit	 is	 a	 primary	 active	 compound	 with	 non-promiscuous	
binding	 behavior,	 exceeding	 a	 particular	 threshold	 value	 in	 a	 given	 assay;	 it	







discover	 a	 lead.	 The	 rapid	 development	 of	 computation	 enables	 the	
researchers	 to	 test	 an	 enormous	 number	 of	 compounds	 against	 the	







• Nature	 Researchers	 turn	 to	 nature	 to	 discover	 interesting	 compounds	
for	 treating	 diseases.	 	 For	 instance,	 bacteria	 found	 in	 soil	 and	 moldy	
plants	are	found	and	developed	into	innovative	medical	products.		
	












likely	 to	 interact	with	other	chemical	pathways	 in	 the	body,	 thus	reducing	 the	
potential	for	side	effects	(Innovation.org	2007).	During	lead	optimization,	some	

















in	 the	 lab	 to	 observe	 their	 effects.	 Finally,	 only	 a	 tiny	 proportion	 exhibits	 a	
promising	 potential.	 However,	 random	 screening	 was	 extremely	 successful	
during	 the	 period	 between	 1950s	 and	 1970s.	 A	 number	 of	 the	 significant	















process	 has	 hardly	 been	 successful	 by	 only	 one	 organization	 since	 the	 1990s,	
especially	 for	discovering	an	orphan	drug.	Many	organizations	are	 involved	 in	






the	 formation	 of	 a	 company,	which	 facilitates	 knowledge	 transfer	 from	 lab	 to	








Especially,	 academic	drug	discovery	 is	 an	 ideal	 choice	 to	 tackle	neglected	 and	
orphan	diseases,	because	both	have	insufficient	market	size	to	recoup	the	cost	
of	 development.	 Drug	 discovery	 can	 be	 carried	 out	 using	 public	 funding	 and	
then	the	project	can	be	passed	on	to	drug	companies	for	further	development.	
Moreover,	academic	drug	discovery	provides	a	test	bed	for	the	development	of	
new	 techniques	 of	 drug	 discovery	 and	 research	 in	 the	 practice	 of	 drug	 R&D.	
Although	universities	have	played	an	essential	role	in	drug	discovery,	they	are	






Different	 from	 the	 traditional	 model	 of	 drug	 research	 and	 development,	
advocacy	 groups	 are	 very	 important	 in	 increasing	 awareness	 and	 facilitating	
therapies	 for	 the	rare	disease	patients.	Firstly,	 they	provide	support	 for	early-
stage	 R&D,	 such	 as	 offering	 research	 funds	 and	 tools.	 Raising	 money	 and	




and	 career	 development	 to	 attract	 more	 investigators.	 Secondly,	 patient	
organizations	have	played	an	active	role	in	drug	development	especially	clinical	
trials.	 They	 maintain	 a	 close	 relationship	 with	 FDA	 and	 drug	 companies	 to	
organize	members	to	participate	clinical	trials.	These	patient	groups	evolved	a	
new	 kind	 of	 partnership	with	 industry	 and	 public	 agencies	 to	 bridge	 the	 gap	
between	basic	research	findings	and	approved	products.						
	
There	 are	 two	 main	 large	 patient	 advocacy	 groups	 in	 the	 US:	 National	
Organization	 for	 Rare	 Disease	 (NORD)	 and	 Genetic	 Alliance.	 NORD	 made	











Since	 the	 industry	 funds	 relatively	 little	 basic	 research,	 publicly	 funded	 basic	
research	is	the	basis	for	orphan	drug	development.	The	main	funding	source	for	
basic	 research	on	rare	disease	 is	 from	NIH.	The	number	of	NIH	 funds	granted	
for	different	 rare	diseases	varies	 from	zero	 for	 tetralogy	of	 Fallot	 and	one	 for	
Ehlers-Danlos	 syndrome	 to	 over	 600	 awards	 for	 Huntington’s	 disease	 and	
approximately	 800	 awards	 for	 cystic	 fibrosis.	 It	 indicates	 that	 some	 rare	
diseases	have	received	substantial	 funding,	while	some	rare	diseases	have	not	
attracted	 any	 funding	 at	 all.	 The	 variation	 can	 be	 attributed	 to	 two	 factors:	
firstly,	 the	 gene	 mutation	 of	 some	 rare	 diseases	 has	 been	 identified,	 which	


























Figure	17   The Requested	and	Granted	Orphan	Drug	Designations	 
	
According	 to	 the	 FDA	 database	 for	 Orphan	 Designated	 and	 or	 Approved	
Products,	until	 the	end	of	2015,	there	are	3500	orphan	designations	 issued	by	
OOPD,	 with	 over	 500	 of	 them	 having	 resulted	 in	 marketing	 approval	 with	
orphan	 exclusivity.	 During	 the	 FY	 2015,	 OOPA	 reviewed	 440	 Orphan	 Drug	
designation	applications;	the	number	of	applications	for	orphan	designation	has	
quadrupled	 since	 FY	 2000.	 In	 FY	 2015,	 76.1%	 (335)	 of	 the	 applications	were	





















Requests	 192	 248	 273	 334	 259	 330	 434	 440	
Designations	
Granted	 164	 152	 177	 225	 179	 235	 285	 335	
Market	






get	benefits	 from	the	formal	 incentives	of	the	Orphan	Drug	Act	 like	tax	credits	
for	 clinical	 development	 and	 seven	 years	 of	 exclusive	 marketing	 after	 FDA	




develop	a	drug	 for	a	 rare	disease.	But,	not	all	 the	drug	developers	might	 seek	
drug	 designation	 through	 FDA	 due	 to	 the	 patent	 consideration,	 and	 the	
information	about	their	drug	development	may	not	be	easy	to	access.	Moreover,	
the	 time	 from	designation	 to	 approval	may	not	 be	 the	 real	 drug	development	
time,	 as	 the	 orphan	 designation	 may	 be	 applied	 at	 any	 time	 of	 drug	
development.	 The	 median	 time	 from	 designation	 to	 approval	 is	 2.49	 years	
(interquartile	 range	 1.13–4.64)	 for	 rare	 cancer	 (Stockklausner,	 Lampert	 et	 al.	
2016);	 the	mean	 time	 for	RRDSs	 (Rheumatologic	Diseases)	 is	 3.9 years	 (Ries,	







designation	does	not	 change	 the	standard	regulatory	 requirements	or	process	













To	 assess	 the	 efficacy	 and	 safety	 of	 a	 drug,	 the	 FDA	 drug	 approval	 process	




collects	data	about	 the	safety	of	 the	drug	 in	humans	 through	a	 small	group	of	
healthy	 volunteers	 (20-100).	 Phase	 Ⅱ	 assesses	 how	 the	 drug	 works	 and	
establishes	the	short-term	single-dose	efficacy	through	larger	groups	of	patients	




and	 every	 drug	 may	 take	 a	 unique	 route.	 Most	 drugs	 undergo	 eight	 steps	 of	
testing	in	animals	and	humans	and	then	get	reviewed	by	the	FDA	(Figure	18).		
	




200,000	 persons	 in	 the	 United	 States”,	 the	 patient	 population	 available	 for	
testing	 orphan	 drugs	 is	 much	 smaller	 than	 non-orphan	 drugs	 for	 more	
prevalent	 diseases.	 In	 addition,	 the	 number	 of	 patients	 with	 specific	 rare	
diseases	 can	 vary,	 and	 some	 rare	 diseases	 affect	 thousands	 of	 patients	 while	




































• Myozyme	 for	 the	 treatment	 of	 infantile	 variant	 and	 rapidly	 fatal	 form	 of	
Gaucher	disease	was	approved	in	April	2006	based	on	a	drug	development	
program	of	fewer	than	80	patients	and	a	pivotal	study	of	18	patients.	
• Ceprotin,	 human	 plasma-derived	 protein	 C	 concentrate,	 is	 used	 to	 treat	
severe	congenital	Protein	C	deficiency.	Less	than	20	patients	were	known	in	
the	 US.	 This	 biologic	 drug	 was	 authorized	 marketing	 approval	 in	 March	






The	 same	 as	 other	 diseases,	 FDA	 is	 fully	 committed	 to	 the	 development	 and	
review	of	products	 for	 rare	disease	 (Goodman	2010).	FDA	grants	an	approval	
for	 a	 new	 drug	 based	 on	 substantial	 evidence	 of	 effectiveness	 derived	 from	
adequate	 and	 well-controlled	 investigations.	 The	 evidence	 for	 effectiveness	










During	 the	 previous	 decades,	 the	 FDA	 has	 introduced	 two	ways	 of	 providing	
flexibility	 for	 reviewing	 new	 drug	 applications.	 Although	 neither	 of	 them	 is	
designed	 for	 orphan	 drugs,	 they	 are	 widely	 used	 for	 orphan	 drug	 approval	
(Sasinowski	2011).	The	first	policy	is	to	review	the	application	based	on	a	single	
adequate	and	well-controlled	trial	for	nine	different	circumstances.	Usually,	the	
FDA	 needs	 at	 least	 two	 adequate	 and	 well-controlled	 studies.	 Within	 this	
guidance,	 FDA	 can	 approve	 a	 drug	 when	 one	 single	 study	 is	 sufficient	 under	
specific	 circumstances.	 The	 second	 one	 is	 ’fast	 approval’	 used	 to	 review	 the	
serious	disease	with	unmet	medical	need,	such	as	AIDS	and	some	cancers.	The	
evidence	 of	 fast	 approval	 should	 be	 based	 either	 on	 an	 invalidated	 surrogate	
that	is	reasonably	likely	to	predict	ultimate	clinical	outcome	or	on	a	result	other	
than	 irreversible	morbidity	or	mortality.	FDA	created	these	programs	to	bring	




their	 evaluation.	 32	 of	 135	 orphan	 drugs	 analyzed	 manifests	 administrative	
flexibility	 and	 another	 58	 orphan	 drugs	 were	 approved	 on	 a	 case-by-case	
application	 of	 flexibility.	 The	 flexibility	 of	 orphan	 drug	 review	 reinforces	 the	
need	 for	 the	 public	 acknowledgment	 that	 orphan	 drugs	 need	 special	
considerations.	In	many	cases,	it	is	not	possible	to	conduct	randomized,	double-
blinded,	 placebo-controlled	 studies	 with	 orphan	 drugs,	 and	 alternative	









used	 to	 reduce	 the	 cumulative	 renal	 toxicity	 associated	 with	 repeated	
administration	of	cisplatin	in	patients	with	advanced	ovarian	cancer.	The	




the	 symptoms	 of	 rare	 genetic	 condition	 Cryopyrin-Associated	 Periodic	










from	 the	published	medical	 literature	 and	a	 retrospective	 study	of	102	
patients	 treated	 by	 the	 US	 Public	 Health	 Service	 (PHS).	 The	 statistical	
data	from	long-term	medical	records	 is	not	 from	an	adequate	and	well-
controlled	study.	
• Sterile	 Talc	 Powder,	 with	 the	 trade	 name	 Sclerosol,	 was	 approved	 in	
December	 1997	 for	 treating	malignant	 pleural	 effusions	 based	 only	 on	
published	literature.	The	statistical	review	of	Sclerosol	notes	that:	“Talc	
has	been	used	for	years	to	treat	patients	with	malignant	pleural	effusions,	
but	 talc	 has	 never	 been	 approved	 by	 the	 FDA	 for	 this	 purpose.”	 	 In	
judging	 that	 substantial	 evidence	 of	 efficacy	 was	 sufficient,	 five	 of	 the	















Different	 parties	 may	 have	 different	 opinions	 on	 the	 trial	 design	 and	 the	
interpretation	 of	 the	 results.	 The	 FDA	 has	 made	 its	 scientific	 judgment	 to	
interpret	 and	 apply	 the	 standards	 in	 a	 flexible	 manner,	 based	 on	 the	
circumstances	of	each	therapy	for	each	rare	disease.	However,	no	clear	formal	
policy	expressing	the	flexibility	is	provided	in	FDA’s	application	of	the	statutory	






The	 clinical	 trials	 for	 drugs	 treating	 rare	 diseases	 are	 subject	 to	 the	 same	
requirements	 for	 efficacy	 and	 safety	 as	 other	 drugs.	 Although	 orphan	 drug	
development	can	take	advantage	of	flexibility	the	FDA	provided,	it	faces	severe	
challenges	and	difficulties	 that	are	not	usually	encountered	 in	 the	clinical	 trial	

















RDCRN	 (Rare	Disease	Clinical	Research	Network)	 is	 a	patient	 contact	 registry	
sponsored	 by	 NIH.	 This	 organization	 collects	 data,	 such	 as	 patient	 contact	




RDCRN	 provides	 assistance	 for	 drug	 development	 as	 it	 maintains	 the	 close	
relationship	with	patients.	The	RDCRN	has	supported	 the	rare	disease	R&D	 in	
the	following	ways:	








The	 FDA	 organizes	 a	 series	 of	 workshops	 to	 discuss	 important	 and	 difficult	
research	on	orphan	drug	discovery	and	development.	FDA	also	strengthens	the	
network	 to	 increase	 transparency,	 share	 advice	 and	 establish	 new	 programs	
with	several	patient	organizations,	 including	NORD,	ORDR,	TRND,	the	National	
Institute	 of	 Neurological	 Disorders	 and	 Stroke	 (NINDS),	 patient	 advocacy	
groups,	academia	and	the	Institute	of	Medicine	(Goodman	2010).		
	
With	 the	 responsibility	 to	 assure	 the	 safety	 and	 efficacy	 of	 orphan	 drugs,	 the	
FDA	is	 fully	committed	to	applying	the	requisite	 flexibility	 in	 the	development	









Disease	 Review	 Group,	 were	 established	 by	 FDA.	 These	 two	 internal	 review	
groups	 are	 aiming	 to	 address	 the	 rare	 and	 neglected	 disease	 and	 report	 to	






reduce	 the	 drug	 development	 time,	 costs	 and	 risks	 (Kollewe	 2012).	 In	 2010,	
OOPD	announced	a	new	tool	called	Rare	Disease	Repurposing	Database,	which	
provides	data	about	drugs	already	approved	by	FDA	for	another	disease	and	are	
deemed	with	 potential	 for	 treating	 rare	 disease	 nowadays.	 According	 to	 FDA	
RDRD	 (Rare	 Disease	 Repurposing	 Database),	 until	 2010,	 there	 were	 168	
orphan-designated	 drugs	with	 at	 least	 one	marketing	 approval	 for	 a	 common	
disease	 indication,	 183	 orphan-designated	 drugs	 with	 at	 least	 one	marketing	
approval	for	a	rare	disease	indication,	and	105	orphan-designated	drugs	with	at	
least	 one	 marketing	 approval	 for	 both	 common	 and	 rare	 disease	 indication	
(RDRD	 2012).	 The	 feature	 of	 this	 database	 is	 to	 shorten	 the	 duration	 and	




Researchers	 have	 defined	 the	 genetic	 basis	 of	 over	 2,000	 rare	 diseases	 and	
discovered	potential	drug	 targets	 for	many	rare	conditions,	but,	 there	exists	a	
large	 gap	 between	 the	 outcomes	 of	 basic	 science	 and	 applied	 product	
development	 (Goodman	 2010).	 FDA	 regulatory	 science	 research	 intends	 to	
bridge	 this	 gap	 and	 accelerate	 the	 transformation	 of	 research	 into	 medical	







to	 strengthen	 the	 scientific	 infrastructure	 and	 capacity	 to	 leverage	 the	
opportunities	 to	 enhance	 the	 scientific	 collaborations.	 FDA	 helps	 drug	






would	 be	 considered	 too	 small	 to	 develop	 and	 market	 medical	 products	 for	
them.	With	the	aim	to	assist	and	stimulate	the	identification,	development,	and	
availability	of	both	safe	and	effective	products	 for	patients	with	 rare	diseases,	
the	 FDA	 Office	 of	 Orphan	 Products	 Development	 (OOPD)	 has	 three	 primary	
missions:	 the	 first	 mission	 is	 conducting	 scientific	 and	 regulatory	 review	 of	
orphan	drug	designation;	secondly,	OOPD	awards	and	manages	grants	to	defray	
orphan	 products	 clinical	 study	 costs;	 and	 the	 third	 is	 serving	 as	 a	 liaison	 for	
drug	 companies,	 FDA	 review	 divisions,	 patient	 advocacy	 groups	 and	 other	
government	 agencies	 (Needleman	 2012).	 It	 also	 plays	 an	 essential	 role	 in	




Patient	advocacy	group	plays	a	 significant	 role	not	only	 in	 the	 introduction	of	
the	 ODA	 in	 the	 US,	 but	 in	 the	 supporting	 orphan	 drug	 development.	 Patient	
advocacy	 group	 facilitates	 the	 drug	 development	 process	 by	 helping	 with	
patient	 recruitment,	 research	 funding,	 administration	 of	 patient	 assistance	
programs	 and	 improving	 the	 communication	 between	 patients	 and	 doctors	
(Griggs,	Batshaw	et	al.	2009).	The	largest	advocacy	group	in	the	United	States	is	
National	Organization	for	Rare	Disease	(NORD).		NORD	provides	assistance	with	






assistance	 for	 the	 patients	 and	 their	 families	 who	 have	 to	 travel	 to	 a	 distant	
place	to	participate	in	clinical	trials.	
	
The	 efforts	 of	 different	 organizations	 work	 together	 to	 help	 to	 make	 the	





The	 Office	 of	 Rare	 Disease	 Research	 (ORDR)	 was	 established	 in	 1993	 within	
NIH,	and	it	became	a	centralized	dataset	on	rare	disease	clinical	research	and	a	
communication	 media	 among	 patient	 groups,	 research,	 and	 government.	 The	







The	ORDR	 started	 a	 second	 phase	 re-competition	 for	 funding	 support	 for	 the	
Rare	Diseases	Clinical	Research	Network	 (RDCRN)	and	Data	Management	and	
Coordinating	Center	(DMCC)	in	2009.		







Number	of	Projects	 9411	 9399	 9239	 9125	 9366	






























RDCRN	 firstly	 established	 in	 2003	 by	 Office	 of	 Rare	 Disease	 (ORDR),	 works	
closely	 with	 patient	 groups	 and	 research	 organizations	 to	 support	 the	 rare	
disease	 R&D.	 The	 Contact	 Registry	 in	 RDCRN	 links	 the	 registered	 patients	 to	
RDCRN,	and	 the	patients	would	be	 contacted	when	 there	are	 clinical	 research	
opportunities	and	informed	about	the	progress	of	research	projects.	RDCRN	has	
22	 Rare	 Diseases	 Clinical	 Research	 Consortia	 (RDCRC).	 DMCC	 supports	 the	
consortia	 through	 providing	 technologies	 and	 tools	 to	 collect	 and	 analyze	
clinical	research	data.			
Each	 consortium	 supports	 the	 clinical	 protocols	 for	 a	 minimum	 set	 of	 three	
related	 rare	 diseases	 with	 guidance	 from	 one	 or	 several	 of	 participating	
institutions.	 The	 rare	 diseases	 have	 been	 funded	 for	 five	 years	 include	
Autonomic	Disorders	Consortium,	Urea	Cycle	Disorders	Consortium,	Lysosomal	
Disease	Network,	Clinical	Investigation	of	Neurologic	Channelopathies,	etc. The	
RDCRC	 on	 Urea	 Cycle	 Disorders	 (UCD)	 has	 been	 funded	 by	 NIH	 since	 2003,	
consists	of	15	sites	in	the	US	and	two	international	sites,	and	involves	over	50	
investigators	 and	 staff.	 The	 main	 duty	 is	 to	 carry	 on	 a	 longitudinal	 natural	
history	 study	 investigating	 morbidity,	 mortality,	 and	 biomarkers	 in	 over	 500	
adults	 and	 children	with	 UCD	 in	 the	 US,	 Canada,	 and	 Europe;	 supporting	 the	
Phase	 II	 trials	 of	 new	 drugs,	 and	 assessing	 neural	 mechanisms	 of	 injury	 by	
innovative	neuroimaging	and	neuropsychological	testing	procedures. 
	
Between	 2009	 and	 the	 end	 of	 September	 2013,	 18000	 participants	 had	 been	
enrolled	in	84	multi-site	clinical	research	studies;	151	clinical	researchers	have	
been	 trained	 in	 the	 rare	 diseases	 research;	 24	 studies	 had	 finished	 the	
recruitment	and	were	in	the	final	analysis	phase	(NIH	2016).	Most	of	the	funded	




	In	 2014,	 the	 entire	 rare	 disease	 research	 program	 was	 relocated	 under	 the	





which	 is	 the	new	home	 for	NIH	ORDR.	 It	has	22	 funded	consortia	 to	 study	on	







and	 provide	 grants	 and	 fellowships	 for	 the	 studies	 of	 rare	 disease.	 A	 lot	 of	
patient	 advocacy	 groups	 have	 developed	 sophisticated	 and	 highly	 effective	
strategies	to	support	the	research	of	rare	disease	(Griggs,	Batshaw	et	al.	2009).	










clinical	 development	 of	 products	 for	 the	 treatment	 of	 rare	 diseases	 and	
conditions	 through	 helping	 sponsors	 in	 defraying	 the	 costs	 of	 clinical	 trials.	
Since	1983,	the	OOPD	has	provided	over	$350	million	to	fund	more	than	7000	



























The	 total	 amount	 of	 OOPD	 funding,	 which	 includes	 Orphan	 Product	 Grants,	
Pediatric	Consortia	Grants	and	program	administration,	has	 increased	steadily	
since	 2016.	 But,	 orphan	 product	 grant	 doesn’t	 grow	 as	 fast	 as	 OOPD	 funding	











Nearly	 half	 of	 the	 grants	 have	 been	 awarded	 to	 research	 organizations.	 	 For	
instance,	 in	 FY	 2012,	 13	 of	 the	 17	 new	 grants	 were	 awarded	 to	 research	
organizations	 such	 as	 University	 of	 California	 San	 Diego,	 University	 of	
Pennsylvania	 and	 Massachusetts	 General	 Hospital;	 three	 were	 awarded	 to	
biotechnology	 companies	 including	 Apogee	 Biotechnology	 Corporation,	
Spineform	 LLC,	 and	 Tolera	 Therapeutics	 Inc.;	 one	 was	 granted	 to	 non-profit	
medical	care	organization,	Mayo	Clinic.	23%	of	the	grants	were	used	to	support	
Phase	I	clinical	study,	while	66%	grants	were	used	to	support	Phase	II	clinical	














































support	 research	on	 the	natural	history	of	 rare	diseases.	The	objective	of	 this	
project	 is	 to	 “help	 characterize	 the	 natural	 history	 of	 rare	 diseases,	 identify	
subpopulations,	 and	 develop	 and/or	 validate	 clinical	 outcome	 measures,	
biomarkers	 and	 companion	diagnostics	 (OOPD	2016)”.	 It	 is	 the	 first	 time	 that	
FDA	 offers	 funding	 through	Orphan	 Product	 Grants	 to	 support	 these	 types	 of	
research.	 Rare	 diseases	 are	 usually	 poorly	 understood,	 without	 the	
understanding	 of	 how	 rare	 disease	 progress	 it’s	 hard	 to	 develop	 the	medical	






From	pre-clinical	 trial	 to	 final	 review,	 the	drug	development	process	 is	 a	 long	













Fast	 track,	 which	was	 developed	 by	 FDA,	 a	 process	 designed	 to	 facilitate	 the	
development	and	shorten	the	review	of	drugs	to	treat	serious	diseases	and	meet	




developed	 to	 treat	 a	 severe	 disease,	 some	 of	 the	 examples	 are	 AIDS,	 heart	
failure,	 and	 cancer;	 2)	 filling	 an	 unmet	 medical	 need	 is	 defined	 as	 providing	
therapy	which	does	not	exist	in	the	market	or	is	superior	to	existing	therapies.	
Most	of	the	orphan	drug	meet	one	of	the	above	requirements	and	qualifies	the	
Fast	 Track.	Once	 a	 drug	 receives	 Fast	 Track	 designation,	 drug	 companies	will	
meet	more	 frequently	with	 FDA	 to	 discuss	 the	 plan	 of	 drug	 development	 and	
receive	more	 frequent	 feedbacks	 from	 FDA	 about	 the	 design	 of	 clinical	 trials.	
Drug	 companies	 are	 encouraged	 to	 meet	 with	 the	 FDA	 early	 and	 frequently	
throughout	the	whole	process	of	drug	development	and	review.	The	frequency	
and	 early	 communication	 makes	 the	 questions	 and	 problems	 be	 resolved	




In	 1992,	 the	 FDA	 established	 a	 two-tiered	 system	 of	 review	 times,	 including	
Standard	Review	and	Priority	Review.	Standard	Review	is	applied	to	a	drug	that	
offers	 a	minor	 improvement	over	 existing	marketed	drugs;	 the	goal	of	 review	




Both	 drugs	 treating	 serious	 diseases	 and	 less	 serious	 diseases	 are	 eligible	 to	




















ERWINAZE	 11/18/11	 ✔  
JAKAFI	 11/16/11	 ✔  
KALYDECO	 11/31/11	 ✔  
VORAXAZE	 01/17/12	 ✔  
BOSULIF	 09/04/12	  ✔ 
ELELYSO	 05/01/12	  ✔ 
FERRIPROX	 10/14/11	  ✔ 
KYPROLIS	 07/20/12	  ✔ 





disease	 and	 filling	 an	 unmet	medical	 need.	 The	method	 used	 to	 stimulate	 the	
approval	 is	 based	 on	 the	 surrogate	 endpoint	 that	 is	 a	 measurement	 in	 the	
laboratory	or	physical	sign	applied	in	clinical	trials	as	an	indirect	or	substitute	










accelerated	 approval	 products	 were	 approved	 4.7	 months	 faster	 than	 non-
accelerated	 products	 (Faden	 and	 Kaitin	 2008).	 Phase	 4	 trials	 are	 required	 to	





Based	 on	 20	 orphan	 drugs	 approved	 between	 2000	 and	 2005,	 the	 mean	
approval	duration	for	products	approved	by	FDA	was	15.5	months	(Faden	and	
Kaitin	2008).	This	can	be	considered	as	resulting	from	the	effect	of	regulations	
enacted	 by	 FDA	 to	 facilitate	 drug	 review	 process.	 In	 all,	 Fast	 Track,	 Priority	
Review	and	Accelerated	Approval	combined	with	 flexible	clinical	development	






orphan	 drug	 application	 usually	 has	 a	 smaller	 number	 of	 patients	 and	 fewer	
clinical	 trials.	 Secondly,	 a	 more	 significant	 proportion	 of	 orphan	 drugs	 were	
benefited	 from	priority	 review	and	accelerated	 review	procedures,	which	was	
designed	 to	 accelerate	 the	 development	 and	 approval	 of	 drugs	 and	 biological	
products	 treating	 unmet	 serious	 or	 life-threatening	 diseases.	 Thirdly,	 OOPD	
















start-up	biotechnology	 companies,	 rely	heavily	 on	patent	protection	 to	 secure	
the	 investment	 on	 R&D.	 However,	 a	 number	 of	 the	 orphan	 drugs	 are	 not	
patentable,	and	some	drug	has	already	been	patented,	so	the	market	exclusivity	
is	of	significant	value	 for	 these	drug	companies.	The	market	exclusivity	makes	













development	 cost,	 such	 as	 application,	 product	 and	 establishment	 fee	waiver,	
tax	credit	enabling	drug	company	a	50%	off	of	the	cost	for	human	clinical	trials,	













Because	of	 the	high	 cost	of	R&D	and	 the	 small	probability	of	 success	 for	 each	
drug	 candidate,	 drug	 companies	 should	work	 extensively	on	 the	marketing	 to	
ensure	 their	 share	 in	 the	 competitive	 market.	 Whether	 the	 approved	 drug	
delivers	considerable	returns	and	profits	to	the	company	depends	on	the	ability	
to	set	a	reasonable	price	and	sufficient	sales	volume	over	the	period	of	market	
protection.	 In	 the	 orphan	 drug	 market,	 the	 active	 networked	 relationships	






will	 drive	 some	 people	 out	 of	 the	market.	 The	 pricing	 of	medicine	 is	 entirely	
different	from	pricing	other	products;	firms	control	the	price	to	make	sure	that	
the	public	 takes	 the	 expected	quantities	 at	 that	price	 (Reekie	1977).	 Setting	 a	
reasonable	 but	 adequate	 price	 for	 a	 new	 product	 is	 crucial	 for	 the	 drug	
company.	If	the	price	is	set	too	low,	the	return	on	investment	is	not	sufficient	to	
recoup	the	R&D	cost	and	support	the	continuing	business;	if	the	price	is	set	too	
high,	 customers	 may	 choose	 not	 to	 use	 this	 product,	 resulting	 in	 the	 same	
problems	for	the	company.	
	
The	 price	 paid	 for	 a	medicine	 comprises	 a	 number	 of	 components.	 Along	 the	
supply	 chain	 from	 manufacturer	 to	 patient,	 various	 components	 are	
cumulatively	added	into	the	manufacturer’s	selling	price	(MSP),	such	as	freight	














drug	 company.	 In	 the	 following	 sections,	 we	 describe	 the	 methodological	




Pharmaceutical	 industry	 features	a	 low	ratio	of	variable	or	direct	 cost	 to	 total	
costs.	Variable	costs	refer	to	the	cost	of	production,	distribution,	and	promotion,	
while	 the	pharmaceutical	 research	and	development	 costs	are	 substantial	 and	




process	 is	 like	 a	 black	 box,	 as	 they	 know	 little	 about	 the	 details	 of	 how	
companies	 price	 a	 drug.	 Pricing	 strategy	 employed	 by	 drug	 company	 varies	
widely	 according	 to	 a	 number	 of	 factors,	 including	 the	 perceived	 therapeutic	
value	of	the	drug,	the	degree	of	novelty	that	the	drug	compared	to	the	existing	




















the	 return	 through	 a	 structured	 evaluation	 of	 products	 cost	 and	
outcomes.	The	value-based	pricing	model	is	able	to	help	create	the	true	
benefits	 to	 the	 society;	 it	 has	 been	 highlighted	 by	 many	 experts	 and	
governments.	 It	offers	 the	best	value	 for	money	spent,	but	 it’s	 tough	 to	
evaluate	and	quantify	the	value	of	the	drug’s	outcome.	
	
3. Target	 return	pricing	 (TRP):	This	model	of	pricing	 firstly	 estimates	 the	
drug	company’s	desired	return	on	the	investment	and	then	add	them	in	
the	price	of	 the	drug.	The	objective	of	 this	 strategy	 is	 to	achieve	 target	
return-on-investment.	
	
4. Reference	 pricing:	 In	 this	 model,	 the	 price	 of	 the	 drug	 is	 determined	
according	 to	 its	competitors’	price	 in	 the	market.	The	reference	drug	 is	
another	drug	in	the	same	therapeutic	class,	and	it	may	be	the	drug	with	
the	 same	 clinical	 indications	 or	 the	 drug	 not	 available	 in	 the	 country	
where	 it	 launches.	 This	 strategy	 is	 widely	 used	 in	 the	 countries	 with	
government	intervenes	pharmaceutical	price,	like	Germany,	Netherlands,	
Spain,	 and	 the	 UK,	 it	 has	 driven	 down	 pharmaceutical	 prices	 in	 these	











All	 the	 strategies	 above	 have	 their	 advantages	 and	 shortcomings,	 and	 drug	
companies	usually	 integrate	 some	of	 them	 to	 set	 the	price	 for	 a	new	product.	
The	 prices	 of	 the	 same	 drug	 may	 differ	 among	 different	 countries.	 Different	
healthcare	 systems	 between	 the	 US	 and	 Europe	 result	 in	 different	 pricing	
environments:	 free-pricing	 and	 price-controlled	 market.	 In	 Europe,	 countries	
impose	 strict	 government	 control	 over	 drug	 price,	 while	 the	 US	 healthcare	
model	 has	 led	 to	 a	 free	 market	 for	 pricing.	 Drug	 price	 is	 controlled	 by	 the	
market	 forces	 in	 the	 US,	 and	 drug	 company	 can	 determine	 the	 price	 for	 its	




product	 starts	 from	 the	 early	 stage	 of	 drug	 development,	 usually	many	 years	
before	 the	 launch.	 The	 drug	 company	 estimates	 the	 value	 of	 the	 drug	 to	 its	
consumers	 and	 the	 desire	 and	 ability	 of	 its	 consumers	 to	 pay	 for	 it	 (VBP).	
Moreover,	 the	 company	 determines	 a	 price	 threshold	 over	 which	 the	 cost	 of	
R&D	 investment	 will	 be	 sufficiently	 covered,	 and	 a	 good	 return	 is	 obtained	
(TRP).	Therefore,	orphan	drug	pricing	includes	the	strategy	of	VBP	and	TRP;	in	
addition,	the	market	monopoly	period	is	of	significance	in	pricing	a	drug.	During	
market	 protection	 period,	 the	 drug	 company	 is	 the	 only	 firm	 in	 the	 sector	




The	 revenue	 flow	 of	 orphan	 drugs	 is	 distinct	 from	 non-orphan	 drugs	 (Milne	
2002).	The	revenues	of	typical	mainstream	drugs	increase	rapidly	after	launch,	
peak	 after	 11–12	 years	 then	decline	 quickly.	 The	 revenue	 curve	 of	 an	 orphan	













traditional	 drug	 discovery	 process	 from	 random	 screening	 to	 rational	 design	
and	 to	 the	 research	 featured	 by	 network	 collaboration;	 the	 regulations	 like	
flexibility	 of	 drug	 development,	 Fast	 Track,	 Priority	 Review	 and	 Accelerated	
Approval	shorten	the	drug	development	process	 for	drugs	treating	severe	and	
unmet	diseases;	 the	orphan	drug	commercialization	 is	different	 from	the	non-
orphan	drug	in	terms	of	 less	marketing	efforts,	 fast	market	penetration	and	7-
year	market	exclusivity;	 the	patients	advocacy	group	plays	an	essential	role	 in	
assisting	clinical	 trials	and	marketing;	 the	most	 important	 is	 the	Orphan	Drug	
Act	 which	 simulates	 the	 cooperation	 among	 different	 organizations	 to	
accelerate	 the	 study	 and	 development	 orphan	 drugs.	 In	 the	 next	 chapters,	 a	















are	 widespread	 in	 the	 social	 area,	 and	 through	 them	 social	 scientists	 have	
adopted	 either	 induction	 or	 deduction	 as	 their	 research	 reasoning.	 Social	




The	 application	 of	 computer	 simulation	 to	 social	 science	 is	 a	 breakthrough,	
through	which	researchers	are	able	 to	use	experimental	methods	 to	study	 the	
social	 phenomena.	 Simulation,	 carried	 out	 through	 modelling	 under	 varying	
conditions	and	parameters,	is	viewed	as	a	sort	of	experimental	methodology	to	
some	 extent.	 Experimental	 research	 is	 difficult	 to	 carry	 out	 in	 most	 areas	 of	






introduced	 the	 evolutionary	 economics	 or	 Neo-Schumpeterian	 economics.	 It	
focuses	on	the	relationship	between	economic	change	and	innovation.	Since	the	
1980s,	 Agent-based	 Models	 (ABMs)	 have	 become	 the	 most	 important	 formal	
modeling	 methodology	 in	 this	 area.	 In	 section	 5.3,	 the	 general	 features	 and	
methodological	 issues	 of	 ABMs	 are	 discussed.	 Section	 5.4	 provides	 a	 brief	
introduction	about	industry	evolution	and	dynamics,	and	analyses	the	essential	
feature	and	methodology	of	History-Friendly	Model.	Section	5.5	introduces	the	


















increasingly	 interested	 in	 the	 computer	 simulation,	 which	 crosses	 the	 gap	
between	 the	 descriptive	 approach	 used	 in	 social	 science	 and	 the	 formal	
approach	 used	 in	 the	 natural	 sciences	 through	moving	 the	 focus	 towards	 the	
process,	mechanisms,	and	behaviors	that	build	the	social	reality.		
The	Application	of	Social	Simulation	
The	 connections	 between	 social	 science	 and	 computer	 simulation	 are	 mainly	
methodological	 in	 character,	 and	 social	 science	 can	 benefit	 a	 lot	 from	 the	
simulation	(Davidsson	2002).	Firstly,	social	scientists	convert	social	theories	to	
computer	 programs,	 and	 then	 apply	 computer	 simulation	 to	 simulate	 social	
processes	and	carry	out	experiments	that	are	impossible	to	do	in	the	real	world.	
Social	 simulation	 is	 especially	 helpful	when	 the	 phenomenon	 to	 be	 studied	 is	
not	accessible	or	is	difficult	to	observe	directly.	
There	are	 two	primary	applications	of	simulation	 in	social	science.	The	 first	 is	
‘understanding’,	whereby	the	model	can	contribute	to	the	understanding	of	the	










The	 validation	 of	 computer	 simulation	 in	 the	 social	 science	 is	 based	 on	 two	
components:	 the	 natural	 science	 and	 the	 underlying	 theory.	 In	 the	 natural	
sciences,	the	computer	simulations	focus	on	reproducibility,	but	this	is	difficult	
to	achieve	in	the	social	sciences.	Compared	to	natural	sciences,	the	application	
in	 social	 science	 is	 still	 in	 its	 early	 stage	 and	 at	 a	 state	 of	 transition.	 The	
knowledge	produced	from	the	model	is	reliable	if	the	model	that	is	constructed	
to	reproduce	the	dynamics	is	correct	in	the	natural	science.	However,	 in	social	
simulations,	 the	 validation	 of	 knowledge	 relies	 on	 the	 exact	 imitation	 of	 the	
characteristics	of	social	dynamics.	
The	 validity	 of	 social	 simulations	 depends	 on	 the	 purpose	 of	 the	 model	
(Küppers	 and	 Lenhard	 2005).	 The	 main	 objective	 of	 social	 simulation	 is	 to	
describe	 the	 actual	 dynamics	 and	 complexities	 of	 the	 real	 world.	 Through	
computational	experiments,	social	simulations	reproduce	the	characteristics	of	
the	 social	 phenomenon	 described	 by	 the	 theoretical	 model.	 Simulations	 are	
based	on	theoretical	models	that	guide	the	simulation	but	do	not	determine	it.	
On	 one	 hand,	 it	 is	 obvious	 that	 simulation	 can	 be	 realized	 via	 the	 underlying	
theoretical	 explanation;	 on	 the	 other	 hand,	 if	 the	 simulation	 can	 imitate	 the	
dynamics	 and	 complexities	 of	 the	 social	 phenomenon	 through	 data	 and	
































The	 first	 and	 most	 crucial	 step	 of	 social	 simulation	 is	 to	 establish	 clear	
objectives	and	research	questions,	which	can	help	researcher	focus	on	the	social	
phenomena	 of	 interest	 and	 determine	 the	 correct	 simulation	 tools.	 	 The	
estimation	 of	 the	 parameters	 is	 essential	 for	 the	 simulation	 of	 the	 complex	
social	 phenomenon.	 To	 build	 a	 simulation	 model	 every	 parameter	 must	 be	
assigned	 an	 appropriate	 value,	 which	 is	 not	 easy.	 The	 vagueness	 of	 what	 the	
parameter	represents	will	lead	to	the	confusion	of	the	simulation.		
	









be	 more	 detailed	 and	 hence	 will	 imitate	 the	 real	 social	 system	more	 closely.	
Conversely,	it	is	risky	to	design	a	model	that	is	more	detailed	than	necessary,	as	
it	can	over-complicate	data	collection	and	processing,	which	will	 influence	 the	
validation	 and	 verification	 of	 the	 model	 and	 the	 conclusion	 drawn	 from	
simulation	 (Gilbert	 and	 Troitzsch	 2005).	 However,	 an	 abstract	 model	 that	
includes	 little	 information	will	 also	 cause	 two	gaps	 in	 interpretation.	The	 first	
gap	 is	 between	 the	 target	 and	 conceptual	 model,	 while	 the	 second	 gap	 is	
between	 the	 outcomes	 of	 the	 model	 and	 the	 conclusions	 derived	 from	 the	







such	 as	 computation	 program.	 Researchers	 can	 program	 the	 model	 through	
modelling	toolkits	or	self-written	codes	in	computing	languages	such	as	C,	C++,	




Simulation	models	 generate	 large	 sets	 of	 data	 while	 avoiding	 the	 problem	 of	
missing	data	and	confounding	variables	(Axelrod	1997).	Researchers	can	study	
the	 influence	of	 the	 specific	 factors	 by	 changing	 the	parameters	 in	 the	model,	
which	 contribute	 to	 our	 understanding	 of	 the	 real	 world.	 For	 example,	 it	 is	
interesting	 to	 study	 how	 a	 certain	 parameter	 will	 change	 over	 time	 if	 the	
parameter	is	assigned	a	different	value.	Furthermore,	researchers	can	compare	
different	versions	of	the	model	by	changing	the	mechanisms	of	agents’	activities.	








Given	 that	 the	 application	 of	 simulation	 is	 increasing	 in	 problem-solving	 and	
decision-making,	 it	 is	 important	 that	 the	 results	 of	 the	 simulation	 are	 correct	
and	 accurate.	 These	 are	 concerns	 that	 can	 be	 addressed	 in	 terms	 of	 model	
verification	and	validation.		
	
From	 Figure	 24,	 it	 is	 evident	 that	 the	 verification	 and	 validation	 process	 are	
embedded	 in	 the	 round-link	 chain	 of	 problem	 entity	 (research	 target),	
conceptual	 model	 (logic	 and	 mathematical	 representation	 of	 the	 target),	 and	





The	 evaluation	 of	 these	 systems	 is	 also	 quantitative	 in	 nature.	 However,	 the	
evaluation	of	the	social	model	 is	also	qualitative.	The	conceptual	model	can	be	
























future	 state	 of	 one	 variable	 is	 dependent	 on	 the	 current	 state.	 The	 system	
dynamic	model	only	provides	equilibrium	values	for	the	variables.	
	
Micro-analytical	 simulation	 is	 widely	 used	 in	 social	 policy	 interventions.	 It	
uses	 a	 random	 population	 cohort	 with	 a	 large	 sample	 size	 to	 calculate	 the	
aggregate	statistics	and	subsequently	estimate	the	future	characteristics	of	the	
population	 (Gilbert	 and	 Troitzsch	 2005).	 The	 policy	 intervention	 can	 be	
analyzed	 because	 there	 are	 two	 levels	 and	 a	 number	 of	 agents	 with	 higher	
complexity	in	the	model.	The	primary	use	of	the	micro-simulation	is	to	predict	
fiscal	 distribution,	 and	 the	 results	 of	 the	 micro-analytical	 simulation	 have	
influenced	 the	 policy-making	 in	 the	 areas	 of	 pensions	 and	 graduate	 taxes.	
However,	 the	 micro-analytical	 simulation	 cannot	 model	 the	 interactions	















development	 of	 multi-agent	 simulation	 that	 provided	 the	 opportunity	 to	
simulate	 autonomous	 individuals	 and	 the	 interactions	 among	 them.	 Distinct	
from	the	conventional	statistical	methods	for	analyzing	the	social	system	based	
on	 the	 assumption	 of	 the	 linear	 relationship	 between	 the	 variables	 and	 the	
conventional	 simulation	model	 based	 on	 that	 agents	 are	 not	 autonomous	 and	
heterogeneous,	 multi-agent	 simulation	 stems	 from	 the	 research	 of	 nonlinear	
dynamics	and	artificial	intelligence.		
	
The	 linear	 assumption	 is	 very	 restrictive,	 because	 research	 targets	 in	 social	
sciences	are	always	dynamic	entities	 that	change	over	 time	and	react	 to	other	
entities	 in	 the	 environment.	 A	 key	 feature	 of	 social	 phenomena	 is	 that	 every	
agent	 follows	 the	 simple	 rules	 of	 that	 system,	which	 aggregate	 to	 produce	 its	
complex	behavior.	Simulation	is	the	best	way	to	analyze	such	complex	systems.		
	
Distinct	 from	 other	 social	 simulation	models,	multi-agent	 simulation	 contains	






interrelationship	 between	 other	 agents),	 knowledge	 representation	














Agent-based	 modeling	 explores	 the	 collective	 behavior	 of	 agents	 obeying	
certain	rules	 in	 the	multi-agent	system.	 In	 the	social	 research	area,	 the	Agent-
Based	Model	(ABMs)	is	the	convergence	of	social	science,	computer	science	and	
agent-based	 computing	 (Davidsson	 2002).	 ABMs	 have	 been	 used	 in	 social	
science	 areas,	 such	 as	 politics,	 sociology,	 and	 economics.	 As	 discussed	 earlier,	
the	 social	 simulation	 model	 can	 be	 abstract	 or	 descriptive,	 positive	 or	
normative,	 artificial	 or	 realistic,	 spatial	 or	 network,	 and	 complex	 or	 simple	
agents.	 Most	 agent-based	 simulation	 is	 positive,	 descriptive	 and	 analytical	 of	
social	 phenomena	 for	 the	 purpose	 of	 understanding	 it,	 while	 the	 normative	
model	is	designed	to	provide	advice	for	the	policy-maker.		
In	 economics,	 there	 is	 an	 upsurge	 in	 the	 use	 of	 ABMs	 to	 explore	 various	
phenomena.	The	neo-classic	economics	assume	that:	1)	the	economy	is	not	in	an	
equilibrium	 state;	 2)	 the	 economic	 agents	 are	 homogenous	 with	 hyper-
rationality;	3)	all	their	behaviors	are	based	on	the	maximization	principle.	The	
evolutionary	 economics	 does	 not	 assume	 the	 characteristics	 of	 homogeneity,	
rationality,	and	equilibrium;	instead,	it	focuses	on	the	disequilibrium	processes,	
which	emerge	from	the	heterogeneous	and	bounded-rational	economic	agents.	
Nelson	 and	 Winter	 are	 important	 contributors	 to	 the	 field	 of	 evolutionary	
economics	and	pioneered	the	development	of	ABMs	with	heterogeneous	agents	
to	 explain	 the	 evolution	 of	 industry.	 Since	 then,	many	more	 ABMs	 have	 been	












rationality.	 	 Different	 agents	 have	 different	 behavioral	 rules	 that	modify	 over	
time	 to	 match	 to	 their	 changing	 environment.	 ABMs	 are	 path-dependent,	 so	
their	 agents’	 behaviors	 rely	 on	 their	 statuses	 in	 the	 past.	 As	 the	 agents	 are	
bounded	 rational,	 they	 can	 accumulate	 the	 ability	 of	 R&D	 or	 marketing	 by	
learning	 from	 past	 experiences.	 For	 the	 learning	 process,	 ABMs	 in	 economic	
apply	 simulation	 methods	 such	 as	 genetic	 algorithms	 and	 the	 NK	 model	
(Kauffman	1993).	
	
The	 selection	mechanism	 is	 the	 core	of	 analyzing	 the	evolutionary	economics.	
The	most	common	selection	mechanism	is	driven	by	the	competition	within	the	
market.	 Firms	 compete	with	 each	 other	 in	 the	market;	 some	 of	 them	 survive	
while	 others	 may	 be	 forced	 out.	 Another	 force	 of	 selection	 is	 science	 and	
technology.	 The	 selection	 mechanism	 is	 dynamic	 rather	 than	 static,	 because	
while	 the	market	 and	 science	 are	 always	 changing,	 the	 routines	 of	 firms	may	
vary	 to	 suit	 these	 changes	 as	 well.	 Firms	 are	 continuously	 modifying	 their	
strategies	 to	 survive	 in	 the	 industry.	 The	 ABMs	 can	 simulate	 the	 selection	
mechanism	 through	 a	 continuous	disequilibrium,	macro-micro	 loop	 and	path-





































Each	 agent	 in	 the	 model	 has	 a	 set	 of	 behavioral	 rules	 that	 affect	 the	
micro-status	 of	 the	 agent.	 The	 behavioral	 rules	 simulate	 the	 way	 of	




The	 aggregated	 variables	 of	 micro-variables	 or	 the	 macro-variables	








ABMs	have	gained	widespread	use	 in	many	areas	of	 social	 sciences.	However,	
they	 are	 not	 the	 perfect	 modelling	 methodology	 either	 due	 to	 several	
limitations.	 ABMs	 have	 many	 methodological	 issues,	 such	 as	 its	 arbitrary	




ABMs	 are	 ignorant	 or	 lack	 the	 historical	 evidence,	 so	 they	 hold	 value	 on	 a	
theoretical	level	but	still	need	the	empirical	validation.	Some	of	the	parameters	
in	the	ABMs	can	be	calibrated	by	real	data.	In	other	situations	where	this	is	not	
possible,	 the	 modelers	 calibrate	 the	 values	 of	 parameters	 arbitrarily,	 which	
influences	 the	 robustness	 of	 the	 results.	 In	 addition,	 there	 is	 no	 standard	
procedure	 of	 model	 building	 and	 analysis.	 With	 the	 advance	 of	 computer	
science	 and	more	 applications	 of	 ABMs,	 researchers	 have	 intended	 to	 design	
procedures	 to	 overcome	 the	 limitations	 and	 to	 integrate	 other	 modeling	
















(HFM)	 bridged	 the	 generic	 formal	 models	 with	 appreciative	 theories	 by	
incorporating	historical	details	of	these	theories	into	the	models	(Yoon	and	Lee	
2009).		
The	 HFM	 is	 a	 formal	 modelling	 tool	 based	 on	 the	 theory	 of	 evolutionary	
economics	 that	 specifically	 focuses	 on	 industrial	 evolution	 and	 dynamics.	
According	to	Malerba	and	Orsenigo	(1996),	 there	are	 three	 levels	 in	analyzing	
industrial	 evolution	 and	 dynamics:	 the	 first	 level	 is	 industrial	 dynamics;	 the	
second	 level	 is	structural	dynamics;	and	the	 third	 level	 is	structural	evolution.	
The	first	level	refers	to	the	specific	features	of	the	industry	such	as	the	growth	
and	 distribution	 size	 of	 firms.	 The	 second	 level	 refers	 to	 the	 dynamics	 of	
structure	 in	 the	 industry	 life	 cycle	 such	 as	 the	 entry,	 exist,	 and	 concentration.	
Apart	 from	 the	 dimensions	 mentioned	 in	 previous	 levels,	 the	 structural	
evolution	approach	focuses	on	the	evolution	of	the	industry	over	time,	including	
the	 emergence	 of	 the	 new	 industry,	 the	 changing	 boundaries	 of	 firms,	 the	




size	 and	 growth,	 product	 and	 process	 innovation	 does	 not	 give	 us	 a	 deep	
understanding	of	many	issues	about	the	evolution	of	industries.	The	third	level	
is	a	broader	and	more	complex	level	of	analyzing	the	evolution	of	the	industries.	
First,	 it	 highlights	 the	 transformation	 of	 existing	 products	 and	 innovation	
processes,	 the	 emergence	 of	 new	 technology	 and	 applications	 of	 technical	
advance	 in	 different	 ways.	 Moreover,	 in	 some	 cases	 the	 emergence	 of	 new	
industry	 is	 from	 the	 existing	 industry	 and	 science.	 In	 other	 cases,	 the	 new	
industry	 is	 not	 related	 to	 the	 past	 and	 composed	 of	 new	 firms.	 Besides,	 the	
organization	and	boundaries	of	firms	are	changing	continuously	throughout	the	
evolution	 of	 an	 industry.	 New	 entrants	 may	 appear	 on	 the	 scene,	 with	 some	
exiting	 and	 others	 surviving	 and	 growing.	 Therefore,	 the	 existing	 firms	 will	






connections	 among	 firms,	 suppliers,	 buyers,	 universities,	 governments	 and	
public	 organizations.	 During	 the	 process	 of	 evolution,	 new	 relationships	 will	
emerge;	some	relationships	may	merge	while	others	may	disappear.				
	
The	 model	 of	 structural	 dynamics	 is	 mostly	 unexplored,	 partly	 due	 to	
theoretical	 and	 methodological	 difficulties.	 The	 main	 reason	 for	 modeling	 of	
industrial	dynamics	 is	 the	 lack	of	 the	empirical	 study	of	 the	phenomenon	and	
the	 understanding	 of	 the	 mechanism	 of	 industrial	 evolution.	 To	 develop	 an	
empirical	understanding	of	structural	evolution,	we	need	to	take	the	historical	
account	 of	 the	 industry.	 At	 the	 preliminary	 level,	 some	 key	 features	 of	 the	





HFM	 (History-Friendly	Model),	 first	 proposed	 by	Malerba	 and	Orsenigo,	 is	 an	
empirically	and	historically-founded	theory	of	exploring	the	industry	evolution,	
economic	 change	 and	 technology	 dynamics.	 It	 is	 useful	 in	 explaining	 the	
industrial	 evolution	 in	 sectors	 such	 as	 the	 computer	 and	 pharmaceutical	
industries.	Malerba,	Nelson,	Orsenigo,	and	Winter	explored	the	effects	of	policy	
on	 the	 structure	 of	 computer	 industry	 (Malerba,	 Nelson	 et	 al.	 2001).	Malerba	
and	 Orsenigo	 explored	 the	 long-term	 dynamics	 of	 market	 structure	 and	
innovation	in	the	pharmaceutical	industry,	and	discussed	different	situations	of	
patent	protection	in	the	age	of	random	screening	(Malerba	and	Orsenigo	2001).	
Malerba	 and	 Orsenigo	 explored	 market	 structure	 in	 the	 dynamics	 of	 the	
pharmaceutical	industry	and	biotechnology	industry,	the	model	replicating	the	
main	 patterns	 of	 industry	 evolution	 including	 the	 demand,	 the	 types	 of	
competition	and	the	period	of	random	screening	and	in	the	period	of	molecular	
biology	 (Malerba	 and	 Orsenigo	 2002).	 Pyka	 and	 Saviotti	 applied	 HFM	 in	 the	









industry,	 there	 is	 a	 broad	 area	 for	 HFM	 to	 explore.	 Fontana,	 Guerzoni	 and	
Nuvolari	(2008)	developed	a	model	exploring	the	influence	of	different	patterns	
of	demand	and	technological	opportunities	on	the	industry	evolution	in	the	UK	
and	 US	 in	 the	 course	 of	 the	 nineteenth	 century,	 the	 model	 stretches	 the	
application	of	HFM	far	from	the	high-tech	industries	to	manufacturing	industry	
(Fontana,	 Guerzoni	 et	 al.	 2008).	 These	 applications	 of	 HFMs	 are	 only	 the	




The	 HFM	 belongs	 to	 the	 family	 of	 multi-agent	 based	 simulation,	 so	 it	 can	 be	
considered	as	one	variant	of	ABMs	(Yoon	and	Lee	2009,	Garavaglia,	Malerba	et	
al.	 2010),	 as	 it	 shares	 the	 same	 features	 of	 ABM,	 such	 as	 bounded	 rational	
agents,	 learning	 process,	 interactions	 with	 other	 agents,	 path-dependency.	
However,	it	has	its	own	unique	features,	too:	
HISTORY	 Orsenigo,	 one	 of	 the	 developers	 of	 HFMs	 pointed	 out	 that	 the	
evolutionary	economics	is	based	on	empirical	and	historical	case	studies	similar	
to	 the	 biological	 evolution	 theories	 (Orsenigo	 2007).	 The	 history	 of	 a	 specific	
industry	plays	a	vital	role	in	HFMs.	Model	building	and	calibrations	are	guided	
by	 historical	 evidence.	 ABMs	 have	 their	 weaknesses	 in	 the	 arbitrariness	 of	
assumptions	 and	 calibrations,	 but	 HFMs	 are	 built	 through	 continuous	







be	 simplified	 or	 eliminated	 for	 the	 efficacy	 and	 effectiveness	 of	 the	 model.	
Through	trial	and	error	experiments,	the	modeler	can	search	for	the	best	set	of	
parameter	 values	 to	 replicate	 the	 stylized	 facts	 in	 the	 history,	 and	 this	 set	 is	
called	 standard	 set.	 In	 summary,	history	provides	 two	methods	 for	evaluating	
HFMs:	 consistency	 of	 assumptions	 and	 consistency	 of	 simulation	 results	with	
historical	evidence.	
SPECIFIC	 Although	 HFMs	 can	 be	 built	 on	 a	 national	 or	 global	 level,	 they	 are	
focused	 on	 a	 certain	 period	 of	 history.	 Science	 and	 technology,	 institutions,	
policies,	 products	 and	 market	 conditions	 are	 different	 in	 terms	 of	 time	 and	
geographical	 location.	Neo-classic	 economics	 explain	 heterogeneous	 economic	
phenomena	 under	 the	 same	 framework,	 but	 evolutionary	 economics	 take	 the	
historical	 and	 geographical	 account	 into	 the	 explanation.	 Drug	
commercialization	 in	 the	 US	 is	 different	 from	 U.K.,	 and	 the	 mechanisms	 of	
orphan	 drug	 R&D	 before	 the	 1980s	 were	 different	 from	 after	 the	 1980s.	 So,	
history	and	geographical	 location	are	 important	 in	explaining	agents’	behavior	
in	 evolutionary	 economics.	 To	 capture	 the	 historical	 and	 geographical	
specificities,	 different	HFMs	 are	 required.	 For	 instance,	Malerba	 has	 built	 one	
HFM	to	describe	the	pharmaceutical	R&D	process	based	on	random	screening,	
and	other	models	to	replicate	the	R&D	process	based	on	molecular	biology.	
CALIBRATION	 HFM	 provides	 an	 important	 way	 to	 calibrate	 the	 model.	 The	
arbitrariness	 of	 ABMs	 is	 due	 to	 the	 lack	 of	 historical	 evidence,	 but	 the	












step	 is	 to	 describe	 the	 history	 of	 a	 specific	 industry	 based	 on	 existing	 or	
appreciative	 theories	 which	 include	 brief	 surveys,	 theoretical	 background	 of	
focused	factors	and	mechanisms	influencing	the	evolution	process.	Based	on	the	
history	 of	 a	 specific	 industry,	 a	 model	 is	 built	 to	 replicate	 the	 history	 by	 a	
computational	program	and	a	 set	of	parameters.	The	 collection	of	parameters	
used	to	build	the	history-replicating	simulation	is	called	the	standard	setting.	An	
HFM	 cannot	 replicate	 every	 detail	 in	 the	 history,	 as	 it	 only	 replicates	 several	
major	features	of	the	history	according	to	selected	appreciative	theories.	After	a	
run	 of	 the	 history-replicating	 simulation,	 the	 last	 step	 is	 to	 build	 history-
divergent	 simulation.	 In	 history-divergent	 simulation,	 the	 values	 of	 important	





industry	 but	 also	 to	 test	 the	 logic	 of	 policy	 heuristically,	 however,	 the	
application	 of	 HFMs	 in	 policy	 implication	 has	 not	 been	 very	much	 addressed	
(Yoon	and	Lee	2009).	The	social	system	is	a	complex	system,	and	the	complexity	
is	 the	core	of	 the	dynamic	economic	system	(Pyka	and	Fagiolo	2007).	But,	 the	
complexity	 is	 lost	 in	 the	 formal	modeling.	ABMs	are	developed	predominantly	
with	the	complex	system	and	evolutionary	program	(Yoon	and	Lee	2009).	Some	
ABMs	 involve	 a	 certain	 level	 of	 complexity	 and	 use	 different	 mathematical	
methods	 to	 replicate	 the	 complexity	 in	 the	 real	 world.	 However,	 the	 current	
applications	of	HFMs	don’t	employ	a	high-level	of	complexity,	and	some	of	the	
assumptions	 in	 the	model	 are	 arbitrary.	 The	 family	 of	 HFMs	 still	 has	 a	 great	







The	 concept	 of	 complexity	 is	 critical	 in	 explaining	 the	 socio-economic	 system,	
and	to	increase	the	level	of	complexity	is	one	of	the	critical	methods	to	improve	
the	HFMs.	Traditionally,	many	systems	were	treated	as	a	linear	system,	like	the	
mechanical	 system,	 biological	 system,	 and	 economic	 system,	 and	 the	way	we	
analyze	them	is	through	decomposition.	However,	with	the	growing	knowledge,	
we	 found	not	all	 the	system	 in	 the	real	world	 is	 linear,	and	not	all	 the	system	








The	 characteristics	 of	 CAS	 are	 described	 in	 Chapter	 2,	 including	 independent	
agents,	 non-linearity,	 emergent,	 and	 self-organization.	 Beside	 those,	 CAS	 is	
embedded	in	another	CAS,	so	each	individual	agent	in	a	CAS	is	itself	a	CAS.	For	
instance,	 in	 pharmaceutical	 innovation	 system,	 a	 biotechnology	 company	 is	 a	






rather	 embraces	 a	number	of	 theories.	Historical	 data	 are	 the	 acute	 source	of	
information	 because	 they	 play	 an	 important	 role	 in	 informing	 the	 future.	
Although	 the	 extents	 to	 which	 systems	 are	 history-friendly	 are	 various,	
complexity	 science	 validates	 the	 history	 data	 to	 the	 states	 of	 the	 system.	





system.	 New	 elements	 or	 creative	 behavior	 can	 emerge	 in	 CAS	 at	 any	 time.	
Several	 tools	 are	 used	 to	 study	 CAS,	 such	 as,	 Markov	 chain	 that	 is	 the	 most	





The	 computational	model	 implemented	 by	 computer	 program	 represents	 the	
behavior	of	the	social	system.	The	model	is	an	approximation,	simplification	of	
the	 real	 world.	 It	 consists	 of	 a	 set	 of	 variables,	 mathematical	 equations	 to	
stimulate	 the	 changes	 of	 the	 phenomenon.	 Because	 of	 the	 high	 complexity	 of	
CAS,	 traditional	 modeling	 methodologies	 are	 considered	 inadequate.	 The	







other	 agents.	 The	 interactions	 and	 feedback	 loops	 between	 agents	 can	 create	
change	or	stability	in	the	system.	To	better	understand	these	complex	systems,	
agent-based	 simulation	 is	 designed	 to	 simulate	 the	 complexity	 using	 tools	 as	
genetic	algorithms,	artificial	neural	networks,	and	other	mathematical	methods.	
	
There	are	 three	key	elements	 for	 complex	adaptive	 system	design:	 the	 first	 is	
creating	environments	in	which	the	system	can	evolve	naturally	over	time;	then	
setting	 the	 simple	 rules	 and	 minimum	 specifications;	 and	 finally,	 providing	
broad	boundaries	 for	 the	natural	 creativity	 to	 emerge	 from	 the	 system	 (Plsek	
and	Greenhalgh	2001).	The	model	 analysis	process	 is	 also	 a	process	of	model	
improvement.	The	data	 generated	 from	 simulation	will	 be	 evaluated	 from	 the	









Our	research	objective	 is	 the	orphan	drug	 innovation	system	 in	 the	US,	which	
can	 be	 considered	 as	 part	 of	 the	 healthcare	 system.	 In	 the	 past,	 some	
researchers	 in	 the	 healthcare	 sector	 considered	 the	 health	 care	 system	 as	 a	
machine.	The	mechanic	metaphor	shed	lights	on	how	the	system	can	be	studied:	
through	breaking	down	the	system	into	units,	identifying	the	broken	units,	and	
replacing	 or	 improving	 it.	 Actually,	 due	 to	 the	 interactions	 and	
interdependences	 of	 system	 determinants,	 the	 health	 care	 system	 does	 not	
follow	the	simple	linear	mechanism;	policy-makers	should	adopt	new	methods	
to	design	their	interventions	better.	Recently,	researchers	and	managers	in	the	




perhaps	 the	 most	 complex	 system	 in	 the	 domain	 of	 the	 social	 system.	
Healthcare	system	is	composed	of	a	large	number	of	players,	and	it	is	embedded	
in	 other	 social	 systems,	 such	 as	 industrial	 and	 political	 systems.	 There	 is	 no	
uniform	central	control	in	the	system,	where	the	order	is	emergent.	The	system	
is	 adaptive,	 so	 organizations	 learn	 and	 adapt	 to	 new	 policies	 over	 time	 and	
behaviors	 converge	 to	 develop	 the	 novel	 collective	 pattern.	 Because	 of	 the	
diversity	of	organizations	and	interactions	among	them,	the	healthcare	sector	is	
an	 ideal	 field	 for	 the	 application	 of	 complexity	 science.	 Moreover,	 the	 CAS	
simulation	 is	 a	 productive	 means	 by	 which	 to	 apply	 complexity	 science	 to	
address	health	care	issues	(Dooley	2002).	
	
Social	 science	 has	 begun	 to	 use	 the	methods	 and	metaphors	 from	 complexity	
theory	since	the	early	1990s,	and	an	increasing	number	of	researchers	explored	





during	 the	same	period,	 the	application	of	 complexity	 science	extended	 to	 the	
innovation.	 Until	 now,	 a	 large	 number	 of	 researchers	 have	 applied	 complex	
theory	to	explain	the	innovation	system	from	various	perspectives.		
	
Begun,	 Zimmerman	 and	 Dooley	 analyzed	 the	 healthcare	 organization	 as	 a	
complex	 adaptive	 system	 from	 the	 perspectives	 of	 healthcare	 innovation	 and	
healthcare	 integrated	 system,	 their	 research	 focused	 on	 managing	 the	
relationships	 among	 organizations	 and	 motivating	 changes	 and	 innovations	
(Begun,	Zimmerman	et	al.	2003).	Plesk	explored	the	spread	of	innovation	in	the	
healthcare	sector—since	the	healthcare	system	is	complex,	how	that	complexity	
affects	 the	 generation	 and	 spread	 of	 innovations	 (Plsek	 2003).	 Rouse	
emphasized	 the	 ‘information’	 and	 ‘incentives’	 in	 the	 healthcare	 system:	 the	
improvement	 of	 the	 system	 requires	 the	 stakeholders	 have	 abundant	
information	 about	 the	whole	 system,	 information	 can	 be	 used	 to	 evaluate	 the	
situations	 in	 this	 complex	 adaptive	 system	 and	 drive	 the	 adjustments	 of	
incentives	 and	 inhibitions	 to	 stimulate	 stakeholders	 to	 alter	 their	 activities	 to	
provide	 high-value	 health	 care	 (Rouse	 2008).	 Moore	 and	 other	 researchers	
modeled	 the	 precaution	 of	 changes	 in	 medical	 demand	 and	 evaluated	 the	
relevant	policy	actions	(Moore	and	Moore	2011).	Complex	theory	broadens	and	
deepens	the	scope	of	study	of	the	healthcare	system,	moreover,	provides	better	




Policy-makers	 face	 big	 challenges	 in	 designing	 robust	 policy	 for	 the	 complex	
social	 system.	Policymakers	have	always	drawn	on	a	wide	range	of	sources	of	
evidence	in	making	decisions	(Mays,	Pope	et	al.	2005).	The	ideal	policy-making	
process	 starts	 from	 setting	 clear	 objectives,	 and	 then	 finds	 the	 relevant	
information	 and	 possible	 solutions,	 at	 last	 devises	 alternatives	 to	 fit	 the	







Policy-makers	 should	 firstly	 create	 rich	 evidence	 base	 through	 studying	 the	
problem,	then	exploring	alternative	solutions	and	testing	them	in	the	system.	To	
arrive	 at	 the	 agreement,	 stakeholders	 need	 to	 understand	 all	 the	 possible	
benefits	 and	 losses.	 The	 robustness	 of	 policy	 design	 requires	 an	 extensive	
exploration	 and	 exploitation	 of	 the	 internal	 and	 external	 factors	 that	 may	
influence	the	effect	of	new	policies.	
	
Designing	 the	 policy	 for	 the	 complex	 adaptive	 system	 is	 extremely	 difficult	
regarding	 the	 ambiguous	 objective,	 uncertain	 methods,	 diverse	 stakeholders	
and	the	difficulty	to	get	access	to	information.	In	the	complex	adaptive	system,	
the	 individual	 agent	 has	 the	 ability	 to	 adapt	 their	 behavior	 to	 the	 dynamic	
environment	 including	 new	policies.	 The	 adaptation	 process	 is	 progressive;	 it	









Policy	 issues	 for	 public	 health	 can	 be	 characterized	 as	 designing	 within	 a	
complex	 adaptive	 system	 (Holland	 1992,	 Moore	 and	 Moore	 2011).	 Public	
healthcare	 as	 a	 complex	 adaptive	 system	 of	 systems,	 policy	 design	 for	 such	
system	 requires	 an	 understanding	 of	 the	 various	 interests,	 actions,	 and	
resources	 of	 multiple	 stakeholders.	 Although	 the	 complex	 adaptive	 system	
cannot	 be	 controlled,	 it	 can	 be	 designed.	 The	 design	 of	 the	 healthcare	 system	
should	 start	 with	 the	 recognition	 that	 the	 system	 involves	 all	 stakeholder	
organizations,	 including	 customers,	 partners,	 competitors,	 channels	 or	






satisfaction	 for	 all	 the	 stakeholders	 within	 or	 beyond	 the	 system.	 The	
malfunction	of	the	current	system	is	because	of	the	complexity,	which	leads	to	




vast	 number	 of	 information	 and	 relationships	 hidden	 under	 the	 scenarios	 in	
support	 of	 their	 solutions.	 The	 CAS	 model	 can	 simulate	 the	 various	
environments	 and	 interventions	 and	 the	 processes	 in	 which	 the	 possible	
outcomes	 emerge	 from	 the	decisions	of	 policymakers.	Thus,	 the	CAS	provides	





The	same	as	evolutionary	economics,	 the	evolutionary	program	 is	 inspired	by	
the	Darwin’s	 ‘biological	evolution’	 theory.	The	Darwinian	principle	of	 ‘survival	
of	 the	 fittest’	 is	 the	 theoretical	 basis	 of	 evolutionary	 computation	 including	
genetic	algorithms,	evolutionary	program,	and	evolution	strategy	(Fogel	1994).	
The	theory	of	natural	selection,	first	introduced	by	Darwin	in	1859	in	the	book	





role	 in	 improving	 the	 chances	 of	 the	 survival	 of	 the	particular	 individual.	 The	
traits	that	increase	the	survival	of	an	organism	will	often	lead	to	the	rise	of	its	
reproductive	 rate.	 The	 advantageous	 traits	 can	 be	 passed	 from	 parents	 to	







parents	 are	 better	 adapted	 to	 the	 environment.	 In	 this	 way,	 the	 natural	
environment	of	an	organism	 ‘selects’	 for	 traits	with	a	 reproductive	advantage,	
causing	the	gradual	evolution	of	life.	
	
In	 the	 20th	 century,	 genetics	 was	 integrated	 with	 Darwin’	 theory	 of	 natural	
evolution,	and	the	evolutionary	phenomena	had	been	further	explained	in	way	
of	 genetic	 mechanisms.	 Natural	 selection	 is	 the	 non-random	 process	 through	
which	biologic	characteristics	of	 the	population	become	more	or	 less	common	
because	 of	 the	 function	 of	 differential	 reproduction.	 Natural	 selection	 occurs	
through	 changes	 in	 heritable	 traits	 and	 acts	 on	 the	 phenotype-the	 complete	
collection	of	traits.	Evolution	processes	give	rise	to	the	diversity	of	population;	
the	genetic	diversity	existing	in	the	population	is	a	key	factor	 in	the	evolution.	
Evolution	 also	 influences	 the	 form	 and	 behavior	 of	 organisms;	 the	 most	
important	 feature	 is	 the	 adaption	 that	 increases	 the	 fitness	 of	 an	 organism	 to	





principle	 of	 natural	 selection	 and	 genetics.	 It	 was	 first	 introduced	 and	
investigated	by	 John	Holland	 in	 the	1960s	and	then	developed	by	him	and	his	
students	 and	 colleagues	 in	 the	 1970s.	 The	 original	 objective	 of	 genetic	
algorithms	is	not	to	deal	with	the	specific	problem,	but	rather	to	shed	lights	on	
the	 phenomenon	 of	 adaptation	 through	 the	 computational	 system.	 The	 first	
book	‘Adaptation	in	Nature	and	Artificial	Systems’	of	Holland	published	in	1975	
introduced	 genetic	 algorithms	 in	 light	 of	 biological	 evolution	 and	 theoretical	
foundation	for	adaptation	through	GA.		
 
Genetic	 algorithms	 are	 efficient,	 adaptive	 and	 robust	 search	 and	 optimization	





there	have	been	extensive	 interactions	among	 researchers.	 It	has	been	widely	
and	successfully	used	in	simulating	the	living	system	of	biology,	sociology,	and	
economics.	 Some	 classic	 applications	 include	 scheduling	 (Hou,	 Ansari	 et	 al.	
1994,	Gonçalves,	Mendes	 et	 al.	 2008),	 stock	market	 trading	 (Conrad	 and	Kaul	
1998,	 Allen	 and	 Karjalainen	 1999)	 ,	 transportation	 (Potvin	 1996,	 Altiparmak,	










of	 chromosomes	 (Figure	25).	A	 chromosome	 is	 a	 string	of	DNA,	 and	 it	 can	be	
divided	into	genes-	the	functional	blocks	of	DNA.	DNA	encodes	a	particular	type	
of	 protein	 that	 determines	 a	 trait	 in	 the	 organism,	 such	 as	 hair	 color.	 The	
different	possible	settings	(black,	blonde,	red)	for	a	trait	are	called	alleles.	Each	
gene	 has	 a	 particular	 locus	 on	 the	 chromosome	 and	 holds	 the	 information	 to	














solve	 complex	 optimization	 problems.	 In	 genetic	 algorithms,	 chromosome	
means	a	possible	solution	to	a	given	problem,	with	most	of	them	encoded	as	a	
bit	string.	The	gene	 is	a	single	bit	or	 some	adjacent	bits	 that	encode	a	specific	
element	 of	 the	 possible	 solution.	 The	 allele	 in	 a	 bit	 string	 is	 either	 1	 or	 0.	
Crossover	typically	exchanges	the	subparts	of	two	single	chromosome	parents;	
mutation	 randomly	 changes	 the	 allele	 values	 of	 one	 or	 more	 locus	 of	 the	
chromosome.	
	
As	 shown	 in	 Figure	 26,	 the	 procedures	 of	 GA	 are	 typically	 implemented	 as	
follows:	
1)	 Translation	 The	 problem	 to	 be	 solved	 is	 defined	 and	 translated	 to	 an	
evaluation	function	that	indicates	the	fitness	of	any	candidate	solution.	






3)	 Evaluation	 Each	 chromosome	 in	 the	 population	 is	 decoded	 into	 a	 form	
appropriate	 for	evaluation	and	 is	assigned	a	 fitness	score	according	to	the	
objective.	
4)	 Selection	 Each	 chromosome	 is	 assigned	 a	 probability	 of	 reproduction;	 it	
refers	 to	 the	 likelihood	of	selection.	The	higher	 fitness	a	chromosome	has,	
the	more	it	is	likely	to	be	selected	to	reproduce.	
According	 to	 the	 assigned	 probability	 of	 reproduction,	 a	 new	 population	 of	
chromosomes	 is	 generated	 by	 selection	 from	 the	 current	 population.	 The	
generation	is	via	specific	genetic	operator:	crossover	and	mutation.		
5)	 Crossover	 This	 operator	 selects	 a	 locus	 and	 exchanges	 the	 subsequence	
between	 two	 chromosomes	 to	 generate	 two	 offspring	 with	 possibility	 Pc.	
For	instance,	two	8-bit	binary	strings	10000001	and	11111111	are	crossed	
over	from	the	third	locus	in	each	to	generate	two	offspring	10011111	and	
11100001.	 Without	 crossing-over,	 the	 offspring	 are	 precisely	 the	 same	
copies	of	the	parents.	











8)	 The	 process	 is	 ceased	 once	 a	 suitable	 solution	 has	 been	 found	 or	 if	 the	
available	computing	 time	has	expired;	otherwise,	 the	process	continues	 to	




























Encoding	 is	 the	 central	 factor	 in	 the	 success	 of	 genetic	 algorithms.	 Binary	
encoding	 is	 the	 most	 common	 encoding,	 while	 other	 applications	 use	 the	
alphabet	 character	 or	 real	 number	 to	 form	 chromosomes.	 Binary	 encoding	 is	
widely	 used	 because	 the	 genetic	 algorithm	 was	 developed	 based	 on	 such	
encoding	and	some	GA	applications	 tended	 to	 follow	this	 lead.	The	 theory	has	




According	 to	 Darwin’s	 theory	 of	 evolution,	 the	 fittest	 one	 can	 survive	 and	
generate	new	offspring.	The	problem	is	how	to	select	 the	better	 individuals	 in	
the	 population.	 The	 most	 commonly	 used	 methods	 of	 selection	 are:	 Roulette	
Wheel	Selection,	Rank	Selection,	Tournament	Selection	and	Elitism	Selection.			
	


















runs	 several	 ‘Tournaments’	 among	 them.	 The	 winner	 of	 each	 tournament	 is	
selected.	The	outcome	of	selection	can	be	adjusted	by	changing	the	size	of	 the	
tournament.	The	 larger	the	tournament,	 the	 less	chance	that	weaker	members	
are	selected.	
	
Elitist	 Selection	 copies	 the	member	 with	 highest	 fitness	 from	 parents	 to	 the	
new	 generation;	 the	 rest	 is	 done	 in	 a	 classical	 way.	 When	 generating	 new	
offspring	through	mutation	and	crossover,	there	is	a	significant	chance	of	losing	















The	 crossover	 operator	 has	 been	 considered	 as	 the	 distinguishing	 feature	 of	
genetic	 algorithms.	 The	 idea	 behind	 crossover	 is	 that	 the	 new	 generation	 is	















Two	 Points	 Crossover	 selects	 two	 crossover	 points	 (red	 lines),	 copies	 the	
binary	 string	 from	beginning	 to	 the	 first	 crossover	point	 from	 the	 first	parent	















Mutation	 is	 a	 crucial	 genetic	 operator	 that	 alters	 one	 or	more	 of	 the	 bit	 gene	














in	 the	 population	 is	 very	 low,	 only	 a	 small	 portion	 (usually	 Pm=0.1%)	 of	







without	 any	 genetic	 operators	 in	 the	 process	 of	 genetic	 algorithms,	 the	 new	
generation	 is	always	 the	copies	of	best	 individuals	 from	 the	population.	Using	
selection	and	crossover	will	 lead	 to	 the	algorithms	 to	 converge	on	a	good	but	
not	 the	best	 solution.	 If	only	using	mutation,	 the	algorithms	are	 similar	 to	 the	
random	 walk	 through	 the	 search	 space.	 If	 using	 selection	 and	 mutation,	 the	
algorithms	 are	 similar	 to	 hill	 climbing	 algorithms	 that	 starts	 at	 an	 arbitrary	




Since	 population	 contains	 thousands	 of	 information	 (knowledge),	 genetic	
algorithms	combine	 the	good	 information	 in	a	 solution	with	good	 information	
from	 another	 solution	 to	 create	 a	 better	 solution	 with	 good	 information	
inherited	 from	 both	 parents.	 Via	 the	 combination	 of	 selection,	 crossover,	 and	
mutation,	genetic	algorithms	converge	over	successive	generations	towards	the	
global	 optimum.	 These	 operations	 produce	 a	 fast,	 powerful	 and	 robust	
technique	 because	 genetic	 algorithms	 integrate	 direction	 and	 chance	 in	 the	
process	of	optimization	in	an	effective	and	efficient	way.			
	
The	 evolution	 is	 a	 method	 for	 designing	 innovative	 solutions	 to	 the	 complex	
system	 (Mitchell	 1998).	 Genetic	 algorithms	 are	 different	 from	 most	 of	 the	









deterministic	 rules;	 forth,	 it	 can	 be	 used	 to	 adapt	 solution	 to	 changing	
environment,	 in	 contrary,	 traditional	 methods	 are	 not	 robust	 to	 dynamic	
changes.	 However,	 genetic	 algorithms	 are	 not	 the	 best	 way	 to	 solve	 every	






on	 the	natural	phenomenon	but	also	on	 the	 social	phenomenon.	A	 steady	and	
sharp	 growing	 use	 of	multi-agent-based	 simulation	 accelerates	 the	 growth	 of	
software	platform	for	modeling.	Recently,	an	increasing	number	of	Agent-Based	
Software	Toolkits	(ABST)	have	become	available	for	agent-based	modeling,	for	
instance,	 NetLogo,	 Swarm,	 Repast,	 MASON,	 Ascape,	 and	 Anylogic.	 The	 aim	 of	
these	toolkits	is	to	(1)	provide	a	certain	level	of	abstraction	in	which	users	can	
develop	their	objects;	(2)	incorporate	some	features	of	visual	programming	that	
make	 the	 development	 easier;	 (3)	 have	 run-timing	 tests	 and	 debugging	





















a	 powerful	 too,	 but	 users	 should	 be	 experienced	 in	 Objective	 C	 or	 Java	 and	
familiar	with	object	orientation	methodology	and	learn	some	Swarm	code.		
	
MASON	 was	 developed	 as	 a	 smaller	 and	 faster	 alternative	 to	 Repast,	 and	 it	
demands	a	 significant	amount	of	 Java	knowledge	on	 its	users.	NetLogo	has	 its	
own	programming	language	that	is	easier	t o s t ar t  than	Java	and	Objective	C;	
moreover,	 it	 has	 a	 very	 accessible	 model	 library	 in	 which	 models	 can	 be	
extended.	 It’s	 believed	 to	 be	 by	 far	 the	 most	 professional	 platform	 in	 its	
appearance	and	documentation	(Allan	2009).	A	review	identifies	 that	NetLogo	
is	well	designed	and	documented	and	very	easy	to	learn	and	use	while	Repast	is	
the	 platform	 that	 is	 recommended	 for	 models	 that	 are	 especially	 demanding	














Swarm	 Large-scale	 Slow	 Objective	C;	Java	 General	purpose	 Stable	and	clear	but	difficult	to	use	











Multi-Agent	 Based	 Simulation	 of	 the	 complex	 system.	 It	 is	 free	 and	 available	
from	 http://ftp.swarm.org.	 Swarm	 contains	 a	 set	 of	 libraries	 that	 user	 can	
choose	 and	 call	 features;	 it	 helps	 users	 to	 develop	 the	 model	 through	 well-
defined	protocols	and	powerful	tools.	It	was	initially	developed	for	multi-agent	
simulation	of	CAS	(Zheng,	Son	et	al.	2013).		Since	its	first	release,	it	has	become	
one	 of	 the	 most	 famous,	 widespread	 and	 influential	 simulation	 frameworks	
(Haupt	and	Haupt	2004).		
	
In	 the	 Swarm	 model,	 there	 are	 some	 agents,	 some	 agents	 representing	 the	















NetLogo	 is	 best	 suited	 for	 modeling	 complex	 system	 over	 time.	 Users	 set	 up	
‘agents’	 and	give	 ‘commands’	 to	 them	 to	 let	 them	operate	 independently.	This	










Nowadays	 we	 can	 see	 complexity	 is	 everywhere,	 but	 our	 understanding	 of	 a	
phenomenon	 always	 follows	 the	 pattern	 from	 simplicity	 to	 complexity.	 For	
instance,	 our	 understanding	 of	 innovation	 system	 is	 from	 linear	 system,	 non-
linear	system	and	finally	to	complex	system.	Our	need	to	understand	the	more	
complex	 system	 is	 a	 result	of	 the	growth	 in	human	knowledge,	 so	we	 created	
more	 sophisticated	 tools	 enabling	 us	 to	 ask	 and	 answer	 questions	 about	 the	
complex	world	(Wilensky	and	Rand	2015).		
	
The	 agent-based	 modeling	 is	 a	 method	 to	 investigate	 the	 complex	 adaptive	
system.	 An	 ‘agent’	 is	 an	 autonomous	 computational	 individual	 or	 object	 with	
particular	 properties	 and	 behavior,	 and	 agent-based	 modeling	 is	 a	 kind	 of	
computational	modeling	whereby	a	social	or	natural	phenomenon	is	modeled	in	
terms	of	agents	and	their	actions.	ABMs	are	a	powerful	technique	for	simulating	
the	 complex	adaptive	 system	with	 the	 features	of	 ‘dynamics’	 and	 ‘emergence’.	
There	 is	 currently	 a	 growing	 interest	 in	 developing	 ABMs	 as	 a	 method	
applicable	 to	 the	 study	 of	 the	 large-scale	 system.	 The	 agent-based	 modeling	
provides	a	unique	potential	for	the	research	of	innovation	system.	The	potential	
has	 only	 been	 partially	 explored,	 but	 there	 are	 still	many	 new	 and	 promising	
areas	to	investigate.	
	
Recently,	an	 increasing	number	of	modeling	 toolkits	have	become	available	 to	
facilitate	ABMs,	like	Swarm,	NetLogo,	Repast,	and	MASON.	In	this	research,	the	
model	was	firstly	built	based	on	the	software	Swarm,	which	is	the	earliest 	and	
most	 stable	 toolkit	 for	 Multi-Agent	 Based	 Simulation.	 It	 uses	 both	 JAVA	 and	






to	 complete	 all	 the	 tasks	 except	 the	 difficulties	 in	 installation	 and	 very	 few	
supports	 from	 the	 community.	But,	when	 it	was	extended	 further	by	applying	
Genetic	 Algorithms	 to	 model	 the	 drug	 R&D	 process	 and	 the	 networks	 of	 the	




some	 experts,	 it	 has	 become	 outdated	 (Robertson	 2005).	 Overall,	 Swarm’s	






























The	 second	 model	 is	 built	 by	 NetLogo,	 which	 is	 developed	 by	 Centre	 for	
Connected	Learning	and	Computer-Based	Modeling	of	Northwestern	University.	
Like	 Swarm,	 NetLogo	 provides	 an	 integrated	 library	 of	 classes	 for	 creating,	
running,	displaying	and	 collecting	data	 from	 the	ABMs.	Extensive	user	 guides,	
tutorials	and	demonstration	models	are	available	from	the	system	website,	and	





NetLogo	 model	 is	 written	 in	 its	 own	 programming	 language.	 Compared	 with	
SWARM,	NetLogo	shows	the	advantages	of	 the	simple	and	clear	structure,	 fast	
speed	 and	 especially	 the	 ability	 to	 model	 the	 complex	 adaptive	 system.	
Furthermore,	NetLogo	provides	more	powerful	display	 tools	 (2D	and	3D)	 that	
help	users	 to	do	 the	 thorough	analysis.	Finally,	because	users	can	develop	 the	
model	without	learning	any	comprehensive	programming	language,	it	is	quite	a	












perform	considerable	adaption	process	 to	achieve	 successful	 innovation.	They	
can	 change	 their	 innovation	 output	 incrementally	 by	 exploitation	 or	 radically	
through	 exploration.	 	 In	 most	 cases,	 organizations	 exhibit	 a	 mixture	 of	 both	
learning	 paradigms.	 The	 company	 should	 reach	 an	 appropriate	 equilibrium	
between	 the	 exploitation	 and	 exploration;	 otherwise,	 it	may	 end	 up	 suffering	
from	 sub-optimization.	 For	 instance,	 if	 the	 company	 invests	 too	 much	 on	
exploiting	 old	 knowledge,	 it	 may	 lose	 its	 competitive	 advantage	 among	 its	
competitors.		
	
In	 this	 chapter,	 we	 first	 recall	 the	 concept	 of	 the	 organizational	 learning	 and	
summarize	 the	characteristics	of	 it.	Subsequently,	 the	model	of	 ‘organizational	
learning’	 is	 articulated	 through	 Genetic	 Algorithms	 (GAs),	 and	 the	
characteristics	 of	 organizational	 learning	 activities	 are	 simulated	 and	
experimented.	 The	 differences	 and	 relationships	 between	 exploration	 and	
exploitation	 at	 the	 level	 of	 intra-organizational	 learning	 and	 inter-






based	 theory	 of	 the	 firm	 offers	 a	 platform	 for	 considering	 the	 company	 as	 a	
dynamic,	 evolving,	 quasi-autonomous	 system	 of	 knowledge	 production	 and	












knowledge	 into	 a	 product	 (Madhavan	 and	 Grover	 1998).	 To	 get	 a	 more	
comprehensive	understanding	of	 the	 relationship	between	 the	knowledge	and	
drug	 innovation	 process,	 we	 need	 to	 consider	 the	 paradigm	 of	 learning	
embedded	 into	 the	 product	 during	 the	 various	 stage	 of	 the	 drug	 innovation	
process.	
	
Different	 stages	 of	 S&T	 development	 and	 different	 types	 of	 companies	 imply	
different	 paradigms	 of	 learning.	 In	 this	 section,	 the	 research	 employs	March’s	




The	 organizational	 learning	 is	 a	 routine-based,	 history	 dependent	 and	 target-
oriented	 process;	 within	 this	 framework,	 organizational	 learning	 can	 be	
considered	 as	 encoding	 inferences	 from	 the	 history	 into	 routines	 that	 guide	
behavior	(Levitt	and	March	1988).	The	‘routines’	include	the	rules,	procedures,	
strategies,	 and	 technology,	 all	 of	 which	 are	 the	 basis	 of	 organization	
construction	 and	 operation.	 Knowledge	 is	 stored	 in	 their	 routines,	 and	
organizations	accumulate	knowledge	over	time	(March	1991).		
	
Learning	 occurs	 through	 two	 primary	 mechanisms:	 trial-and-error	












This	 section	 is	 organized	 into	 three	 parts.	 First,	 the	 account	 is	 given	 of	 two	
learning	processes:	exploitation	and	exploration.	Then,	attention	is	given	to	the	
intra-	 and	 inter-	 organizational	 learning	 processes.	 The	 last	 part	 will	 be	




Learning	 is	 an	 important	 way	 to	 adaptively	 improve	 organizational	
performance	 and	 strengthen	 competitive	 advantage.	 The	 adaptive	 intelligence	
of	organization	can	be	divided	into	two	activities,	exploration	and	exploitation.	
The	outcome	of	exploitation	is	predictable,	while	the	outcome	of	exploration	is	
much	 more	 uncertain	 (Powell,	 Koput	 et	 al.	 1996).	 If	 the	 organization	 only	
engages	in	exploration,	it	will	possibly	never	discover	the	useful	knowledge,	and	
the	 organization	 that	 engages	 exclusively	 in	 the	 exploitation	will	 trap	 itself	 in	
the	 situation	 of	 ‘suboptimal	 equilibrium’	 (Cohen	 and	 Levinthal	 1989).	
Organizations	 should	 engage	 in	 both	 exploitation	 and	 exploration	 to	 sustain	
current	viability	as	well	as	develop	the	future	competitive	advantage.		
	
Exploration	 is	a	risky,	costly	process	but	 the	return	of	 it	 is	negative,	uncertain	
and	 distant;	 while	 exploitation	 is	 a	 stable	 and	 inexpensive	 process,	 and	 the	
returns	of	exploitation	are	more	positive,	predictable	and	close	(March	1991).	
Exploration	can	be	considered	as	 the	 innovation	capability	of	 the	company	by	
creating	 new	 knowledge,	 while	 exploitation	 is	 to	 improve	 or	 develop	 the	
current	 knowledge.	 The	 process	 of	 exploitation	 that	 is	 dependent	 on	
incremental	learning	is	in	a	continuous	way;	in	contrast,	the	exploration	that	is	
dependent	 on	 radical	 learning	 follows	 a	 discontinuous	 way.	 Both	 occur	





companies	 engage	 in	 both	 learning	 activities	 simultaneously	 because	 once	
potentially	 valuable	knowledge	has	been	gained	 through	exploration,	 the	 firm	
tries	 to	 exploit	 them	 further.	 The	 exploration-exploitation	 model	 implies	 a	
sequence	 for	 the	 use	 of	 this	 process	 by	 organizations	 (Rothaermel	 and	Deeds	
2004).	
	
Both	 exploration	 and	 exploitation	 are	 essential	 components	 in	 organizational	
learning	 and	 are	 critical	 for	 an	 organization’s	 competency.	 However,	
organizations	should	make	choices	in	allocating	resources	between	exploration	
and	exploitation;	 the	choice	 is	affected	by	 their	distributed	costs,	benefits	and	
ecological	interactions	(March	1991).		
	
An	 exploration-exploitation	 model	 of	 organizational	 learning	 built	 by	 March	
(1991)	explored	the	relations	of	exploration	and	exploitation	in	organizational	
learning	 and	 examined	 how	 to	 allocate	 resources	 between	 them.	 The	 way	 of	
development	 and	 diffusion	 of	 the	 organizational	 knowledge	 are	 modeled	 as	
individuals	 learn	 continuously	 from	 organizational	 knowledge	 while	
organizational	 knowledge	 is	 adapting	 to	 individual’s	 knowledge.	 The	





focuses	 on	 intra-organizational	 learning	 process	 and	 another	 one	 focuses	 on	
inter-organizational	learning	process.			
	
Intra-organizational	 learning	 refers	 to	 that	 the	new	knowledge	 is	 created	 and	
developed	 within	 the	 boundaries	 of	 the	 firm;	 inter-organizational	 learning	
refers	 to	 that	 knowledge	 is	 transferred	 from	 outside	 sources	 through	
collaboration	and	acquisition.	The	 intra-	and	 inter-	organizational	 learning	are	
mutually	 interdependent	 and	 complementary	 processes.	 On	 one	 hand,	





for	 better	 learning	 from	 outside;	 on	 the	 other	 hand,	 the	 process	 of	 intra-









an	 important	 source	 of	 knowledge	 creation.	 The	 more	 connections	 a	








both	of	 them	must	be	 applied	 together	 to	 accomplish	 a	 successful	 innovation.	
Exploitation	and	exploration	take	place	both	within	and	between	organizations,	
and	 they	 interact	 through	 intra-	 and	 inter-	 organizational	 learning	 process	
(Holmqvist	 2003).	 Exploration	 and	 exploitation	 can	 occur	 simultaneously	
within	 an	 organization	 or	 through	 interactions	 between	 organizations.	 In	 the	
first	instance,	the	organization	exploits	and	explores	its	knowledge	base	to	find	
the	best	solution;	in	the	second	case,	the	organization	exploits	and	explores	its	
own	 knowledge	 base,	 but	 also	 obtains	 complementary	 knowledge	 from	 other	
organizations.		
	






of	 new	 knowledge,	 or	 the	 employment	 of	 new	 equipment.	 Between	 the	
organizations,	 exploration	 is	 about	 seeking	 new	 partners	 that	 have	 the	
complementary	 competence.	 The	 intra-organizational	 learning	 is	 the	 essential	
part	of	inter-organizational	learning	process	because	what	can	be	learned	from	
inter-organizational	 learning	 lies	 in	 the	 confrontation	 and	 combination	 of	




Intra-organizational	 learning	 favors	 exploitation	 while	 inter-organizational	
learning	favors	exploration	(Holmqvist	2003).	This	is	because	the	higher	extent	
of	 the	 stable	 environment,	 centralized	 coordination	 mechanism,	 and	 formal	
authority	makes	 intra-organizational	 learning	more	stable	and	 less	 innovative.	




Intra-	 and	 inter-	 organizational	 learning	 do	 not	 occur	 separately	 but	 are	
integrated	into	the	learning	process	through	the	transformations	of	exploration	
and	 exploitation.	 A	 model	 built	 by	 Holmqvist	 (2003)	 describes	 the	 dynamics	
between	 learning	 process	 within	 and	 between	 organizations.	 The	
transformations	 between	 exploitation	 and	 exploration	 are	 ‘opening-up’	 and	
‘focusing’.	 ‘Opening-up’	 depicts	 a	 transformation	 from	 an	 ongoing	 process	 of	
exploitation	to	an	ongoing	process	of	exploration;	it	indicates	that	organizations	
choose	 to	 open	 itself	 up	 to	 the	 external	 knowledge.	 ‘Opening-up’	 avoids	
suffering	from	obsolescence	resulting	from	engaging	exclusively	in	exploitation.	
After	 ‘opening	 up’,	 organizations	 discard	 obsolete	 and	 misleading	 knowledge	
from	 a	 variety	 of	 knowledge	 imported	 into	 the	 organization	 by	 exploration.	








• Exploitative	 extension	 occurs	 as	 a	 transition	 of	 exploitation	 inside	 the	
organization	to	exploitation	between	organizations.	Through	exploitative	
extension,	 organizations	 extend	 their	 knowledge	 and	 enable	 their	
knowledge	to	be	exploited	by	their	partners.		
• Exploitative	 internalization	 takes	 place	 as	 a	 transition	 of	 exploitation	
between	organizations	to	exploitation	inside	the	individual	organization.	
After	 exploiting	 partners’	 knowledge,	 organizations	 should	 refine	 and	
incorporate	the	knowledge	they	get	into	its	own	knowledge	base.		
• Explorative	 extension	 occurs	 as	 a	 transition	 of	 exploration	 inside	 the	
organization	 to	 between	 organizations.	 Through	 collaboration,	
organizations	 are	 able	 to	 get	 access	 to	 their	 partners’	 knowledge	 and	
create	new	knowledge	with	their	partners.		
• Explorative	 internalization	 takes	 place	 as	 a	 transition	 of	 exploration	
































Since	 GAs	 have	 drawn	 analogies	 from	 biology	 (Table	 15)	 to	 solve	 an	
optimization	 problem,	 GAs	 start	 with	 the	 chromosomal	 representation	 of	 a	
parameter	set.	The	set	is	coded	as	a	finite-length	binary	string,	and	each	binary	
string	 represents	 selected	 characteristics	 of	 one	 of	 the	 candidates	 in	 the	


















The	 Genetic	 Algorithm	 applied	 in	 our	 model	 is	 an	 abstract	 model	 of	 the	
evolution	 with	 a	 fixed	 population	 of	 individuals	 represented	 by	 fixed-length	





phenomena	 characterized	 as	 complex,	 non-linear	 and	 emergent	 behavior,	
rather	 than	 for	 solving	 a	 particular	 problem.	 The	 key	 point	 of	 the	 GAs	 is	 the	
adaptation	 process	 by	making	 new	 individuals	 using	 genetic	 operators	 rather	
than	 making	 incremental	 changes	 to	 a	 single	 individual,	 and	 GAs	 are	 best	
viewed	as	the	design	tool	for	the	learning	system	(De	Jong	1988).	In	the	learning	
model,	 the	 environment	 defines	 one	 or	more	 tasks,	 and	 the	 learning	 process	
includes	the	skill	acquisition	and	refinement.	The	learning	model	of	GAs	can	be	
visualized	 as	 a	 system	 consisting	 two	 components:	 the	 task	 system	 whose	
performance	 is	 affected	 over	 time	 by	 learning,	 and	 a	 learning	 system	




The	 research	 about	 the	 organizational	 learning	has	 addressed	 the	question	of	
the	location	of	 learning	and	explained	that	it	could	take	place	at	the	individual	
and	 organizational	 level	 (Bapuji	 and	 Crossan	 2004).	 In	 our	 model,	 the	
organizational	 learning	 is	modeled	 at	 the	 organizational	 level,	which	 not	 only	
includes	 the	 intra-organizational	 level	 but	 the	 inter-organizational	 level.	 The	






as	population,	which	 is	 a	 collection	of	 knowledge.	 Each	 chromosome	means	 a	




with	 a	 collection	 of	 knowledge.	 The	 collection	 is	 a	Nk×Nbit	matrix	 that	 has	Nk	




















Each	 organization	 has	 an	 initial	 knowledge	 base,	 which	 is	 codified	 through	 a	





3)	the	initial	fitness	value	of	each	piece	of	knowledge	is	0 ≤ 𝑭 ≤ 20	.		
	
The	population	size	is	constant,	which	means	although	the	reproduction	results	








its	 knowledge	 base	 with	 the	 high	 value	 of	 F.	 With	 respect	 to	 exploration,	 an	
organization	 continuously	 improves	 its	 knowledge	 base	 by	 generating	 new	












The	 chromosomes	 are	 selected	 from	 the	 old	 generation	 for	 crossover	 and	
mutation	based	on	their	fitness	value.	Usually,	the	higher	fitness	a	chromosome	
has,	the	more	likely	it	will	be	selected	to	reproduce.	Effective	selection	methods	
should	ensure	 that	 the	best	chromosomes	are	selected.	However,	according	 to	






Tournament	 selection	 is	 used	 to	 model	 the	 exploitative	 learning	 process.	
Tournament	 selection	 is	 a	 selecting	 method	 involving	 running	 several	
















there	 are	 10	 chromosomes	 (from	 A	 to	 J)	 in	 the	 population.	 Because	 the	





Item	 A	 B	 C	 D	 E	 F	 G	 H	 I	 J	















































values	 in	 the	 chromosome.	 This	 operation	 can	 result	 in	 the	 entirely	 new	
chromosome,	with	which	the	GAs	can	arrive	at	the	better	solution.	The	objective	





The	 mechanisms	 of	 crossover	 and	 mutation	 are	 shown	 in	 Figure	 28.	 Two	
chromosomes	(F	and	A)	are	randomly	selected	from	the	collection	to	crossover	
based	 on	 probability	 Pc	 (crossover	 rate),	 and	 the	 last	 five	 binary	 codes	 are	
exchanged	between	F	and	A.	After	the	crossover,	two	new	chromosomes	F’	and	
A’	 are	 created.	 A	 binary	 code	 in	 the	 chromosome	 (I)	 is	 randomly	 selected	 to	








population.	 Therefore,	 selection	 can	 improve	 the	 performance	 of	 the	 drug	
discovery	 but	 only	 in	 the	 short	 term,	 without	 creating	 new	 knowledge	 the	
organization	will	fall	into	a	learning	trap.	Using	selection	and	crossover	will	lead	
to	 the	 GAs	 to	 converge	 on	 a	 good	 but	 not	 the	 best	 solution.	 If	 only	 using	
mutation,	 the	 algorithms	 are	 similar	 to	 the	 random	walk	 through	 the	 search	




















the	solution	by	 incrementally	changing	a	 single	element	of	 the	solution	 (if	 the	
solution	 is	 better,	 the	 change	 is	 made	 to	 the	 new	 solution;	 if	 the	 solution	 is	
worse,	the	original	solution	is	retained.	
	
The	 values	of	 population,	 crossover	 rate,	 and	mutation	 rate	have	 a	 significant	
influence	 on	 the	 performance	 of	 genetic	 algorithms.	 That	 means	 we	 can	 use	
different	 settings	 of	 GAs’	 operators	 to	 show	 the	 differences	 of	 drug	 discovery	
processes.	De	Jong	has	performed	a	systematic	study	of	how	varying	parameters	
influence	 the	 GAs	 performance.	 The	 experiments	 have	 shown	 that	 the	 best	





different	 from	 the	 traditional	 applications	 of	 GAs.	 Therefore,	 the	 parameter	
setting	 in	 this	model	 is	 different	 from	De	 Jong’s	 setting.	 In	 order	 to	 show	 the	
different	level	of	learning	ability,	the	crossover	rate	is	set	as:	
	























Through	 the	 tournament	 selection	 method,	 the	 knowledge	 base	 is	 refined	
through	 the	 process	 of	 exploitation.	 Alternatively,	 the	 organization	 can	 create	
the	knowledge	that	is	new	to	the	existing	knowledge	base.	The	learning	process	
can	 be	 considered	 as	 the	 explorative	 learning.	 Compared	 with	 exploitation,	
which	 refines	 the	 knowledge	 base	 without	 creating	 any	 new	 knowledge,	 the	
exploration	process	changes	the	knowledge	base	by	bringing	in	new	knowledge,	







them	 is	 simulated.	 In	 terms	 of	 the	 isolated	 paradigms,	 as	 shown	 in	 Table	 17,	
Experiment	 1	 has	 six	 settings:	 1)	 the	 intra-organization	 exploitation	 (INTRA-
ET-0);	 2)	 the	 intra-organization	 exploration	 with	 the	 medium	 level	 of	
innovation	 (INTRA-ER-M);	 3)	 the	 intra-organization	 exploration	with	 the	high	
level	 of	 innovation	 (INTRA-ER-H);	 4)	 the	 inter-organization	 exploitation	
(INTER-ET-0-M);	5)	the	inter-organization	exploration	with	the	medium	level	of	
























Org	1	 Exploitation	 -	 0	 INTRA-ET-0	
Org	2	 Exploration	 Medium	 0	 INTRA-ER-M	




Org	4	 Exploitation	 -	 Medium	 INTER-ET-0-M	
Org	5	 Exploration	 Medium	 Medium	 INTER-ER-M-M	
Org	6	 Exploration	 High	 Medium	 INTER-ER-H-M	
	
In	 addition	 to	 the	 above	 six	 settings,	 Experiment	 2	 (Table	 18)	 analyzes	 the	
intra-organizational	 learning	 with	 the	 combination	 of	 exploration	 and	
exploitation:	 7)	 the	 intra-organization	 exploitation	 and	 exploration	 with	 the	
medium	 level	 of	 innovation	 (INTRA-BT-M);	 8)	 the	 intra-organization	
exploitation	and	exploration	with	the	high	level	of	innovation	(INTRA-BT-H);	9)	


















Org	7	 Both		 Medium	 0	 INTRA-BT-M	
Org	8	 Both	 High	 0	 INTRA-BT-H	
Org	9	 Both	 Very	High	 0	 INTRA-BT-V	
	
In	Experiment	3	 (Table	19),	 four	 settings	are	 simulated	 to	examine	 the	 inter-
organizational	learning	with	different	level	of	innovation	and	network	density:	
10)	the	inter-organizational	exploitation	and	exploration	with	the	medium	level	
of	 innovation	 and	 medium	 network	 density	 (INTER-BT-M-M);	 11)	 the	 inter-





and	 medium	 network	 density	 (INTER-BT-H-M);	 12)	 the	 inter-organizational	




















Org	10	 Both	 Medium	 Medium	 INTER-BT-M-M	
Org	11	 Both		 High	 Medium	 INTER-BT-H-M	
Org	12	 Both	 Medium	 High	 INTER-BT-M-H	
Org	13	 Both		 High	 High	 INTER-BT-H-H	
	
In	order	to	prevent	results	with	artifacts	of	idiosyncratic	values,	the	knowledge	




























INTRA-ET-0	 20.300	 27.000	 -	
INTRA-ER-M	 20.150	 36.364	 -	
INTRA-ER-H	 20.200	 67.409	 -	
INTER-ET-0-M	 20.100	 78.000	 -	
INTER-ER-M-M	 20.200	 55.955	 -	
INTER-ER-H-M	 19.900	 75.455	 -	
Broad	
INTRA-ET-0’	 20.075	 29.000	 -	
INTRA-ER-M’	 19.825	 41.727	 -	
INTRA-ER-H’	 20.025	 67.955	 -	
INTER-ET-0-M’	 20.125	 85.000	 89	
INTER-ER-M-M’	 20.000	 49.114	 -	




















In	 Figure	 29,	 intra-organizational	 exploitation	 (INTRA-ET-0,	 solid	 blue	 line)	
shows	 very	 little	 improvement	 of	 the	 knowledge.	 Overall,	 it	 shows	 the	worst	
performance	in	all	six	settings.	Intra-organizational	exploitation	focuses	on	the	
refining	 of	 existing	 knowledge	 within	 an	 organization.	 Hence,	 this	 learning	
paradigm	 only	 offers	 the	 possibility	 to	 improve	 the	 learning	 by	 selecting	 the	

















































The	 uneven	 lines	 of	 intra-organizational	 and	 inter-organizational	 exploration	
show	 the	 random	 trials	 of	 exploration.	 The	 organization	 learning	 with	
exploration	 exhibits	 a	 better	 outcome	 than	 the	 organization	 learning	 with	
exploitation;	and	the	performance	of	intra-organizational	learning	with	the	high	
level	 of	 innovation	 (INTRA-ER-H,	 solid	 green	 line)	 is	 better	 than	 the	





lower	 rate	 of	 improvement	 than	 inter-organization	 learning.	 Inter-
organizational	 exploitation	 (INTER-ET-0-M,	 solid	 purple	 line)	 offers	 the	
possibility	to	obtain	useful	knowledge	from	other’s	knowledge	bases.	Therefore,	
in	 contrast	 to	 intra-organizational	 exploitation,	 the	 more	 extensive	 space	 of	




exploration,	 as	 the	 new	 knowledge	 can	 be	 acquired	 through	 the	 network	 to	
enrich	 the	 knowledge	 base.	 The	 inter-organizational	 exploration	 with	 the	
medium	level	of	 innovation	and	the	medium	level	of	network	density	(INTER-
ER-M-M)	 doesn’t	 show	 the	 advantage	 compared	 with	 intra-organizational	
learning	 with	 the	 high	 level	 of	 innovation	 (INTRA-ER-H).	 This	 indicates	 the	
network	 can	 improve	 the	 organization’s	 learning	 performance,	 but	 the	
organization’s	 own	 ability	 of	 learning	 is	 also	 very	 important.	 All	 the	 four	
configurations	 of	 inter-organizational	 exploration	 (INTER-ER-M-M,	 INTER-ER-




















The	 performances	 of	 organizational	 learning	 with	 both	 exploration	 and	
exploitation	in	the	first	and	last	period	of	the	simulation	are	shown	in	Table	21.		
Regarding	 the	 breadth	 of	 knowledge,	 Experiment	 2’	 shows	 the	 different	
performances	 of	 organizational	 learning	 when	 the	 organizations	 have	 the	
broader	 knowledge	 base.	 	 From	 Experiments	 1	 and	 1’,	 it	 is	 evident	 that	 the	
higher	 the	 level	 of	 exploration,	 the	 better	 the	 outcomes	 of	 innovation	 an	
organization	can	achieve.	However,	when	the	mutation	rate	is	set	at	a	high	level	
(V),	 it	 will	 influence	 the	 outcome	 of	 learning	 by	 bringing	 great	 uncertainty.	
When	the	mutation	rate	is	set	at	5%	(INTRA-BT-V	or	V’),	the	curve	of	learning	




















INTRA-BT-M	 20.300	 58.864	 -	
INTRA-BT-H	 20.150	 94.136	 49	
INTRA-BT-V	 20.200	 76.227	 -	
Broad	
INTRA-BT-M’	 20.075	 65.205	 -	
INTRA-BT-H’	 19.825	 94.522	 46	
INTRA-BT-V’	 20.025	 78.250	 -	
	
	
Figure	 30	 depicts	 the	 different	 processes	 of	 the	 organizational	 learning	 with	































Experiments	 1	 and	 2	 show	 that	 organizations	 doing	 both	 exploitation	 and	
exploration	 perform	 better	 than	 organization	 engaged	 in	 only	 doing	
exploitation	or	exploration.	In	addition,	inter-organizational	learning	has	better	




the	 inter-organizational	 exploration	 and	 exploitation.	 The	 broader	 knowledge	
base	brings	less	advantage	to	organizational	learning,	comparing	Experiments	1	












INTER-BT-M-M	 20.300 88.955 64 
INTER-BT-H-M	 20.150 94.182 46 
INTRE-BT-M-H	 20.200 92.000 56 
INTRE-BT-H-H	 20.200	 96.636	 33	
Broad 
 
INTER-BT-M-M’	 20.300 91.978 69 
INTER-BT-H-M’	 20.150 96.659 41 
INTRE-BT-M-H’	 20.200 96.655 51 
INTRE-BT-H-H’	 20.200	 96.887	 32	
	
Figure	 31	 depicts	 different	 inter-organizational	 learning	 processes	 over	 time.	
The	 result	 illustrates	 that	 organizations	 with	 a	 high	 level	 of	 exploration	 and	
network	density	 learn	differently	compared	with	the	organizations	with	 lower	
levels	of	exploration	and	network	density.	As	shown	in	Experiments	3	and	3’,	





density.	 For	 the	 same	 level	 of	 network	 density,	 a	 higher	 level	 of	 exploration	
leads	 to	 a	 better	 performance	 of	 the	 organization;	 and	 for	 the	 same	 level	 of	
exploration,	a	higher	value	of	network	density	engenders	a	better	outcome	from	















































The	 results	 of	 the	 simulation	 are	 based	 on	 the	 abstract	 model	 of	 the	
organizational	 learning	 process.	 The	 above	 simulation	 experiments	 examined	




Firstly,	 the	 results	 of	 Experiment	 1	 have	 shown	 the	 different	 evolution	
processes	 of	 the	 organizational	 learning	 through	 either	 exploitation	 or	
exploration.	Exploitation	is	about	creating	reliability	from	the	experience,	and	it	
includes	 activities	 like	 refining	 their	 abilities,	 developing	 their	 existing	
knowledge,	 learning	 on	 specific	 domains	 and	 from	 successful	 or	 failed	
experience	 (Holmqvist	 2003).	 From	 comparing	 the	 case	 of	 INTRA-ET-0	 and	
INTRA-ET-0’,	 we	 can	 find	 that	 firms	 that	 keep	 exploiting	 their	 existing	
knowledge	tend	to	fail.	This	is	because	the	positive	local	feedback	can	produce	
strong	 path	 dependence	 and	 lead	 to	 suboptimal	 equilibrium.	 Therefore,	 it	 is	






of	 exploration,	 strategies	 that	 involve	 a	 high	 level	 of	 exploitation,	 a	 very	 low	
level	of	exploration	or	without	exploration	make	the	adaptive	learning	process	
self-destructive.	 The	 research	 summarized	 three	 different	 learning	 traps	 that	
organizations	 may	 fall	 into:	 organizations	 may	 fall	 into	 the	 familiarity	 trap	
because	 they	 intend	 to	 use	 known	 solutions	 (INTRA-ET-0);	 they	may	 fall	 into	
the	maturity	trap	due	to	aptly	proven	solutions;	and	organizations	may	fall	into	
the	 propinquity	 trap	 because	 of	 tendency	 to	 use	 solutions	 closer	 to	 known	
solutions	 (INTRA-BT-M)	 (Ahuja	 2000).	 The	 strategy	with	 a	medium	 and	 high	





exploitation.	 Exploration	 is	 the	 source	 of	 innovation	 in	 the	 organizational	
learning.	 It	 is	 believed	 that	 big	 companies	 are	 more	 exploitative	 while	 small	
companies	 are	 more	 explorative.	 As	 a	 result,	 smaller	 and	 younger	 firms	 are	
more	likely	to	make	important	innovations	than	older	and	larger	firms,	such	as	




organizations.	 Firm-specific	 factors	 influence	 the	 learning	 strategy,	 such	 as	
culture,	 strategy,	 structure,	 and	 environment	 (Bapuji	 and	 Crossan	 2004).	 The	
exploitation	and	exploration	can	be	understood	as	 the	similarity	and	diversity	
trade-off.	 Exploitation	 prospers	 from	 the	 similarity	 in	 previous	 knowledge;	
while	 exploration	 prospers	 from	 the	 diversity	 in	 new	 knowledge.	 In	 March’s	
model,	an	organization’s	performance	is	characterized	in	terms	of	the	measure	
of	 average	 value	 and	 variability	 of	 knowledge,	moreover,	 only	when	 learning	
increases	 the	 mean	 and	 the	 variance	 of	 the	 knowledge,	 it	 will	 improve	 the	
competitive	 advantage	 of	 the	 organization	 (March	 1991).	 Most	 of	 the	
organizations	 employ	 the	 learning	 strategy	 with	 both	 exploitation	 and	
exploration	 to	 gain	 competitive	 advantage,	 but	 different	 organizations	 have	
different	strategies	for	learning	and	therefore	for	deploying	resources	between	
exploitation	and	exploration.	The	attributes	of	 the	 industry	affect	 the	 learning	
strategy	 of	 companies,	 such	 as	 the	 companies	 in	 service	 industry	 pay	 more	
attention	 to	 exploitation	 compared	 with	 biopharmaceutical	 industry	 where	
companies	 pay	 more	 attention	 to	 exploration.	 The	 evolutionary	 stage	 of	 an	
organization	 also	 affects	 company’s	 learning	 strategy.	 For	 instance,	 some	













suffer	 from	 the	 learning	 trap.	 Mutation	 is	 regarded	 as	 inexplicable	 or	
unpredictable	random	events.	Both	trial-and-error	 learning	and	organizational	
search	 are	 gradually	 adaptive	processes	 that	 lead	 to	desired	outcomes	 (Levitt	
and	March	1988).	Hence,	when	 the	mutation	rate	 is	 set	at	a	very	high	 level	of	
5%	and	above	(INTRA-BT-V),	 the	 learning	curve	exhibits	the	characteristics	of	
the	 uncertainty	 of	 random	 screening.	 The	 learning	 process	 is	 like	 a	 failure-








The	 exploitation	 learning	 process	 contributes	 to	 an	 increase	 in	 the	 similar	
knowledge	rather	than	the	ability	to	find	new	opportunities.	So,	to	overcome	the	
disadvantages	 of	 exploitation,	 organizations	 should	 create	 variety	 by	
experiment	and	innovation.		As	Levin	and	March	(1993)	stated:	“an	organization	
that	 engages	 exclusively	 in	 exploitation	 will	 ordinarily	 suffer	 from	
obsolescence”	 while	 “an	 organization	 engages	 exclusively	 in	 exploration	 will	
ordinarily	suffer	from	the	fact	that	it	never	gains	the	returns	of	its	knowledge.”	
The	 increase	 in	 exploitation	 or	 knowledge	 base	 is	 less	 effective	 than	 the	




These	dynamics	have	 shown	us	 that	 the	best	 strategy	 for	 small	biotechnology	
companies	with	 limited	resource	and	relatively	narrow	knowledge	base	 is	not	
to	enlarge	their	knowledge	base	but	to	increase	the	variation	of	their	knowledge	





exploration	and	exploitation	 to	achieve	 the	optimum	is	a	big	challenge	 for	 the	
company.	
	
Thirdly,	 the	 findings	 exhibit	 considerable	 differences	 between	 the	 intra-	 and	
inter-organizational	 learning	paradigms	with	 respect	 to	 the	 evolution	 and	 the	
final	 organization	 performance.	 From	 Experiment	 3,	 we	 find	 that	 the	 inter-
organizational	learning	improves	the	outcomes	of	learning	efficiently.	The	intra-
organizational	 learning	 paradigms	 stick	 to	 the	 organization’s	 existing	
knowledge,	 while	 the	 inter-organizational	 learning	 paradigms	 depend	 on	 its	
cooperative	partners	to	develop	knowledge.	Given	the	same	intra-organization	
learning	 strategy,	 a	 relatively	 high	 level	 of	 network	 density	 leads	 to	 better	






share	 different	 knowledge	 between	 learning	 entities.	 Although	 inter-
organizational	 learning	 enables	 the	 organization	 to	 enrich	 their	 knowledge	
stock	with	 the	 knowledge	 previously	 unavailable	within	 the	 organization,	 the	






divided	 by	 its	 purpose.	 Company’s	 decision	 on	 the	 cooperation	 can	 be	
differentiated	regarding	its	desire	to	exploit	an	existing	capability	or	to	explore	
new	 opportunities.	 Different	 stages	 of	 product	 innovation	 process	 have	
different	types	of	learning	and	thus	drive	drug	companies	to	enter	into	different	
kinds	of	alliances.	In	biopharmaceutical	sector	exploration	collaboration	usually	






exploration	 collaborations	 are	 built	 with	 the	 aim	 to	 discover	 something	
innovative,	 the	 organizations	 involved	 in	 exploration	 collaboration	 focus	 on	
generating	 new	 knowledge.	 In	 biopharmaceutical	 sector,	 exploration	
collaborations	 are	 motivated	 by	 the	 expectation	 for	 creating	 cutting-edge	
fundamental	 knowledge	 that	 can	 be	 applied	 to	 discover	 novel	 drug	 candidate	
(Rothaermel	 and	Deeds	2004).	An	example	of	 exploration	 collaboration	 is	 the	
alliance	between	research	institutions	and	biotechnology	companies	during	the	
drug	discovery	process.	Exploitation	alliances	are	characterized	by	the	sharing	
of	 complementary	 assets;	 for	 instance,	 biotechnology	 companies	 collaborate	





For	 instance,	drug	 companies	 choose	 to	 cooperate	with	 companies	having	 the	
similar	or	related	research	area.	Moreover,	a	firm’s	knowledge	learned	from	its	
collaborators	relies	on	its	prior	experience	with	that	partner.	Firms	select	their	
partners	 also	 on	 the	 basis	 of	 the	 collaborators’	 knowledge	 base	 and	 their	
inclination	 to	 share	 it.	 If	 two	organizations	have	very	 similar	knowledge	base,	
there	is	no	gain	from	inter-organizational	learning,	and	if	the	organizations	have	
the	 entirely	 different	 knowledge	 base,	 then	 it’s	 likely	 impossible	 for	 the	
organizations	to	learn	from	each	other.	
	
Fourthly,	 according	 to	 the	 three	 experiments,	 the	 effective	mechanism	 of	 the	
cycle	 of	 learning	 is	 discussed.	 The	 learning	 paradigm	 now	 takes	 account	 of	
exploitation/exploration	and	intra-/inter-organizational	learning.	The	ability	to	
redeploy	existing	knowledge	is	fundamental	to	long-term	strategic	advantages.	
First	 of	 all,	 what	 an	 organization	 knows	 at	 the	 beginning	 will	 influence	 its	
learning	 objective,	 learning	 experience	 and	 how	 it	 interprets	 what	 it	
experiences	 (Huber	 1991).	 Therefore,	 the	 initial	 knowledge	 base	 strongly	





learning.	 Generally,	 the	 higher	 rate	 of	 learning	 leads	 to	 achieve	 optimization	
earlier.	The	 level	of	knowledge	attained	by	an	organization	 is	 also	affected	by	
different	learning	paradigms.	Experiment	1	shows	the	results	when	we	assume	
that	 organization	 only	 learn	 by	 exploitation	 or	 exploration.	 The	 results	 have	
confirmed	why	most	organizations	engage	in	both	exploitation	and	exploration.	
The	results	have	been	extended	by	examining	organizational	learning	in	a	more	
open	 system,	 specifically,	when	 the	 role	of	 the	 inter-organizational	 learning	 is	
considered.		
	
The	 learning	 occurs	 between	 organizations	 is	 not	 simply	 copy	 another	
organization’s	 knowledge	 rather	 than	 the	 knowledge	 of	 former	 is	 varied	 by	
adapting	its	present	knowledge.	Knowledge	cannot	be	simply	transferred	from	
one	 organization	 to	 another;	 it	 has	 to	 be	 translated	 and	 integrated	 into	 the	
existing	knowledge	base.	The	translation	process	is	realized	through	the	intra-
organizational	 learning	 process.	 The	 previous	 success	 may	 not	 ensure	 the	
organization	 competent	 at	 the	 end,	 especially	 when	 the	 organization	 cannot	
effectively	 adapt	 to	 the	 changing	 environment.	 In	 a	 research	 about	 the	
pharmaceutical	 industry,	 drug	 companies	 that	 focus	 on	 not	 only	 incremental	





All	 the	 learning	 configurations	 we	 simulated	 differ	 in	 the	 way	 knowledge	 is	
handled.	Therefore,	the	classification	of	both	exploration	and	exploitation	at	the	
intra-organization	 level	 and	 inter-organization	 level	 is	 an	appropriate	 starting	
point	 for	 this	 research.	 The	 results	 of	 the	 simulation	 have	 indicated	 that	 the	
outcome	of	isolated	explorative	and	exploitative	learning	at	intra-organizational	
level	is	not	efficient.	Although	the	intra-organizational	exploitation	has	the	best	






the	 integration	 of	 exploration	 and	 exploitation	 can	 foster	 organizational	
performance	and	 lead	 to	a	better	outcome.	Moreover,	 the	 inter-organizational	




In	 all,	 the	 intra-organizational	 and	 inter-organizational	 learning	 processes	
interact	through	the	processes	of	exploitation	and	exploration.	It	is	not	hard	for	
the	 organizations	 to	 be	 trapped	 in	 the	 innovation	 process.	 Organizations	 can	
avoid	 traps	 by	 employing	 exploitation	 and	 exploration	 as	 well	 as	 intra-	 and	
inter-organizational	learning.		Under	different	conditions,	organizations	develop	





of	 the	 different	 influences	 of	 exploitation/exploration	 and	 intra-/inter-
organizational	 learning	on	 the	outcomes	of	 innovation.	 It	 is	a	general	 learning	
model	 that	 can	 be	 further	 developed	 to	 analyze	 the	 innovation	 activity	 of	 a	















In	 the	 last	 century,	 with	 significant	 changes	 to	 science	 and	 technology,	
pharmaceutical	 research	 has	 evolved	 from	 the	 pattern	 where	 random	
discoveries	 dominated	 drug	 discovery	 to	 a	 more	 rational	 and	 guided	 model	
(Quéré	2004).	The	traditional	R&D	of	drugs	 is	 the	 ‘random	screening’	 through	
serendipity	 (Ratti	 and	 Trist	 2001).	 The	 process	 is	 featured	 by	 extreme	
uncertainty	due	to	 lack	of	 the	knowledge	about	the	causes	of	diseases	and	the	
mechanisms	 of	 the	 action	 of	 drugs.	 From	 the	 late	 1970s,	 the	 advances	 of	
biotechnology	have	improved	the	knowledge	about	the	mechanisms	of	diseases	
as	 well	 as	 the	 action	 of	 drugs.	 In	 turn,	 these	 advances	 contributed	 to	 an	
innovative	way	of	drug	R&D,	from	trial-and-error	approaches	to	 ‘rational	drug	








This	chapter	 is	structured	 into	 two	parts.	 In	 the	 first	part,	different	periods	of	
drug	 discovery	 are	 briefly	 reviewed.	 Specifically,	 we	 focus	 on	 the	 distinct	
learning	patterns	in	each	period	and	apply	the	model	of	organizational	learning	
to	 simulate	 these	 diverse	 innovation	 activities.	 A	 Multi-Agent	 Based	 Model	
integrated	with	 Genetic	 Algorithms	 is	 built	 to	 simulate	 the	 drug	 discovery	 in	
three	periods:	before	the	1980s,	the	1980s	and	after	the	1990s.	
	
The	 second	 part	 of	 this	 chapter	 is	 dedicated	 to	 the	modeling	 of	 orphan	 drug	






drug	 innovation	 process	 are	 presented,	 based	 on	 that	 the	 multi-agent-based	






goal	of	developing	new	products.	Therefore,	 it	 is	vital	 for	 the	organizations	 to	
learn	 quickly	 and	 efficiently.	 In	 the	 last	 several	 decades,	 pharmaceutical	
research	 has	 evolved	 from	 a	 pattern	where	 random	 screening	 dominated	 the	
drug	discovery	to	a	more	rational	and	guided	model.		
	
The	 steps	 of	 the	 complicated	 drug	 discovery	 process	 can	 be	 divided	 into	 five	
major	 phases:	 target	 identification	 and	 validation,	 lead	 identification,	 lead	
optimization,	and	drug	selection	(Figure	32).	The	outcome	(drug	candidate)	of	



























disease	 areas	 (Cockburn	 and	 Henderson	 2001).	 Pharmaceutical	 companies	
focusing	 on	different	 diseases	may	have	 their	 specific	 expertise.	Modern	drug	
discovery	 requires	 the	 input	 of	 the	 scientists	 skilled	 in	 a	 wide	 variety	 of	




discovery,	 which	 can	 be	 considered	 as	 evolution	 (Tsinopoulos	 and	 McCarthy	
2002).	 The	 strategy	 for	 drug	 discovery	 meets	 the	 four	 requirements	 of	
evolution.	The	first	requirement	of	evolution	requires	a	certain	number	of	drug	
discovery	strategies	to	form	populations.	The	second	one	is	variation,	which	is	
caused	 by	 both	 the	 disease	 and	 the	 discovery	 environment.	 Different	
organizations	 commit	 themselves	 to	 different	 therapeutic	 areas.	 For	 instance,	
some	 developers	 focusing	 on	 cardiovascular	 science	while	 others	 concentrate	
on	 cancer.	 They	 often	 pursue	 unique	 strategies	 to	 achieve	 the	 competitive	
advantages.	The	environment	factors	include	the	knowledge	and	experience	of	




successful	 strategy	 will	 survive	 and	 transfer	 their	 characteristics	 to	 their	
descendants,	 while	 unsuccessful	 strategies	 will	 be	 replaced.	 The	 feature	 of	
population,	 variation,	 selection,	 and	 reproduction	 exhibits	 the	 evolutionary	
characteristics	of	drug	discovery	process.		
	
Along	 with	 the	 development	 of	 rational	 drug	 discovery,	 the	 complexity	 of	
knowledge	 has	 increased	 dramatically.	 Discovering	 a	 drug	 requires	 the	
integrated	 expertise	 of	 various	 areas,	 including	 screening,	 combinatorial	
chemistry,	 genomics,	 bioinformatics,	 drug	 delivery	 as	 well	 as	 numerous	 drug	








the	current	biopharmaceutical	 sector	 (McKelvey	and	Orsenigo	2001).	There	 is	
an	 increasing	 number	 of	 companies	 relying	 on	 inter-organizational	
collaboration	 for	 their	 adaptation	 and	 learning	 in	 the	 changing	 environment.	
Biotechnology	 companies	 play	 an	 important	 role	 in	 exploring	 knowledge	 and	








such	 as	 drug	 discovery	 process,	 can	 be	modeled	 in	 the	 context	 of	 search	 and	
optimization	 theory	 (Gambardella	 1995).	 The	 first	 innovation	 model	 was	
introduced	by	Stigler	 (1961).	Then	 the	 framework	of	modeling	 the	 innovation	
was	set	up	by	Dasgupta	and	Stiglitz	(1980),	and	Nelson	and	Winter	(1982).	 In	
our	 model,	 the	 drug	 discovery	 process	 is	 modeled	 as	 a	 knowledge	 evolution	
process,	in	which	the	drug	is	depicted	as	a	collection	of	qualified	knowledge	and	
the	 discovery	 process	 is	 translated	 into	 an	 optimization	 knowledge	 process	
towards	the	qualification.		
	
The	 model	 in	 Chapter	 6	 examined	 different	 paradigms	 of	 organizational	
learning,	the	ways	in	which	organizations	improve	their	knowledge	set	towards	
desired	 goals.	 In	 the	 previous	 experiments,	 it	 was	 shown	 that:	 firstly,	 the	
organizations	 learning	 through	 both	 exploitation	 and	 exploitation	 performs	
better	compared	with	the	organizations	learning	through	either	exploitation	or	
exploration;	 secondly,	 exploration	 maintains	 the	 diversity	 of	 the	 knowledge	











process	 is	 viewed	as	 a	 learning	process;	 the	outcome	of	drug	discovery	 is	 the	
embodiment	 of	 knowledge	 learned	 through	 exploration	 and	 exploitation.	 The	





organizations	 are	 represented	 by	 agents	 with	 a	 high	 degree	 of	 heterogeneity	
and	bounded-ration.	The	agents	can	be	modeled	as	either	isolated	or	connected	
with	 other	 agents.	 The	 agents	 have	 different	 behavioral	 rules	 they	 can	 show	




about	 an	 initially	 poorly	 understood	 or	 unknown	 space	 to	 guide	 subsequent	
research	 (De	 Jong,	 1988).	 The	 GAs	 are	 domain-independent	 search	 methods	
used	 to	 search	 the	 irregular	 and	 poorly	 understood	 space.	 The	 space	 to	 be	
searched	in	our	model	is	the	knowledge	area	about	one	of	the	rare	diseases	and	

















successive	 generations	 in	 the	 inherited	 characteristics	 of	 the	 biological	
population.	To	address	 the	evolutionary	features	of	drug	discovery,	examining	
the	 key	 elements	 of	 evolution	 as	 originally	 developed	 by	 biology	 and	


































The	 preclinical	 trial	 is	 usually	 done	 on	 animals	 to	 see	 whether	 the	 drug	




whether	 it	 is	 effective	 for	 the	 condition	 it	 is	 intended	 to	 treat	 and	 further	
evaluate	 its	 safety.	 Phase	 III	 Clinical	 Trial	 is	 given	 to	 a	 large	 group	 of	 the	









On	 one	 hand,	 orphan	 drugs	 have	 significantly	 less	 generic	 competition	 than	
other	 medications	 (Seoane-Vazquez,	 Rodriguez-Monguio	 et	 al.	 2008);	 on	 the	
other	hand,	because	of	the	complexity	of	most	rare	diseases	and	vulnerability	of	
patients,	the	generic	substitution	of	orphan	drug	is	more	challenging	than	non-
orphan	 drug	 and	 should	 be	 undertaken	 carefully	 in	 rare	 disease	 patients	 (Di	
Paolo	2018).		
	
At	 the	 beginning	 of	 each	 simulation	 run,	 every	 organization	 is	 set	 with	 a	
collection	of	Nk	knowledge,	which	is	implemented	as	binary	bit	strings	with	the	
same	 length.	 The	 more	 disciplines	 of	 knowledge	 an	 organization	 has,	 the	
broader	 its	knowledge	base	 is,	 and	 the	bigger	 the	number	Nk	 is.	Each	piece	of	
knowledge	is	composed	of	Nbit	binary	code	(1	or	0).	The	strings	are	generated	
randomly	to	comprise	the	organizations’	initial	knowledge	base.		The	amount	of	
knowledge	 is	 constant	 during	 the	 whole	 process	 of	 simulation,	 which	 means	










time	 can	 be	 assessed	 by	 the	 fitness	 function.	 The	 quality	 of	 drug	 candidate	
represented	in	the	organization’s	knowledge	level	can	be	determined	by	fitness	
















the	 group	 finding	 the	 promising	 drug.	 For	 instance,	 the	 fitness	 value	 of	










The	 knowledge	 level	 depends	 on	 the	 initial	 conditions	 and	 the	 parameters	
influencing	 learning.	As	 the	organization	becomes	more	knowledgeable	 in	 the	
field	of	rare	disease	and	the	orphan	drug	they	research	on,	there	are	more	‘1’	in	












first	 one	 is	 that	 each	 binary	 string	 has	 20	 binary	 codes	 instead	 of	 100	 in	 the	






In	 generation	N,	 there	are	10	binary	 strings	named	 from	A	 to	 J,	 and	as	 stated	
before,	the	number	of	binary	strings	in	each	generation	remains	constant	during	
the	 process	 of	 GA.	 Their	 fitness	 value	 is	 calculated	 according	 to	 the	 fitness	
function,	shown	in	Table	24.	Since	the	crossover	rate	is	20%	and	the	population	























































the	 Generation	 N+1,	 3	 new	 binary	 strings	 are	 created	 by	 crossover	 and	






Item	 Chromosome	 Fitness	 Action	 Item	 Chromosome	 Fitness	
A	 1010101110		1011010110	 12	 Selected	/	Crossover	 A	 1010101110		1011010110	 12	
B	 0010001100		1011010001	 7	 Eliminated	 K	 1010111101	1011001010	 12	
C	 1001001000		1001000100	 6	 Elimination	 L	 1001101110	0011010110	 11	
D	 1001100101		0011001010	 10	 Selected	/	Crossover	 D	 1001100101		0011001010	 10	
E	 1110001110		0101000000	 8	 Selected	 E	 1110001110		0101000000	 8	
F	 1001011100		1011101001	 11	 Selected	 F	 1001011100		1011101001	 11	
G	 1000011100		0101010001	 8	 Selected	 G	 1000011100		0101010001	 8	
H	 0100101010		1010000100	 7	 Selected	/	Mutation	 M	 0100101010		1010000100	 8	
I	 0000110010		0010000100	 5	 Eliminated	 F	 0000110010		0010000100	 11	
J	 1100001010		0011000000	 6	 Eliminated	 G	 1100001010		0011000000	 8	




The	previous	 sections	 showing	 companies	 innovating	without	network	 (intra-
organizational	learning),	organizations	discover	the	drug	on	the	basis	of	its	own	
knowledge	 base	 given	 at	 the	 beginning	 of	 the	 simulation	 run.	 In	 case	 of	




in	 the	 model	 have	 different	 collaboration	 strategies	 during	 the	 innovation	
process;	 biotechnology	 companies	 collaborate	 closely	 with	 research	
organizations	 in	 the	 drug	 discovery	 process	 and	 cooperate	 with	 big	





pharmaceutical	 companies	 seek	 to	 build	 alliance	with	biotech	 to	 expand	 their	
pipelines.	 In	 the	 model,	 based	 on	 the	 different	 collaboration	 strategies,	 the	
collaborative	 partners	 are	 selected	 randomly	 from	 the	 collection	 of	 objective	
collaborators,	 which	 could	 be	 a	 collection	 of	 research	 organizations,	
biotechnology	 companies,	 or	 pharmaceutical	 companies.	 2)	 The	 organizations	
in	 the	 model	 have	 different	 degree	 of	 intent	 to	 collaborate	 with	 others.	 The	
biotechnology	company	is	smaller	and	lack	of	experience,	which	makes	it	more	
flexible	 in	 building	 network	 than	 big	 pharma.	 In	 the	 model,	 biotechnology	
companies	 are	 set	 with	 higher	 intent	 to	 collaborate	 than	 pharmaceutical	
companies.	 3)	 The	 number	 of	 collaborators	 determines	 the	 density	 of	 the	
collaboration	 network.	 The	 organization	 gets	 access	 to	 the	 complementary	








Experiment	 4	 is	 used	 to	 show	 the	 drug	 discovery	 process	 during	 different	
periods.	The	simulation	setting	of	Experiment	4	is	shown	in	Table	25.	There	are	
three	models	in	this	experiment.	The	first	model	is	about	the	random	screening	
period,	 organizations	 discover	 the	 drug	 within	 the	 organization	 based	 on	
limited	 knowledge	 and	 randomly	 screen	 the	 potential	 targets	 (INTRA-BT-V).	
The	second	model	is	about	the	rational	discovery	period.	With	the	cutting-edge	
knowledge	 about	 genomics,	 molecular	 biology,	 and	 bioinformatics,	
organizations	have	more	knowledge	about	the	mechanism	of	the	disease	at	the	
molecular	level,	so	they	changed	from	random	screening	to	more	rational	drug	






rapid	 advances	 in	 science	 make	 the	 drug	 companies	 identify	 and	 unitize	 the	
externally	generated	knowledge.	The	third	model	is	about	the	period	of	network	
collaboration.	 Drug	 companies	 usually	 take	 advantage	 of	 research	 conducted	














Random	Screening Narrow INTRA-BT-V	 20.200 76.227 - 
Rational	Design Broad INTRA-BT-H’	 19.825 94.522 53 
Network	Collaboration Broad INTER-BT-H-H’	 20.200 96.887 40 
	
	
Figure	 34	 shows	 the	 differences	 of	 drug	 discovery	 in	 three	 periods.	 In	 the	
random	screening	phase,	the	knowledge	is	accumulated	very	quickly	during	the	
period	 from	period	0	 to	20,	 from	period	20	 to	40	 the	 learning	 speed	 turns	 to	
slow	down,	from	period	50	towards	90	the	learning	curve	exhibits	small	waves.	
In	the	rational	design	phase,	at	 the	 first	20	periods,	organizations	 learn	not	as	
quickly	as	 in	 the	 random	screening	period,	but	organizations	keep	 learning	at	
that	 speed	 and	 get	 a	 qualified	 drug	 candidate	 (F>=80)	 at	 period	 53.	 	 In	 the	











We	 modeled	 the	 history	 of	 drug	 discovery	 from	 the	 1970s.	 Drug	 discovery	
usually	 starts	 with	 identifying	 an	 appropriate	 drug	 target.	 Before	 the	 1980s,	
drugs	were	discovered	without	knowledge	about	 the	disease	 (EXPERIMENT	1	
INTRA-BT-V).	 A	 massive	 number	 of	 early	 discoveries	 in	 the	 pharmaceutical	
industry	were	through	serendipity,	where	thousands	of	chemicals	are	applied	to	
an	assay	that	allows	identification	of	compounds	that	produce	the	desired	effect.	
Although	 companies	 can	 get	many	drug	 candidates	 quickly	 in	 the	 early	 stage,	
without	 the	 knowledge	 about	 the	 disease	 and	 the	mechanisms	 of	 drug	 action	
companies	 get	 stuck	 in	 small	 fluctuations	 towards	 qualification	 as	 random	
screening	these	candidates	in	the	late	stage.		
	
With	 the	 advance	 of	 biotechnology,	 from	 the	 1980s,	 most	 targets	 currently	
selected	 for	 drug	 discovery	 are	 proteins	 that	 can	 be	 selected	 based	 on	 the	
understanding	of	human	disease	and	 the	biotechnological	process	 that	 lead	 to	
disease	 (EXPERIMENT	 2’	 INTRA-BT-H’).	 There	 are	 two	 kinds	 of	 target:	
‘established	targets’	are	those	for	which	there	is	a	good	scientific	understanding,	



























proteins	 or	 proteins	 whose	 function	 has	 now	 become	 clear	 through	 basic	
scientific	research.	Once	a	potential	disease-causing	target	has	been	identified,	a	




linkage	studies	showing	an	association	between	 the	mutation	 in	 the	biological	
target	and	certain	disease	states	should	be	achieved.	But	 it	 is	more	efficient	 in	









March	 1993).	 For	 research	 organizations,	 strategic	 alliance	 is	 an	 excellent	
opportunity	 to	 commercialize	 their	 research	 discoveries;	 for	 biotechnology	
companies,	 it	 is	 a	 good	 strategy	 to	 obtain	 in-license	 knowledge	 created	 in	
research	 organizations	 and	 further	 develop	 and	 then	 transfer	 it	 to	 big	
companies	 that	 own	 the	 resources	 to	 commercialize	 the	 product;	 for	
pharmaceutical	 companies,	 it	 is	 a	 response	 to	 expected	 capacity	 because	 of	
patent	 expiration	 and	 gaps	 in	 pipeline.	 The	 alliance	 connecting	 research	
organizations,	 biotechnology	 companies,	 and	 pharmaceutical	 companies	 is	 to	
get	access	to	the	complementary	specialized	expertise.	As	the	experiment	shows,	
in	this	period,	although	the	new	knowledge	obtained	from	outside	increase	the	








In	 the	 period	 of	 random	 screening,	 there	 are	 two	 main	 players:	 research	
















Narrow INTRA-BT-V	 20.200 76.227 101  






































They	 are	 featured	with	 a	 specified	knowledge	base	 and	 the	medium	and	high	
level	 of	 exploration.	 During	 the	 same	 period,	 pharmaceutical	 companies	















Narrow INTRA-BT-H	 20.150 94.136 49 
Pharmaceutical	
Companies 
Broad INTRA-BT-M’	 19.825 65.205 - 
		
As	 shown	 in	 Figure	 36,	 the	 learning	 strategy	 of	 pharmaceutical	 companies	 is	
efficient	during	the	random	screening	period,	but	in	the	new	environment,	the	






























In	 the	 network	 period,	 research	 organizations,	 biotechnology	 companies,	 and	















Narrow INTER-BT-H-H	 20.000 96.636 33 
Pharmaceutical	
Companies 
Broad INTER-BT-M-M’	 20.025 91.978 69 
	
	
Because	 of	 the	 collaboration	 with	 other	 organizations,	 pharmaceutical	
companies	represent	a	better	performance	compared	with	intra-organizational	
drug	discovery.	 Pharmaceutical	 companies	 discover	 the	 drug	 candidate	 at	 the	
period	of	69	and	biotechnology	companies	find	the	drug	candidate	at	the	period	
of	 33	 (Figure	 37).	 The	 network	 facilitates	 the	 information	 flow	 among	


































driver	 of	 all	 other	 competence.	 Especially	 the	 biotechnology	 firms,	 they	 are	
founded	and	obtain	investment	on	the	prospects	of	transforming	technological	
knowledge	 into	 potential	 economic	 benefits	 through	 the	 R&D	 and	
commercialization	 of	 an	 innovative	 product.	 Different	 performances	 among	
firms	in	the	sector	can	be	considered	as	the	result	of	their	knowledge	base	and	
capabilities	 of	 learning	 and	 developing	 knowledge.	 The	 factors	 influencing	
organizational	 learning	 are	 various,	 including	 culture,	 strategy,	 structure,	





at	 protecting	 intellectual	 property,	 spinning	 out	 new	 firms,	 licensing	 the	
technology	 to	 the	 private	 sector	 and	 developing	 their	 venture	 arms	 to	
support	 commercial	 development	 of	 their	 discoveries	 since	 1970s.	
Universities	 and	 research	 institutions	 have	 contributed	 a	 lot	 to	
biopharmaceutical	 innovation.	Research	organizations	are	particularly	good	
at	creating	novelty	knowledge	about	disease	processes.	The	learning	strategy	
of	 them	 is	more	 explorative,	 and	 their	 knowledge	base	 is	wider	 than	other	
organizations.		
	
The	 Bayh-Dole	 Act	 of	 1980	 stimulated	 universities	 to	 translate	 their	
academic	research	discoveries	to	commercial	products.	In	subsequent	years,	
many	 patents	 funded	 by	 public	 source	 have	 been	 licensed	 to	 the	 industry,	
resulting	 in	 the	 commercialization	 of	 hundreds	 of	 drug	 products.	 A	 large	
number	 of	 biotechnology	 firms	 are	 university	 spin-offs	 and	 established	 by	
scientists	with	 their	 research	 outcomes.	Many	 universities	 and	 institutions	





business	 expertise	 from	 business	 school	 to	 encourage	 and	 facilitate	 the	
commercialization.	 Public	 research	 plays	 a	 significant	 role	 in	 providing	
fundamental	 insights	 into	 the	 sector	 as	 the	 foundation	 for	 further	 drug	
discovery,	 and	 with	 the	 drug	 discovery	 moved	 from	 random	 screening	 to	






market	 force	 to	 recoup	 the	 cost	 of	 development	 (Wyatt	 2009).	 The	 drug	
discovery	can	be	carried	out	using	public	funding	at	the	beginning	and	then	






Knowledge	 and	 understanding	 of	 disease	 serve	 as	 a	 foundation	 for	 orphan	
drug	R&D.	From	the	results,	we	can	find	developing	a	few	critical	knowledge	
bases 	 is	 of	 great	 strategic	 importance	 for	 drug	 companies.	With	 a	 broader	
knowledge	 base,	 the	 company	 will	 be	 in	 a	 better	 position	 to	 learn	 and	
integrate	 related	 technologies.	 The	more	 extensive	 a	 company’s	 knowledge	
base	 is,	 the	 better	 performance	 the	 company	 will	 achieve	 in	 the	 random	
screening	 period	 (Experiment	 4).	 This	 reflects	 the	 fact	 that	 big	
pharmaceutical	 companies	 dominated	 the	 sector	 before	 1970	 and	 they	 are	
still	the	influential	player	in	the	following	period	as	they	are	rich	in	a	broad	
range	 of	 science	 and	 technology	 and	 experience. The	 knowledge	 base	
includes	 not	 only	 rare	 diseases	 but	 also	 about	 other	 common	 diseases.	 In	
orphan	 drug	 R&D	 field,	 pharmaceutical	 companies	 have	 the	 advantages	 in	
repositioning	approved	drugs	to	orphan	drugs.	Since	drug	discovery	is	based	









but	 also	helps	 a	 lot	 in	drug	development	 and	marketing.	 Larger	 companies	
with	 diverse	 projects	 can	 share	 knowledge	 and	 experience	 about	 clinical	
trials	 among	 different	 projects	 within	 the	 company	 (Cockburn	 and	
Henderson	 2001).	 Marketing	 a	 drug	 is	 also	 knowledge	 intensive.	 Business	
knowledge	refers	to	the	knowledge	and	skills	of	management,	marketing,	and	
relationship	 with	 other	 companies.	 Each	 drug	 is	 marketed	 with	 a	
comprehensive	 and	 costly	 campaign,	 so	 already	 established	 marketing	
infrastructure	 like	marking	and	distribution	capability	 is	very	beneficial	 for	
the	new	drug	launch	(Rasmussen	2010).			
	
The	 traditional	 innovation	 model	 of	 pharmaceutical	 companies	 lost	 its	
advantage	 in	 the	 rational	 design	 period	 compared	 with	 emerging	
biotechnology	companies	(Experiment	5).	For	biotechnology	companies,	due	
to	 their	 limited	 resources,	 one	 company	 only	 focuses	 on	 very	 few	 specific	
diseases,	 so	 that	 the	 company	 can	 become	 the	 leader	 in	 those	 areas.	Most	
biotechnology	companies	are	 founded	on	only	one	drug	R&D	project	 in	one	
particular	 area.	 However,	 pharmaceutical	 companies	 have	 the	 broader	
knowledge	 base,	 which	 results	 in	 the	increased	 strategic	 flexibility	 and	
adaptability	 to	 environmental	 changes.	 Although	 orphan	 drug	 R&D	 was	
neglected	by	pharmaceutical	 companies	before	 the	1980s,	 because	of	more	
expected	 returns	 of	 orphan	 drugs	 after	 1983,	 pharmaceutical	 companies	
start	 to	 consider	 orphan	 drugs	 seriously	 to	 strengthen	 their	 R&D	 pipeline	
through	the	alliance,	such	as	 joint	R&D	project,	merge	and	acquisitions,	etc.	
Large	 pharmaceutical	 companies	 now	 play	 a	 critical	 role	 in	 the	 growth	 of	
orphan	 drugs.	 They	 account	 for	 over	 50%	 of	 the	 orphan	 drug	market,	 for	
instance,	 Abbott,	 Bayer,	 Bristol-Myers	 Squibb,	 GlaxoSmithKline,	 Johnson	 &	








The	 biopharmaceutical	 sector	 is	 the	 innovation	 source	 of	 traditional	
pharmaceutical	 industry,	 while	 biotechnology	 companies	 have	 become	 the	
effective	 instruments	 of	 knowledge	 transfer	 to	 bridge	 the	 gap	 between	
academic	research	and	big	pharmaceutical	companies	(Drews	2000).		
The	 most	 important	 resource	 of	 biotechnology	 companies	 is	 the	 highly	
expert	scientists	and	specialized	technology.	The	exploration	characteristic	of	
the	biotechnology	company	is	a	dynamic	capability	to	renew	and	adjust	their	
research	 in	 response	 to	 rapid	 technology	 and	 market	 changes.	 It	 is	 also	 a	
significant	 competitive	 advantage	 of	 biotechnology	 companies	 (Experiment	
5).	On	the	other	hand,	biotechnology	companies	lack	capital	and	experience,	
so	 they	 are	 struggling	with	 taking	 the	 task	 of	 sales	&	marketing	 compared	





companies	 have	 been	 focusing	 on	 orphan	 drug	 R&D.	 In	 the	 short	 term,	









the	 consideration	 of	 the	 fact	 that	 start-up	 drug	 companies	 face	 resource	
constraints,	 it	 is	highly	possible	 that	 they	must	depend	on	collaboration	 for	





Biogen	 employed	 an	 exploration	 alliance	 with	 University	 of	 Zurich	 and	 an	
exploitation	 alliance	 with	 Schering-Plough	 to	 discover,	 develop	 and	
commercialize	 its	 product	 Intron	 A	 (Rothaermel	 and	 Deeds	 2004).	 After	
biotechnology	 companies	 obtain	 a	 promising	 drug	 candidate,	 they	 should	
decide	to	develop	it	alone	or	collaborate	with	pharmaceutical	companies	that	
will	 commercialize	 the	 drug	 candidate	 if	 it	 approved.	 Big	 pharmaceutical	
companies	have	long-standing	experiences	and	competencies	to	develop	and	
commercialize	new	drug	candidate	through	the	regulatory	process.	Moreover,	
big	 pharmaceutical	 companies	 have	 adequate	 financial	 resources	 to	 afford	







The	 key	 steps	 of	 biopharmaceutical	 sector	 along	 the	 value	 chain	 are	 drug	


















During	 the	 period	 from	 drug	 discovery	 to	 development,	 a	 sponsor	 (drug	
company)	with	a	promising	candidate	submits	the	application	for	orphan	drug	
designation	 to	 FDA.	 In	 our	model,	 we	 assume	 that	drug	 companies	 apply	 the	
designation	 before	 drug	 development.	 FDA	 gives	more	 than	 one	 sponsor	with	
orphan	 drug	 designations	 for	 the	 drug	 treating	 the	 same	 rare	 disease	 or	
condition.	Due	to	the	small	market	of	orphan	drugs,	we	assume	that	if	sponsors	




requests	 are	 granted	 orphan	 drug	 status	 (Figure	 39).	 The	 average	 time	 for	
orphan	 drug	 designation	 application	 is	 1.5-2	 years,	 but	 the	 drug	 R&D	 can	 be	







No	matter	what	the	result	of	orphan	designation	application	 is,	 the	cost	of	 the	
application	 is	 so	 small	 compared	 to	 the	drug	discovery	 and	development	 cost	
that	we	can	assume	it	equals	to	zero	in	our	model.		
The	cost	of	drug	designation:	









The	 drug	 development	 process	 is	 very	 risky	 in	 that	 the	 majority	 of	 the	 drug	



























Drug	Designation	 0.25	 -	 -	
Preclinical	Test	 0.25	 -	 38	
Phase	I	Testing	 0.5	 38	 39	
Phase	II	Testing	 1	 38	 40	






first	 one	 is	 the	 Efficacy	 E	 and	 Safety	 S	 of	 the	 candidate;	 both	 determine	 the	
results	of	FDA	orphan	drug	approval.	Each	step	has	an	attrition	rate,	and	if	the	
drug	 company	has	 enough	 capital	 and	 the	Efficacy	E	 and	 Safety	S	of	 the	 drug	
candidate	 is	 higher	 than	 the	 requirement,	 this	 candidate	 can	 get	 the	 market	
approval.	 The	 second	 one	 is	 the	 Prevalence	 PVL	 of	 Indication	 In,	
𝑷𝑽𝑳𝒏~𝑼 𝟏,𝟐𝟎𝟎𝟎𝟎𝟎 2.	Obviously,	candidates	differ	in	the	cost	and	time	of	their	




	 𝑪𝑫𝑬𝑽𝒏𝒚 = 𝟎.𝟔𝟕+ 𝟎.𝟏×𝑳𝒈 𝑷𝑽𝑳𝒏∗ ×𝝉𝒚×𝑩𝑼𝑫𝒅𝒆𝒗 	 (6)	
The	time	of	STEPy		
	 𝑻𝑫𝑬𝑽𝒏𝒚 = 𝝉𝒚× 𝒕𝒅𝒆𝒗 + 𝟎.𝟓×𝑳𝒈 𝑷𝑽𝑳𝒏∗ 	 (7)	
Standardized	Prevalence																																																							






ten	 time-step,	 one	 biotechnology	 company	 and	 one	 research	
organization	 enter	 the	 orphan	 drug	 innovation	 system;	 every	 twenty	
time-step,	 one	 big	 pharmaceutical	 company	 enters	 the	 orphan	 drug	
innovation	system.		
• To	 better	 observe	 the	 model	 at	 this	 stage,	 each	 organization	 conducts	
one	orphan	drug	R&D	project	at	 the	same	time,	 if	 the	drug	candidate	 is	




















































Before	 the	ODA,	 drug	 companies	 rely	 on	 the	 patent	 to	 protect	 the	 technology	
and	 market	 of	 their	 products.	 Drug	 companies	 typically	 apply	 for	 a	 patent,	
which	 precludes	 other	 firms	 from	 acquiring	 a	 patent	 on	 the	 same	 drug	 and	
selling	 it.	 The	 biotechnology	 companies	 rely	 heavily	 on	 sufficient	 patent	
protection	 to	 recover	 the	 costs	 of	 R&D	 from	 sales	 and	 to	 attract	 investors	 to	
invest	 in.	A	number	of	orphan	drugs	are	not	patentable,	and	even	some	drugs	
have	already	been	patented	before,	so	market	exclusivity	is	of	significant	value	
for	 orphan	 drug.	 It	 makes	 the	 small	 orphan	 drug	 market	 with	 big	 potential.	








































$1.3	 billion	 in	 2006	 (DiMasi	 and	Grabowski	 2007).	 	 The	 cost	 structure	 of	 the	
pharmaceutical	industry	is	much	different	from	other	sectors.	Firstly,	drug	R&D	
involves	 a	 significant	 amount	of	 sunk	 costs.	Drug	 companies	have	a	 very	high	
upfront	cost	of	R&D	and	commercialization	cost,	but	sunk	costs	also	stem	from	







the	 marketing	 to	 ensure	 their	 share	 in	 the	 competitive	 market.	 Whether	 the	
approved	drug	delivers	considerable	return	and	profits	to	the	company	depends	
on	 their	 ability	 to	 set	 a	 reasonable	 price	 and	 sufficient	 sales	 volume	 over	 the	
period	 of	market	 protection.	 The	 condition	 is	 slightly	 different	 in	 the	 orphan	
drug	 marketing,	 as	 the	 active	 networked	 relationships	 among	 patients,	
advocacy	 groups	 and	 an	 experienced	 body	 of	medical	 expertise	make	market	





The	 price	 paid	 for	 a	medicine	 comprises	 some	 components.	 Along	 the	 supply	





added	 into	 the	manufacturer’s	selling	price	 (MSP),	 such	as	 freight	costs,	 taxes,	
markup,	and	procurement	fee.	The	sum	of	these	fees	is	not	low,	accounting	for	
30%-45%	 of	 the	 dispensed	 medicine	 price	 on	 average,	 and	 it	 can	 be	 much	
higher.	 In	our	model,	drug	pricing	refers	 to	 the	price	set	by	 the	manufacturer.	
The	 price	 of	 the	 orphan	 drug	 is	 set	 to	 recoup	 the	 research,	 development	 and	
marketing	 cost	 and	 to	 acquire	 a	 certain	 profit.	 Moreover,	 the	 pricing	 of	 the	
orphan	drug	should	account	for	the	efficacy	and	safety	of	the	product,	the	value	




2. Important	 new	 medicine	 offering	 a	 substantial	 advantage	 for	 the	
majority	of	patients.	
3. Basic	 new	 medicine	 offering	 the	 advantage	 for	 the	 minority	 of	
patients.	


















2005).	 Clinical	 trial	 data,	 especially	 the	 Phase	 III	 trial	 is	 the	 primary	
evidence	of	demonstrating	the	value	of	a	new	medicine.	Drug	companies	
charge	a	price	premium	for	higher	efficacy	and	safety	and	obtain	higher	
financial	 returns.	 In	 our	 model,	 the	 value	 of	 the	 drug	 is	 evaluated	 in	
terms	 of	 effectiveness	 and	 safety	 based	 on	 the	 pharmacological	 and	
clinical	performance.		
MARKET	 POSITION	 The	market	position	of	 the	new	product	 is	 one	of	
the	 leading	 factors	 for	pricing.	The	market	of	 the	drug	 is	determined	 in	
the	early	stage	of	drug	R&D.	The	start	of	drug	discovery	is	choosing	the	
indication,	and	it	is	evident	that	a	different	indication	generally	refers	to	
different	 groups	 of	 customers,	 competing	 products,	 dosages,	 and	
durations.		
Developing	 innovative	products	 is	 the	primary	objective	of	many	 firms.	
The	 medicine	 with	 the	 preferred	 market	 position	 is	 the	 primary	
incentive	 for	 the	 objective.	 The	 market	 position	 ranges	 from	 strong	
market	 power	 (newly	 patented	 drug)	 to	 perfect	 competition	 (generic	
drugs).	 After	 the	 launch,	 7-year	 market	 protection	 allows	 drug	
companies	to	charge	a	monopoly	price	over	the	marginal	cost	and	make	
an	 enormous	 profit	 to	 recover	 the	 cost	 of	 drug	 development	 and	 give	
motivation	for	companies	to	develop	the	orphan	drug.		
































In	 our	 model,	 we	 do	 not	 simulate	 the	 pricing	 decision	 explicitly;	 instead,	 we	
assume	that	drug	companies	will	set	a	price	based	on	some	factors.	According	to	
that,	 we	 use	 ‘Merit’	 U	 to	 evaluate	 these	 factors	 influencing	 the	
commercialization	of	the	orphan	drug.	

















𝑴𝑺𝒎𝒏 = 𝑼𝒎𝒏 𝑼𝑰	 (10)	
The	Price	Pn	 is	expressed	by	the	drug’s	price	P*	,	which	is	set	according	to	the	
total	 R&D	 cost	 and	 condition	 of	 the	 perfectly	 competitive	 market.	 But	 the	





















market	 exclusivity	 and	 the	 competition	 among	 companies	 after	 the	 market	













In	 the	 first	 7	 years,	 orphan	 drug	 faces	 no	 competition	 because	 of	 market	
exclusivity,	and	 it	 dominates	 the	whole	market.	 But	with	 the	 increase	of	 drug	
price,	the	demand	for	orphan	drug	will	decrease.	The	market	share	of	this	drug	
is			
	 𝑴𝑺𝒎𝒏𝒏𝟕 = 𝟎.𝟗𝟓𝛍																																																					 (13)	
	
Grants	
FDA	 has	 invested	 over	 $246	 million	 in	 orphan	 product	 grants,	 which	 have	
contributed	to	approximately	28%	of	designations	and	15%	of	approved	orphan	
drug	 (Milne	 and	 Tait	 2009).	 The	 funding	 of	 research	 institutions	 accounts	 for	
most	of	the	grants	for	orphan	drug	discovery.	Every	period	of	simulation,	there	
will	 be	 five	 new	 grants	 to	 support	 research	 institutions	 finding	 a	 promising	
candidate.	The	value	of	this	grant	is	set	randomly	as	the	initial	research	budget.	
𝑮𝒅𝒊𝒔~𝑼 1000, 2000  
Grants	also	support	drug	companies	to	do	the	clinical	studies	for	no	more	than	
three	 years	 for	 Phase	 I	 trial	 and	no	more	 than	 four	 years	 for	 Phase	 II	 and	 III	




∅~𝑼 10%, 40% 	
	
Accordingly,	the	cost	of	STEPy		(y=2,3,4)	is	







The	tax	credit	 is	normally	half	 the	costs	of	clinical	 testing	on	all	orphan	drugs,	
including	both	successful	 and	unsuccessful	products	under	drug	development.	
So,	 the	 cost	 of	 drug	 development	 after	 tax	 credit	 is	 50%	 of	 qualified	 clinical	




sized	 pharmaceutical	 firms	 and	 large-sized	 biotechnology	 firms	 have	 the	
approved	 drug	 in	 the	market,	 so	 they	 can	 benefit	 from	 this	 provision.	 Once	
small-sized	 pharmaceutical	 companies	 and	 medium-and	 small-sized	
biotechnology	companies	have	one	approved	orphan	drug,	they	can	get	the	50%	









gets	 the	 orphan	 designation.	 In	 our	 simulation,	 all	 the	 drugs	 in	 development	













fundamental	 characteristics	 of	 the	 orphan	 drug	 sector	 but	 also	 presents	 the	
orphan	drug	innovation	system	in	a	highly	qualitative	way.	These	settings	of	the	




The	 entry	 is	 defined	 as	 the	 date	 of	 the	 firm’s	 founding.	 In	 order	 to	 start	 a	
biotechnology	 company,	 companies	 should	 consider	 four	 factors—expertise	 in	
scientific	 research,	management	 skills	 in	business,	 sufficient	 cash	 flows	and	at	
least	a	promising	product.	The	main	barrier	to	market	entry	is	the	high	amount	
of	funding	to	finance	their	massive	R&D	budget.	The	early-stage	biotechnology	
companies	 can	 get	 access	 to	 research	 funding	 from	 numerous	 programs.	
Venture	 capital	 firms	 play	 a	 significant	 role	 in	 financing	 start-up	 biotech	
companies,	but	half	of	them	are	supported	by	venture	capital	(Burns,	Housman	
et	 al.	 2009).	However,	 it	 needs	 to	 undertake	 strategic	 planning	 for	 its	 further	
development.		
	
The	 majority	 of	 funding	 is	 used	 for	 R&D	 purposes.	 To	 raise	 funds,	 many	
companies	seek	venture	capital,	partner	with	big	pharma,	or	other	companies,	
or	 secure	 help	 from	angel	 investors	 and	 government	 or	 small	 business	grants	
(Tsai	 and	 Erickson	 2006).	 Biotechnology	 companies	 need	 to	 achieve	 R&D	
milestones	on	time	and	on	budget	as	well	as	meet	the	needs	of	investors.	
	
A	 small	 number	 of	 biotechnology	 companies	 in	 the	 sector	 are	 extremely	












In	 conclusion,	 there	 are	 three	 factors	 influencing	 the	 market	 entry	 of	
biotechnology	 and	 pharmaceutical	 companies:	 technology,	 capital,	 and	
environment.	Technology	（𝑇𝑒𝑐ℎ）	is	the	prerequisite,	companies	have	to	get	a	
great	 idea	 for	 a	biotech	product	 to	 start	 a	biotechnology	 companies;	capital	 is	
the	 lifeblood	 to	 the	 industry,	 and	 it	 is	 the	 foremost	 focus	 of	 biotechnology	
companies;	 the	 least	 but	 most	 important	 is	 the	 environment,	 in	 which	 good	
investment	 climate	 (𝐼𝑛𝑣𝑒𝑠𝑡),	 profitability	 of	 current	 companies	 (𝑃𝑟𝑜𝑓𝑖𝑡!!!"#$)	
and	public	support	(𝑃𝑢𝑏𝑙𝑖𝑐)will	drive	more	companies	to	enter	into	the	market.	













𝑇𝑒𝑐ℎ ∈ 1,2,3,4,5 	
𝑃𝑢𝑏𝑙𝑖𝑐 ∈ 1,2,3,4,5 	




the	 dissolution	 of	 the	 firm	 (acquisition	 and	merge	 by	 another	 company).	 The	
large	 incumbent	 firms,	 like	 big	 pharmaceutical	 companies,	 are	 more	
conservative	 and	 at	 the	 same	 time	 eager	 to	 keep	 their	 technology	 advance.	
Therefore,	 they	 acquire	 smaller	 new	 entrants	 to	 fuel	 their	 growth	 through	
combining	 the	 innovative	 technology	 of	 new	 entrants	 with	 their	 established	
marketing	 and	 distribution	 channels.	 During	 the	 simulation,	we	 can	 see	 some	





companies	 exit	 because	 they	 lack	 money	 to	 continue	 the	 project	 or	 the	 big	
pharmaceutical	companies	acquire	them.		
	
The	 entry	 and	 exit	 rate	 are	 important	 for	 public	 policy	 reasons:	 firstly,	 the	
pressure	of	new	entry	and	the	risk	of	exit	stimulate	incumbent	firms	to	compete	
and	 the	 competition	 will	 drive	 the	 cost	 down	 and	 the	 quality	 up,	 which	 will	
benefit	 the	 customers;	 secondly,	 the	 entry	 and	 exit	 of	 companies	 increase	 the	
diversity	 of	 industry.	 Moreover,	 it	 prompts	 technological	 learning	 and	








The	 organization	 in	 the	 system	 collaborates	 to	 get	 access	 to	 complementary	
resources.	When	companies	run	out	of	money,	they	will	seek	financial	support	
from	 other	 companies	 with	 abundant	 capital	 in	 the	 system;	 when	 research	
organizations	 want	 to	 commercialize	 their	 research	 outcomes,	 they	 will	
collaborate	 with	 drug	 companies;	 when	 companies	 need	 the	 complementary	
knowledge	 from	other	organizations,	 they	will	 find	a	partner	 in	 the	 system	 to	





companies	 entering	 the	 industry.	 Figure	 42	 shows	 the	 evolution	 of	 the	







organization	 and	 a	 biotechnology	 company;	 the	 pink	 line	 indicates	 the	
collaboration	 between	 a	 pharmaceutical	 company	 and	 a	 biotechnology	
company;	 the	 blue	 line	 indicates	 the	 collaboration	 between	 a	 pharmaceutical	




Figure	 42b	 and	 42c	 show	 the	 collaboration	 network	 in	 the	 open	 innovation	
system;	b.’	and	c.’	show	the	collaboration	network	when	the	inter-organizational	
learning	 is	 not	 free.	 From	 comparing	 c	 and	 c’,	 we	 can	 see	 that	 the	 network	

































Figure	 43	 shows	 the	 orphan	 drug	 discovery	 and	 development	 under	 the	











The	 model	 in	 this	 chapter	 is	 the	 first	 model	 simulating	 the	 evolution	 and	





























understanding	 about	 sectoral	 innovation	 and	 the	 influence	 of	 public	
interventions.		
	
Our	 results	have	demonstrated	 that	 the	ODA	 is	 an	 important	 factor	 in	orphan	




these	 drug	 companies.	 The	 inappropriate	 change	 in	market	 exclusivity	would	
decrease	new	entrants	and	the	exit	of	incumbents.		
	
The	 adoption	 of	 multi-tier	 rights	 should	 be	 applied	 to	 the	 orphan	 drug	
legislation	 in	 order	 to	 encourage	 more	 effective	 innovation.	 The	 solution	




The	 multi-tiered	 nature	 of	 the	 ODA	 is	 a	 superior	 incentive	 to	 the	 market	
exclusivity	 in	 both	 theoretical	 and	 practical	 terms.	 Firstly,	 it	 addresses	 the	
criticism	 around	 the	 ODA,	 which	 include	 ‘blockbuster’	 drugs	 that	 have	 been	
immensely	 profitable;	 the	 ‘salami	 slicing’	 through	 which	 drug	 companies	 can	
obtain	 multiple	 orphan	 drug	 designations;	 and	 the	 ‘over-broad	 scope’	 of	 the	
market	 exclusivity.	 Secondly,	 the	multi-tiered	 ODA	 still	 keeps	 the	majority	 of	
rights	 for	 the	 industry	 while	 it	 offers	 substantial	 benefits	 to	 the	 public.	 This	
would	 create	 a	more	 equal	 and	 competitive	 environment	 for	 the	orphan	drug	




be	 willing	 to	 invest	 in	 orphan	 drug	 discovery	 and	 development.	 This	 change	











other	 organizations	 in	 the	 network.	 Moreover,	 the	 performance	 of	 system	
exhibits	emergent	 characteristics	as	 the	 collection	of	 the	 individuals’	behavior	
brings	 about	 phenomena	 at	 the	 aggregate	 level	 that	 goes	 beyond	 the	 sum	 of	
individuals.	 Actors	 in	 the	 system	 create	 and	 shape	 the	 network	 through	 their	
decisions	and	activities.	Simultaneously,	the	structure	of	the	whole	network	and	
the	 position	 of	 actors	 in	 the	 network	 influence	 the	 actors’	 behaviors	 through	
connections	 and	 feedbacks.	 Actors	 engage	 in	 decision-making	 and	 respond	 to	




Pharmaceutical	 research	 had	 evolved	 dramatically	 in	 the	 past	 decades.	






The	 pharmaceutical	 industry	 is	 a	 knowledge-intensive	 sector,	 in	 which	
knowledge	 is	 the	 core	 component.	 In	 order	 to	 understand	 the	 system	
thoroughly,	we	need	to	start	from	‘knowledge’,	which	plays	an	essential	role	in	
the	 innovation	 process,	 but	 what	 happens	 to	 the	 knowledge	 in	 the	 system	
remains	mostly	 unclear.	 One	 of	 the	 objectives	 of	 this	 research	was	 to	 build	 a	
model	to	investigate	the	knowledge	dynamics	in	the	SI.	A	particular	focus	was	to	





objective	of	 exploring	 the	 systemic	dynamics	 in	 this	unique	 sector.	We	hereto	
proposed	 a	 framework,	 in	 which	 two	 types	 of	 knowledge	 (incremental	
knowledge	 and	 radical	 knowledge),	 learning	 patterns	 (exploration	 and	
exploitation),	 and	 organizational	 learning	 (intra-organizational	 learning	 and	
inter-organizational	learning)	are	distinguished.	Based	on	that,	we	investigated	
and	 explored	 the	 dynamics	 of	 organizational	 learning	 and	 how	 different	
learning	strategies	influence	the	knowledge	output	of	the	organization.	
	
Through	 agent-based	modeling,	 this	 thesis	 sought	 to	 improve	 our	 knowledge	




innovation	 (SSI)	 in	 the	 US.	 To	 reach	 this	 aim,	 the	 theoretical	 foundations	
adopted	 in	 this	 research	 moved	 beyond	 the	 linear,	 non-linear,	 and	 network	
models	 of	 innovation	 that	 had	 dominated	 the	 system	of	 innovation	 literature.	
The	 theoretical	 framework	 comprises:	 1)	 the	 system	 of	 innovation	 theory,	
which	 is	 regarded	 as	 the	 most	 comprehensive	 perspective	 of	 innovation	
process;	2)	the	knowledge-based	view	of	 firm,	which	complements	the	system	
of	 innovation	 theory	 on	 the	 micro-level	 analysis;	 3)	 the	 complex	 adaptive	
system	 of	 innovation,	which	 helps	 to	 bridge	 and	 complement	 the	 former	 two	
theories	in	terms	of	dynamics	and	emergent	features.	The	combination	of	these	





of	 innovation	 with	 knowledge-based	 innovation	 and	 models	 related	 to	 the	
creation	 of	 knowledge-based	 innovation.	 Chapter	 3	 introduced	 the	
pharmaceutical	 innovation	process	 in	different	periods.	The	ODA,	 as	 the	most	
critical	 factor	 influencing	 orphan	 drug	 innovation	 in	 US	 was	 presented	 in	





Agent-based	 Model	 and	 the	 modeling	 toolkit,	 NetLogo,	 were	 introduced	 in	
Chapter	5.	Based	on	the	conceptual	framework	proposed	in	Chapter	2,	reflecting	
on	 the	preliminary	 findings	 in	Chapter	3	and	4,	and	according	 to	 the	research	
design	 in	 Chapter	 5.	 Chapter	 6	 described	 how	 to	 build	 the	 orphan	 drug	




of	 the	 thesis	and	highlights	 the	main	results	of	 research.	This	 is	 followed	by	a	
summary	 of	 the	 key	 findings	 and	 their	 implications.	 The	 contribution	 to	
knowledge	 is	 addressed	 through	 the	 outline	 of	 the	 theoretical	 and	
methodological	contributions	as	well	as	social	and	political	implications.	Finally,	








were	addressed	 in	Chapter	3	and	4.	This	 section	 reflects	on	 the	achievements	
based	on	the	research	objectives.	
	
Objective	 1:	 To	 establish	 a	 theoretical	 framework	 of	 knowledge-based	
















mechanism	 of	 knowledge	 creation	 inside	 the	 organization	 and	 between	
organizations.	The	organizational	learning	model	was	applied	for	identifying	the	
dynamics	 of	 knowledge	 in	 the	 organizational	 learning.	 Moreover,	 the	 model	
examined	the	influence	of	different	learning	strategies	and	network	types	on	the	




Objective	 3:	 To	 establish	 a	 multi-agent	 based	 model	 for	 simulating	
knowledge-based	 innovation	 at	 the	 sectoral	 level	 based	 upon	 the	
analysis	and	findings	of	biopharmaceutical	innovation.	
	
Based	on	 the	 empirical	 findings	 of	 the	dynamics	 and	 evolution	 of	 knowledge-
intensive	 pharmaceutical	 innovation,	 the	 traditional	 research	 methods	 have	
been	 challenged	 concerning	 the	 dynamics	 of	 knowledge	 and	 the	 complex	
network	of	 cooperation.	 	A	multi-agent	based	model,	 in	which	 there	are	 three	
main	 actors	 (research	 organizations,	 biotechnology	 companies,	 and	 big	
pharmaceutical	 companies),	 networks	 (cooperation),	 and	 the	 environment	
(public	acts),	has	been	established	to	model	the	biopharmaceutical	 innovation.	











Objective	 4:	 To	 examine	 the	 effectiveness	 of	 the	 ODA	 through	 multi-
agent	based	model.	
The	 effectiveness	 of	 the	 ODA	 has	 been	 critically	 examined	 through	 the	
simulation	 experiments	 of	 how	 different	 settings	 of	 the	 ODA	 incentives	




The	 research	 objectives	 have	 been	 achieved	 in	 this	 study	 by	 applying	 social	
simulation	method	 to	 the	 system	 of	 innovation	 theory.	 The	 research	 strategy	
has	provided	a	 rich	 combination	of	 the	 empirical	 data,	 statistical	 analysis	 and	
simulation	 findings,	 all	 of	 which	 have	 advanced	 our	 knowledge	 about	 the	






or	 regional,	 and	 it	 can	 be	 sectoral	 within	 any	 of	 these	 geographical	
demarcations.	National,	 regional	 and	 sectoral	 systems	 of	 innovation	 are	 three	





interactions.	 Various	models	 have	 been	 applied	 to	 analyze	 the	 SI:	 linear,	 non-
linear,	 network	 and	 complex	 system.	 The	 system	 of	 biopharmaceutical	





traditional	 model	 is	 too	 simple	 to	 analyze	 the	 dynamic,	 evolutionary	 and	
connected	SI.	
	
The	 overall	 findings	 suggest	 that	 innovation	 network	 is	 not	 something	 new,	
instead	 the	 organizational	 learning	 should	 be	 considered	 as	 a	 strategy	 for	
further	 improving	 existing	 knowledge	 and	 exploring	 new	 knowledge	 by	
creating	new	patterns	of	inter-organizational	interactions.	The	strategic	value	of	
organizational	 learning	 is	 its	 emphasis	 on	 the	 significance	 of	 cooperation	
between	the	organizations	regarding	the	learning	patterns	between	exploration	
and	exploitation.	Given	the	main	actors	and	networks	addressed	within	the	SSI	
for	 generating	 knowledge-based	 innovation,	 the	 public	 intervention	 is	 a	
determining	factor	in	influencing	the	innovation	system	of	a	specific	sector.	The	




One	 of	 the	 objectives	 of	 this	 study	 is	 to	 answer	 the	 questions	 about	 the	
evolution	of	the	biopharmaceutical	sector	and	the	response	of	companies	to	the	
advancements	in	science	and	technology.	The	concept	of	a	technological	regime	
was	 applied,	 and	 the	 description	 of	 drug	 innovation	 period	was	 presented	 in	














two	 technological	 regimes	 accounted	 for	 the	 evolution	 of	 company	 business	
model,	which	includes	the	learning	strategy	and	business	strategy.		
	
Our	study	addressed	the	change	of	 the	 technology	regime	and	accordingly	 the	
evolution	 of	 the	 sector.	 The	 largely	 vertically-integrated	 pharmaceutical	 firms	
dominated	 the	 industry,	 since	drug	discovery	 and	development	 are	 related	 to	
“economies	 of	 scale	 and	 scope,	 large	 sunk	 costs	 and	 advantages	derived	 from	
integrated	value	chain	(Rasmussen	2010)”.	The	changing	of	the	knowledge	base	
since	 the	 1980s	 has	 reshaped	 the	 pharmaceutical	 sector.	 With	 the	 declining	
productivity	 of	 traditional	 drug	 pipelines	 and	 the	 expiration	 of	 patents,	 large	
pharmaceutical	 companies	had	 to	acquire	new	 technology	and	share	 the	 risks	
through	 alliances.	 It	 is	 notable	 that	 the	 most	 successful	 pharmaceutical	
companies	still	 retained	their	 large	scales	and	 integrated	business	models,	 the	
value	 of	 which	 was	 not	 impaired	 in	 drug	 development	 (clinical	 trial)	 and	
marketing	by	the	impact	of	biotechnology.	But,	large	pharmaceutical	companies	
looked	 for	 new	 strategies	 to	 develop	 innovative	 drugs	 by	 using	 latest	 science	
and	technology	to	strengthen	their	positions.	They	have	undertaken	joint	R&D	
projects	 with	 biotechnology	 companies	 through	 strategic	 technology	




a	 complex	 system	 with	 various	 participants	 connecting	 with	 each	 other.	
Companies	 in	 the	 network	 have	 strengthened	 their	 positions	 and	 enhanced	
their	core	competencies	by	accessing	complementary	knowledge	and	resources.	
Companies	 have	 gained	 opportunities	 to	 share	 the	 risk	 of	 development	 of	
innovative	 products	 and	 the	 risk	 of	 new	 emerging	 market.	 The	 complex	 and	
costly	 orphan	 drug	 R&D	 process	 requires	 more	 advanced	 and	 strategic	
relationships	 with	 the	 involvement	 of	 patient	 groups,	 research	 originations,	
FDA	authorities,	 investors	and	other	companies.	Nowadays,	biopharmaceutical	
companies	 have	 engaged	 in	 various	 alliances	 with	 universities	 and	 research	


















Knowledge	 is	 the	critical	concept	of	understanding	 innovation,	and	 learning	 is	
the	 critical	 concept	 of	 the	 theory	 of	 the	 system	 of	 innovation.	 The	 idea	 of	
learning	 in	 the	 SI	 approach	 stresses	 on	 the	 interaction	 that	 is	 the	 most	
important	locus	for	innovation.	In	this	study,	the	knowledge-based	view	of	the	
firm	 is	 selected	 because	 it	 stresses	 on	 the	 micro-level	 analysis	 and	 pays	
attention	 to	 the	 company’s	 learning	 activities	 and	 interactions.	 The	model	we	
introduced	 in	 the	 thesis	 enables	 us	 to	 find	 out	 how	 the	 different	 patterns	 of	
cooperation	influence	the	outcome	of	innovation.	
	
Our	 research	 showed	 that	 the	 inter-organizational	 learning	 network	 can	
facilitate	knowledge	 flow	and	creation.	There	are	many	factors	 influencing	the	
innovation	 activities	 of	 companies	 involved	 in	 the	 network,	 such	 as	 network	
position,	 absorptive	 capacity	 and	 network	 structure	 (Tsai	 2001,	 Reagans	 and	
McEvily	 2003).	We	 introduced	 the	 concept	 of	 exploration	 and	 exploitation	 as	
explanatory	 factors	 underpinning	 the	 organizational	 learning.	We	 studied	 the	
performance	 of	 companies	 through	 different	 learning	 strategy	 settings	 and	
found	 that	 there	were	 significant	 differences	 across	 companies	 implementing	









In	 the	US	 orphan	 drug	 innovation	 system,	 the	 network	 does	 not	 only	 include	
research	 organizations,	 biotechnology	 companies,	 and	 pharmaceutical	
companies	but	also	include	the	NORD,	the	FDA,	and	the	NIH.	As	the	first	and	the	
largest	 patient	 organization	 in	 the	 US,	 the	 NORD	 connects	 the	 patients,	 drug	
developers	 and	 authority	 to	 facilitate	 information	 flow	 and	 advance	 medical	
research.	Patients	are	willing	 to	contribute	 to	 the	clinical	 trial	 to	get	access	 to	
the	 latest	 treatment;	 while	 drug	 developers	 and	 FDA	 look	 for	 patients	 to	 be	
enrolled	 in	 the	 drug	 development	 process.	 The	 NORD	 is	 a	 bridge	 connecting	
patients	 and	 the	 industry	 by	 establishing	 the	 patient	 database	 as	 well	 as	
connecting	 patients	 to	 treatments.	 Although,	 most	 of	 the	 orphan	 drug	
innovation	activities	are	 located	 in	the	US,	 there	 is	a	 trend	that	 the	 innovation	
network	has	been	enlarged	 to	 the	 international	 level	 in	 recent	 years.	 Some	of	
the	orphan	drugs	approved	in	the	US	were	developed	by	foreign	companies,	and	
the	US	companies	have	sought	global	resources	to	enrich	their	product	pipeline.	
The	 FDA	 works	 closely	 with	 industry,	 patient	 groups,	 research	 organizations	
and	 government	 agencies.	 By	 connecting	 the	 expertise	 with	 drug	 developers,	
the	uncertainty	of	clinical	trials	has	been	reduced	to	a	lower	level.	The	NIH	links	















that	 includes	the	essential	 information	about:	science	and	technology,	 funding,	
investment	 opportunities,	 labor,	 cooperation,	 standard,	 and	 market.	 These	
kinds	 of	 information	 are	 especially	 crucial	 in	 the	 knowledge-intensive	 and	
capital-intensive	 sector,	 like	 biopharmaceutical	 sector.	 The	 evidence	 from	 the	
ODA	 suggested	 that	 public	 intervention	 could	 solve	 the	 market	 failures	 that	
obstruct	the	innovation,	which	we	will	address	in	the	next	section.	However,	the	




The	balance	between	private	 rights	 and	public	 interest	 as	well	 as	 the	balance	
between	 innovation	 and	 accessibility	 or	 affordability	 are	 at	 the	 center	 of	 the	
present	controversy	surrounding	orphan	drugs.	There	is	no	doubt	that	the	ODA	
is	 a	 successful	 public	 intervention	 in	 creating	 incentives	 for	 the	 companies	 to	
develop	orphan	drugs.	The	orphan	drug	was	featured	as	unprofitable	due	to	the	
small	market	and	huge	cost,	so	there	was	no	opportunity	for	drug	companies	to	
recover	 their	 investment	 costs	 or	 even	 to	 make	 a	 profit.	 Therefore,	 the	
pharmaceutical	industry	had	largely	focused	on	investing	in	drugs	for	common	
diseases.	When	 the	market	 force	 failed	 to	 bring	 orphan	drugs	 to	 patients,	 the	
public	 force	was	 required	 to	 offer	 some	 incentives	 for	 companies	 to	 invest	 in	
orphan	 drugs.	 In	 1983,	 the	 US	 was	 the	 first	 country	 to	 pass	 the	 legislative	
intervention	 targeting	 the	 issue	 of	 orphan	 drugs.	 In	 order	 to	 encourage	 the	
research,	development	and	marketing	of	orphan	drugs,	 the	ODA	was	designed	











been	 widely	 accepted	 by	 patient	 groups,	 drug	 companies	 and	 legislators	 as	
fairly	 successful	 stimulus,	market	exclusivity	has	been	considered	as	 the	most	










drug.	 Patents	 expire	 20	 years	 from	 the	 date	 of	 filing,	 and	 it	 is	 highly	 possible	
that	 they	can	expire	even	before	drug	approval.	Exclusivity	works	 in	a	similar	
way	with	patent,	but	 it	 is	 granted	by	FDA	upon	 the	approval	of	 a	drug,	 and	 it	
provides	7-year	market	protection	for	the	orphan	drug.		
	
Orphan	 drugs	 are	 generally	 very	 expensive,	 with	 some	 drugs	 costing	 from	
$200,000	 to	 $300,000	 per	 patient	 per	 year,	 and	 treatments	 usually	 last	 for	 a	
patient’s	 lifetime.	 Despite	 the	 high	 price,	 payers	 have	 little	 scrutiny	 on	 the	
coverage	 because	 of	 the	 high	 unmet	 need	 of	 rare	 disease	 patients	 and	 the	







44).	With	the	 increasing	number	of	orphan	drugs	 in	the	market,	 the	aggregate	
budget	 impact	 for	many	payers	 has	 grown,	 and	 the	 payers’	 attitudes	 towards	






patients	 with	 rare	 diseases.	 Based	 on	 this	 criterion,	 the	 ODA	 might	 be	
considered	 a	 success,	 as	 most	 evident	 from	 the	 difference	 in	 the	 number	 of	
approved	orphan	drugs	before	and	after	ODA.	From	the	simulation	results,	we	
could	 see	 the	market	 exclusivity	 had	 a	 significant	 influence	 on	 the	 number	 of	
authorized	orphan	drugs.	The	 cancellation	of	market	 exclusivity	would	 totally	






The	 research	 results	 suggested	 that	 the	 incentives	 should	 be	 designed	 and	
implemented	 in	 a	 way	 that	 can	make	much	 attention	 to	 the	 fairness	 and	 the	
sustainability.	 Alternative	 methods	 should	 be	 considered	 for	 resolving	 the	
exposed	 problems	 of	 the	 ODA.	 First	 of	 all,	 it	 is	 essential	 that	 these	 methods	
should	 be	 based	 on	 the	 balance	 between	 public	 and	 private	 interests.	 The	
proposed	solutions	include	the	reduced	exclusivity	period	once	the	use	of	drugs	
extended	 to	 other	 diseases	 or	 the	 return	 of	 a	 reasonable	 rate	 of	 profit	 to	 the	
government	if	an	orphan	drug	is	exceptionally	profitable.	Despite	the	significant	
progress	the	ODA	has	made,	much	work	remains	to	be	done.	Around	7000	rare	
diseases	 have	 already	 been	 identified,	 and	 many	 of	 them	 are	 with	 the	 high	
mortality	rate,	but	only	5%	of	them	have	the	approved	therapy	for	the	patients.	
Another	way	of	encouraging	the	innovation	without	taking	the	undue	advantage	









The	 US	 ODA	 has	 set	 a	 good	 example	 for	 other	 countries	 to	 design	 the	 public	
interventions	for	orphan	drug	innovation.	Our	analysis	of	the	ODA	has	achieved	






linear	 towards	 the	 complex	 adaptive	 model	 as	 a	 result	 of	 the	 in-depth	
understanding	of	the	SI.	An	increasing	attention	has	been	paid	to	the	network	of	
innovation	 that	 plays	 a	 vital	 role	 in	 generating	 new	 knowledge.	 However,	






In	 conclusion,	 this	 section	 has	 succeeded	 in	 addressing	 the	 critical	 problems	
emerging	from	the	ODA,	which	is	closely	related	to	the	effective	implementation	
of	 the	 complex	 adaptive	 system	 model	 of	 knowledge-based	 innovation.	 The	
complex	 adaptive	 system	 was	 still	 at	 the	 conceptual	 or	 theoretical	 level	 to	
analyze	the	innovation.	There	was	little	attention	paid	to	the	implementation	of	
the	complex	adaptive	model	both	at	the	micro	level	and	the	strategy	and	policy	
intention	 at	 the	 macro	 level.	 In	 the	 light	 of	 the	 analysis	 within	 the	 thesis,	











The	 literature	 from	 the	 research	 of	 the	 SI	 indicated	 that	 the	 current	 research	
method	 of	 the	 SI	 was	 facing	 challenges	 in	 practice	 and	 needed	 to	 employ	 a	
different	method.	Complex	adaptive	system,	as	a	heuristic	concept	from	the	area	
of	 natural	 science,	 has	 undoubtedly	 offered	 a	 valuable	 framework	 that	
reinforces	 our	 understanding	 of	 the	 knowledge-intensive	 innovation	 system.	
The	distinctness	of	this	research	lies	in	to	enrich	the	existing	theories	of	the	SI	
by	 highlighting	 the	 network,	 complexity,	 adaptiveness,	 emergent	 feature	 and	
public	 intervention.	 This	 could	 enable	 researchers,	 innovation	 actors	 and	
policy-makers	 to	 think	 beyond	 the	 preceding	 model,	 by	 taking	 into	 the	
consideration	 of	 the	 dynamics	 of	 organizational	 learning	 and	 the	 complicated	
networking	 process.	 The	 research	 findings	 have	 significant	 implications	 for	









it	 has	 been	 addressed	 by	 a	 wide	 range	 of	 research,	 for	 instance,	
organizational	theory,	economics,	and	innovation	studies.	Although	some	
researchers	 have	 discussed	 the	 difference	 between	 exploration	 and	






work	 together	 in	 the	 SI	 remained	 rather	 unclear.	 	 This	 research	 has	
extended	the	current	work	by	addressing	the	dynamic	 learning	process	
at	 the	 intra-organization	 and	 inter-organization	 level	 in	 terms	 of	
exploration	 and	 exploitation,	 and	 by	 examining	 the	 ways	 in	 which	
organizational	learning	may	be	facilitated	through	balancing	exploration	
and	 exploitation.	 Furthermore,	 this	 study	 has	 moved	 beyond	 the	
conceptual	model	 and	 examined	 our	 assumptions	 about	 organizational	
learning	 by	 social	 simulation.	 Through	 our	 findings,	 the	 research	 has	




• The	second	theoretical	contribution	of	 this	research	 lay	 in	updating	the	
theoretical	foundation	of	the	SI	from	the	linear,	non-linear	and	network	
view	of	 innovation	 to	a	 complex	 systematic	viewpoint.	The	 linear,	non-
linear	 and	 network	 models	 were	 three	 main	 innovation	 models	
dominating	 the	 past	 and	 current	 innovation	 research,	 the	 features	 and	
shortcomings	 of	 them	 have	 been	 identified	 after	 reviewing	 its	 main	
concepts	 in	Chapter	2,	 and	 it	was	argued	 that	 the	 further	development	
and	extension	of	the	SI	theory	is	very	much	needed	as	the	systems	have	
become	 more	 and	 more	 complex,	 particularly	 when	 it	 is	 going	 to	 be	
applied	 in	 the	 knowledge-intensive	 systems	 of	 innovation	 (Figure	 45).	
This	 study	 has	 adopted	 the	 complex	 adaptive	 system	 in	 the	 theory	
construction.	We	advanced	the	growing	amount	of	the	literature	focusing	









• The	 third	 noteworthy	 theoretical	 contribution	 of	 this	 research	was	 the	
attention	paid	to	the	sectoral	system	of	innovation.	Although	the	system	
of	innovation	is	at	the	center	of	the	innovation	study,	sectoral	system	of	
innovation	 is	 rather	 new	 and	 has	 not	 yet	 attracted	 sufficient	 attention	
from	 scholars.	 Different	 from	 the	 previous	 research	 on	 the	 SSI,	 in	 this	





























All	 the	 research	 results	 heavily	 rely	 on	 the	 methodology	 of	 the	 agent-based	




drive	 their	 evolution	 over	 time.	 For	 the	 social	 research,	 such	models	 are	 still	
rare,	but	there	are	signs	that	indicate	this	is	going	to	change.	Because	the	social	
simulation	 has	 allowed	 us	 to	 gain	 different	 knowledge	 compared	 with	




Firstly,	 this	 study	 made	 an	 important	 step	 to	 simulate	 the	 pharmaceutical	
innovation	 process	 from	 drug	 discovery,	 drug	 development	 to	 drug	
commercialization.	Secondly,	 in	addition	to	the	 first	remark,	we	also	made	the	
innovation	 process	 tangible	 in	 terms	 of	 knowledge.	 We	 measured	 the	









the	 dynamics	 posed	 a	 challenge	 to	 the	 traditional	 research	 methods.	 In	 the	
research	of	the	SI	with	intense	interactions,	the	networks	are	too	complicated	to	
solve	 them	 analytically	 and	 therefore	 computational	 experiment	 is	 a	 suitable	
research	method	 to	 understand	 how	 the	 system	works	 and	 to	 do	 the	what-if	





settings	of	model’s	parameters	 influencing	system’s	output.	 In	 the	multi-agent	
based	model,	the	real	world	is	created	and	populated	by	agents	that	are	able	to	
make	 their	 own	 decisions	 and	 to	 act	 and	 interact	 with	 other	 actors	
autonomously	 following	 their	 own	 strategies	 and	 interests.	 The	 agents	 are	
simulated	 as	 actual	 individual	 or	 organization,	 and	 the	 agent-based	 model	 is	
simulated	 as	 a	 social	 system	 with	 emergent	 phenomena.	 Compared	 with	 the	
previous	 linear,	 non-linear	 and	 network	 model,	 CAS	 model	 is	 an	 advanced	
model	of	 the	system	of	 innovation	 in	 terms	of	heterogeneous	agents,	dynamic	
learning	process,	network	formation,	adaptiveness,	and	self-organization.	
	












to	 be	 interpreted.	 Although	 the	more	 information	 the	model	 synthesizes,	 the	
more	accurate	 the	model	 is.	However,	 any	model	 is	not	able	 to	 reproduce	 the	
world	as	exactly	the	same	as	 in	the	reality.	Hence,	balancing	the	complexity	of	
















the	 model	 is	 often	 inspired	 by	 the	 intuition	 of	 the	 modelers	 (Epstein	 1999).	










This	 study	 has	 contributed	 to	 the	 knowledge-based	 system	 of	 innovation	 on	








and	 provide	 rich	 insights	 on	 designing	 innovation	 policy	 for	 the	 orphan	 drug	
innovation.		
	
There	 have	 been	many	 discussions	 on	 how	 to	 create	 an	 effective	 knowledge-
based	 system	of	 innovation	 at	 the	macro-level,	 but	 there	has	been	 lack	of	 the	





innovation	 networks	 are	 formed,	 evolved	 and	 operated	 to	 create	 competitive	
advantages	 for	 actors	 in	 the	network	and	 to	 influence	 the	performance	of	 the	
whole	 network.	 The	 outcome	 of	 this	 research	 revealed	 how	 innovation	
capability	is	enhanced	through	the	dynamic	interactive	process	between	actors.	
The	 research	 also	 has	 the	 enlightening	 influence	 upon	 academic	 researchers,	




political	 and	 historical	 context.	 A	 sustainable	 future	 for	 both	 rare	 disease	
treatment	and	healthcare	system	requires	that	we	do	not	analyze	the	different	
parts	of	the	sector	separately	rather	than	consider	them	as	a	whole	system.	This	
research	 unraveled	 the	 internal	 dynamics	 of	 the	 biopharmaceutical	 industry	
and	 attempted	 to	 examine	 the	 most	 controversial	 incentive	 to	 seek	 the	 best	
trade-off	 between	 quantity	 and	 price.	 The	 interconnections	 between	
pharmaceutical	 developments,	 pharmaceutical	 policy,	 and	 innovation	 theories	
helped	us	 to	understand	how	they	shape	 the	current	situation	of	orphan	drug	
innovation.	 The	 findings	 from	 the	 thesis	 provided	 companies	 with	 a	 deeper	
understanding	of	managing	 the	dynamic	 interactive	 innovation	process	within	








to	 enter	 into	 the	 sector.	 Protecting	 the	 intellectual	 property	 is	 of	 particular	
importance	for	the	knowledge-intensive	sector,	and	when	the	patent	legislation	
is	 not	 applicable	 for	 the	 products	 in	 the	 industry	 giving	 the	market	 right	 for	







obstacles	 in	 the	 drug	 development	 process,	 and	 it	 can	 lead	 to	 a	 timely	 and	
successful	 drug	 approval.	 The	 least	 but	 the	 most	 important,	 the	 advance	 of	
science	 and	 technology	 is	 the	 precondition	 for	 the	 innovation,	 without	 the	
significant	 improvement	 of	 basic	 research	 in	 the	 area	 of	 biotechnology,	 the	
orphan	 drug	 innovation	 cannot	 be	 triggered	 even	 it’s	 lured	 by	 market	 right.	
Although	pharmaceutical	 industry	provides	an	enormous	amount	of	 the	 funds	
for	R&D,	 the	basic	 research	 is	 largely	 funded	by	 the	public	 sector.	Most	of	 the	
basic	 biomedical	 research	 are	 supported	 by	 the	 National	 Institute	 of	 Health	




Based	 on	 the	 analysis	 in	 Chapter	 6,	 it’s	 clear	 that	 the	 ODA	 is	 successful	 in	
promoting	the	innovation	of	not	only	orphan	drugs	but	also	other	biotechnology	
drugs.	 Innovation	 policy	 needs	 to	 focus	 on	 developing	 more	 robust	 and	
endogenous	 innovative	 ability	 for	 knowledge-base	 innovation	 through	
concentrated	action	on	supporting	and	managing	the	key	issues	that	have	been	
raised	during	 the	R&D	process	 in	an	appropriate	and	effective	manner.	As	 the	
most	controversial	incentive,	market	exclusivity	has	played	an	important	role	in	
the	 prosperity	 of	 orphan	drug	 innovation;	 at	 the	 same	 time,	 the	 high	 costs	 of	
some	rare	disease	treatments	have	made	 it	at	 the	center	of	controversy.	From	
the	simulation	results,	we	can	see	shortening	the	duration	of	market	exclusivity	
is	 not	 a	 reasonable	 method	 to	 avoid	 the	 blockbuster	 orphan	 drug	 as	 drug	
companies	are	very	sensitive	to	the	issue,	the	best	way	to	solve	this	problem	is	
to	enact	 the	multi-tier	policy	 for	 the	blockbuster	orphan	drug	and	repurposed	
orphan	drug.	
	
The	 contributions	 from	 the	 case	 study	 based	 on	 a	 unique	 sector	 in	 a	 unique	
country,	unavoidably	bear	many	exceptions.	It’s	very	dangerous	to	simply	copy	
the	US	policy	to	other	countries.	The	uniqueness	of	the	success	of	the	ODA	could	












Firms	 and	 governments	 are	 continuously	 seeking	 new	 ways	 to	 improve	 and	
develop	competence	in	order	to	succeed	in	the	global	market.	It	is	increasingly	
accepted	that	the	core	of	innovation	is	the	creation	of	knowledge.	The	strategy	
and	 environment	 in	 which	 it	 is	 implemented	 play	 a	 prominent	 role	 in	
generating	new	knowledge.	
	
The	 findings	 from	 our	 research	 have	 left	 two	 critical	 issues	 for	 innovation	
researchers	 and	 policymakers:	 firstly,	 regarding	 how	 to	 future	 develop	 the	
model	to	meet	different	research	objectives,	and	secondly	on	how	to	design	the	
innovation	 policy	 to	 stimulate	 sectoral	 innovation	 without	 misuses.	 The	





also	 proves	 that	 the	 patent	 is	 an	 effective	 incentive	 for	most	 of	 the	 high-tech	
products.	Some	of	the	orphan	drugs	own	the	patent	and	enjoy	the	7-year	market	
exclusivity.	Nevertheless,	the	market	exclusivity	and	the	patent	need	to	be	read	
with	 cautions,	 because	 they	 are	 actually	 two	 different	 concepts.	 An	 area	 of	







Moreover,	 the	 process	 of	 drug	 innovation	 has	 been	 only	 partly	 considered	 in	
this	 study.	 The	 innovation	 process	 in	 our	 research	 includes	 drug	 discovery,	
development	 and	 commercialization.	 The	 former	 two	 processes	 were	 fully	
considered	 and	 discussed	 compared	 with	 the	 last	 process.	 This,	 in	 turn,	 was	
mainly	 a	 result	 of	 the	 reality	 and	 the	 objective	 of	 the	 research.	 Firstly,	 our	
research	 objective	 is	 to	 explore	 the	 innovation	 of	 orphan	 drug,	 so	 the	 R&D	
process	 is	 undoubtedly	 our	 research	 priority.	 Secondly,	 it’s	 hard	 to	 get	 the	
detailed	 information	 about	 the	 drug	 commercialization,	 as	 most	 of	 them	 are	
considered	 business	 secrets.	 Limited	 attention	 has	 been	 paid	 to	 drug	
commercialization,	 and	 thus	 further	 updating	 could	 be	 added	 to	 the	model	 in	
the	research	focusing	on	the	drug	marketing.	
	
Within	 the	 scope	 of	 this	 thesis,	 it	 is	 only	 possible	 to	 present	 the	 theatrical	
foundation	 of	 the	model	 and	 exhibit	 the	 capabilities	 of	 this	model	 in	 selected	
settings.	 Further	 applications	 will	 be	 part	 of	 the	 future	 research,	 especially	
because	the	model	requires	a	solid	basis	of	data	describing	the	concrete	system.	





The	 current	 version	 of	 the	 model	 still	 leaves	 room	 for	 exploration	 and	













regarding	 the	 parameters	 that	 control	 their	 cooperation	 activities.	 In	 the	
preceding	 experiments,	 the	 activities	 of	 networking	 were	 all	 for	 the	 entire	
population.	 If	 possible,	 such	 a	 computational	 model	 would	 be	 designed	 in	
conjunction	 with	 empirical	 data.	 Designing	 a	 sensible	 combination	 of	
heterogeneous	 agents	 for	 the	 computation	 model	 to	 capture	 distinct	
characteristics	of	organizations	 in	 the	SI	can	be	very	challenging,	but	 if	 such	a	
setting	 were	 calibrated	 to	 empirical	 data,	 it	 would	 constitute	 another	 strong	
foundation	for	the	validity	of	this	model.	
	
In	 our	 model,	 the	 spatial	 distribution	 of	 the	 agents	 was	 neglected.	 However,	
research	 has	 shown	 that	 the	 distance	 between	 participants	 in	 the	 network	





At	 this	 stage,	 the	model	 has	 simulated	 the	 organizational	 learning	 by	 Genetic	
Algorithms.	 One	 more	 possible	 area	 of	 future	 research	 is	 to	 explore	 the	
variations	of	 the	management	skills.	 In	the	current	model,	 the	agents	were	set	
up	with	heterogeneous	learning	capabilities,	and	these	capabilities	allowed	the	
agents	 to	 learn	 internally	 and	 externally	 to	develop	new	drugs.	However,	 this	
setting	 ignores	 the	 management	 skills	 that	 could	 influence	 the	 companies’	
innovation	activities	and	outputs.	The	model	would	probably	be	more	powerful	
if	more	detailed	data	about	companies’	management	behaviors	can	be	included,	















to	 offer	 some	 incentives	 for	 companies	 to	 invest	 in	 the	 drugs	 for	 neglected	





model	 can	 be	 extended	 to	 represent	 the	 orphan	 drug	 innovation	 systems	 in	
other	countries,	and	it	can	help	these	countries	to	get	a	better	understanding	of	
the	 influence	of	orphan	drug	 legislation	on	 the	drug	 innovation	system	and	 to	
improve	 the	 current	 situation.	 In	 addition,	 the	model	 can	 be	 extended	 to	 the	





been	 amended	 continuously,	 while	 the	 orphan	 drug	 R&D	 and	 market	 have	
evolved	dramatically.	The	current	R&D	and	market	environment	have	changed	
over	the	past	two	decades.	It	is	not	surprising	that	the	orphan	drug	is	no	longer	
considered	 as	 unprofitable.	 Instead,	 it	 is	 viewed	 as	 a	 huge	 commercial	
opportunity	for	drug	companies	(Wellman-Labadie	and	Zhou	2010).	According	
to	the	orphan	drug	report	from	EvaluatePharma	(Hadjivasiliou	2015),	the	sales	
of	orphan	drugs	has	 increased	 from	around	$20	billion	 in	2000	to	about	$100	
billion	in	2015,	and	it	is	projected	to	reach	$180	billion	and	make	up	20.2%	of	
prescription	 drug	 sales	 by	 2020.	 The	 orphan	 drug	 innovation	 has	 moved	 to	
another	 phase,	 in	 which	 the	 orphan	 drug	 is	 never	 a	 neglected	 market.	 Drug	
companies	 have	 started	 to	 pay	 attention	 to	 this	 promising	 market.	 Since	 the	
environment	 is	 entirely	 different,	 rather	 than	 sticking	 onto	 the	 current	






of	 orphan	 drug	 innovation.	 From	 our	 research,	 it’s	 obvious	 that	 the	 market	
exclusivity	 incentive	 is	 an	 important	 determinant	 in	 promoting	 orphan	 drug	






For	 example,	 the	 outcomes	may	have	 specific	 role	 in	 tackling	 the	 controversy	
surrounding	the	ODA	and	improve	the	ODA	to	meet	every	participant’s	need	in	
the	system.	Moreover,	 the	outcomes	may	shed	 light	on	 the	 intentions	 to	make	
orphan	drug	legislation	in	many	less-developed	countries.		
 
It	 is	 possible	 that	 orphan	 drug	 legislation	 could	 be	 an	 essential	 condition	 for	
stimulating	 orphan	 drug	 innovation.	 Moreover,	 orphan	 drug	 legislation	 has	
been	 proven	 to	 make	 big	 scientific	 and	 economic	 contributions	 to	 the	 bio-
pharmaceutical	 sector.	 However,	 this	 needs	 to	 be	 read	 with	 caution	 because	
besides	 the	 ODA,	 there	 are	 other	 contributory	 factors	 to	 orphan	 drug	
development.	For	example,	the	National	Organization	for	Rare	Disorders	(NORD)	
promoted	awareness	of	rare	diseases	among	public	and	professional	audience;	
established	 the	 rare	 disease	 database	 and	 rare	 action	 network;	 and	 provided	
grants	 for	 basic	 and	 translational	 research.	 The	 Office	 of	 Orphan	 Products	
Development	 (OOPD)	 facilitated	 the	 flow	 of	 information	 among	 patients,	
research	 organizations,	 government	 agencies,	 and	 industry.	 The	 OORPD	 also	
supported	 the	 development	 of	 orphan	 drugs	 by	 providing	 grants	 and	
professional	advice.	Getting	access	 to	 the	regulatory	experts	 is	very	 important	








The	 development	 of	 science	 and	 technology	 is	 the	 foundation	 of	 the	 orphan	
drug	 innovation.	 Without	 its	 advance,	 even	 the	 powerful	 market	 exclusivity	
seems	 less	 functional	 in	 generating	 new	 orphan	 drugs.	 The	 governments	 in		
less-developed	 countries	 should	 take	 ‘science	 and	 technology’	 factors	 into	
consideration	when	embarking	on	their	own	legislation	project.	The	legislation	
would	 focus	 on	 funding	 the	 basic	 research	 and	 facilitating	 the	 knowledge	
transfer	 and	 creation	 within	 the	 sector.	 The	 policy-maker	 should	 make	 an	












2.1.1,	which	was	 released	 in	April	 2000.	 Swarm	 software	 contains	 a	 package	 of	 code	
library	 that	 enables	 users	 to	 write	 code	 in	 Objective	 C	 or	 Java	 computer	 language.	





contents	 and	 set	 activity	 schedules	 to	 agents	 through	 programing.	 Object-Oriented	
programming	(OOP)	 is	 ideally	suited	to	create	the	Swarm	model.	Objective	C	and	Java	








Inheritance 	 	 	 	Each	 class	 in	 the	program	 is	designated	 to	a	 subclass	within	an	over-
arching	 superclass,	 all	 variables	 and	methods	 of	 each	 subclass	 are	 inherited	 from	 its	














objects	 can	 behave	 in	 a	 distributed	 manner.	 Building	 Swarm	 model	 is	 by	 means	 of	
incorporating	 Swarm	 objects	 in	 program.	 A	 typical	 object	 consists	 of	 two	 types	 of	




wealth,	 ability	 of	 the	 object	 and	 so	 forth.	 In	 the	 orphan	 drug	 innovation	 model,	 the	
objects	 are	 the	 various	 organizations	 including	 small	 biotechnology	 companies,	 big	
pharmaceutical	 companies	 and	 so	 on;	 the	 states	 of	 objects	 include	 the	 size,	 type,	









In	 Swarm,	 objects	 are	 created	 by	 buildobjects	method.	 Buildobjects	 not	 only	 creates	
objects	in	the	current	class	but	also	manages	the	object	creation	in	the	next	lower	level.	






















time	 sequences,	 Swarm	 model	 has	 two	 methods.	 The	 buildobjects	 method	 creates	
objects	 and	buildactions	creates	 schedules.	Buildobjects	method	 creates	 the	objects	 in	
current	 class	 and	 lower	 level	 class.	 Buildactions	 method	 creates	 two	 classes:	
Actiongroup	 creates	 an	 ordered	 set	 of	 events,	 Schedule	 controls	 the	 frequency	 of	 the	





Actiongroups	 and	 Schedules,	 to	 coordinate	 all	 these	 activities	 logistically	 is	 very	
important.	The	schedule	of	each	swarm	is	merged	into	the	schedule	of	next	higher-level	













Model	 swarm	 is	 the	 core	 of	 Swarm	 simulation.	 It	 encapsulates	 the	 objects	 and	 their	
activities	 in	 the	 simulated	 model.	 It	 creates	 the	 objects	 correspond	 to	 the	 world	 we	






used	 for	 observation	 and	measurement.	 Observer	 Swarm	 is	 the	 top-level	Swarm	 in	 a	
Swarm	model,	and	it	has	a	collection	of	objects	among	which	Model	Swarm	is	one	of	the	
















built-in	 graphical	 interfaces	 and	 comprehensive	 documentation	 (Allan	 2009).	 Its	
programming	 includes	 many	 high-level	 structures	 and	 primitives	 that	 make	 the	
programming	 easier.	 NetLogo	 has	 switches,	 sliders,	 choosers,	 inputs	 and	 other	
interface	elements,	which	make	the	software	user-friendly.	
	
An	 important	 feature	 of	 NetLogo,	 not	 found	 in	 other	 ABSTs,	 is	 the	 ‘agentsets’.	 The		
‘agentsets’	 is	 a	 set	 of	 agents,	 which	 can	 all	 be	 turtles	 or	 patches,	 and	 it	 can	 be	
customized	 with	 specific	 characteristics.	 It	 is	 very	 useful	 when	 giving	 certain	
instructions	 to.	 The	 agents	 are	 responsible	 for	 the	 majority	 of	 NetLogo’s	 expressive	






The	 NetLogo	 can	 be	 run	 on	most	 systems,	 including	Windows,	Mac	 OS	 X,	 Linux	 and	









The	 general	 principles	 of	 NetLogo	 modeling	 take	 the	 following	 forms:	 creating	 an	
artificial	 world	 filled	 with	 turtles,	 patches,	 and	 links.	 The	 NetLogo	 world	 is	 a	 two-










	The	 concept	 of	NetLogo	 can	 be	 compared	 to	 ‘turtles’	 that	move	 around	 and	 interact	
with	 each	other	on	 ‘patches’.	 In	 the	model,	 there	 can	be	 thousands	of	 ‘turtles’,	which	
come	 from	different	 ‘breeds’.	 The	 patches	 are	 portrayed	 as	 a	 lattice	 in	 some	models,	

























follows	the	uniform	distribution	over	the	interval	 1, 200000 .	
	
PVL	 is	 further	 standardized	 as	 PVL*,	 which	 is	 uniformly	 distributed	 over	
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